US6465188B1
(en)
*
|
1990-06-11 |
2002-10-15 |
Gilead Sciences, Inc. |
Nucleic acid ligand complexes
|
US20040033977A1
(en)
*
|
1990-08-14 |
2004-02-19 |
Bennett C. Frank |
Oligonucleotide modulation of cell adhesion
|
US6605712B1
(en)
|
1990-12-20 |
2003-08-12 |
Arch Development Corporation |
Gene transcription and ionizing radiation: methods and compositions
|
CA2135646A1
(en)
*
|
1992-05-11 |
1993-11-25 |
Kenneth G. Draper |
Method and reagent for inhibiting viral replication
|
US20030206887A1
(en)
*
|
1992-05-14 |
2003-11-06 |
David Morrissey |
RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA)
|
US5639647A
(en)
*
|
1994-03-29 |
1997-06-17 |
Ribozyme Pharmaceuticals, Inc. |
2'-deoxy-2'alkylnucleotide containing nucleic acid
|
US6156535A
(en)
*
|
1995-08-04 |
2000-12-05 |
University Of Ottawa |
Mammalian IAP gene family, primers, probes, and detection methods
|
US20040142895A1
(en)
*
|
1995-10-26 |
2004-07-22 |
Sirna Therapeutics, Inc. |
Nucleic acid-based modulation of gene expression in the vascular endothelial growth factor pathway
|
US6274369B1
(en)
*
|
1996-02-02 |
2001-08-14 |
Invitrogen Corporation |
Method capable of increasing competency of bacterial cell transformation
|
US6133437A
(en)
*
|
1997-02-13 |
2000-10-17 |
Apoptogen, Inc. |
Modulation of IAPs for the treatment of proliferative diseases
|
US20050053976A1
(en)
*
|
1996-06-06 |
2005-03-10 |
Baker Brenda F. |
Chimeric oligomeric compounds and their use in gene modulation
|
US20040171031A1
(en)
*
|
1996-06-06 |
2004-09-02 |
Baker Brenda F. |
Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
|
US20050119470A1
(en)
*
|
1996-06-06 |
2005-06-02 |
Muthiah Manoharan |
Conjugated oligomeric compounds and their use in gene modulation
|
US20040147022A1
(en)
*
|
1996-06-06 |
2004-07-29 |
Baker Brenda F. |
2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations
|
US7812149B2
(en)
*
|
1996-06-06 |
2010-10-12 |
Isis Pharmaceuticals, Inc. |
2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
|
US5898031A
(en)
*
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
US20040203024A1
(en)
*
|
1996-06-06 |
2004-10-14 |
Baker Brenda F. |
Modified oligonucleotides for use in RNA interference
|
US9096636B2
(en)
*
|
1996-06-06 |
2015-08-04 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
US20030044941A1
(en)
*
|
1996-06-06 |
2003-03-06 |
Crooke Stanley T. |
Human RNase III and compositions and uses thereof
|
US20060008448A1
(en)
*
|
1996-06-11 |
2006-01-12 |
Minzhen Xu |
Inhibition of li expression in mammalian cells
|
US7709454B2
(en)
*
|
1997-06-20 |
2010-05-04 |
New York University |
Methods and compositions for inhibiting tumorigenesis
|
US20040072345A1
(en)
*
|
1997-06-20 |
2004-04-15 |
Altaba Ariel Ruiz I. |
Method and compositions for inhibiting tumorigenesis
|
US6238876B1
(en)
*
|
1997-06-20 |
2001-05-29 |
New York University |
Methods and materials for the diagnosis and treatment of sporadic basal cell carcinoma
|
US7351578B2
(en)
|
1999-12-10 |
2008-04-01 |
Invitrogen Corp. |
Use of multiple recombination sites with unique specificity in recombinational cloning
|
CN100342008C
(en)
*
|
1997-10-24 |
2007-10-10 |
茵维特罗根公司 |
Recombinational cloning using nucleic acids having recombinatin sites
|
US6506559B1
(en)
*
|
1997-12-23 |
2003-01-14 |
Carnegie Institute Of Washington |
Genetic inhibition by double-stranded RNA
|
FR2782325B1
(en)
|
1998-08-12 |
2002-05-24 |
Proteus |
METHOD OF IDENTIFYING POLYNUCLEOTIDE SEQUENCES AND / OR CORRESPONDING PROTEINS FROM A SAMPLE OF NUCLEIC ACIDS
|
US20060260005A1
(en)
*
|
1998-02-26 |
2006-11-16 |
Zhizhen Chen |
Transformation of Brassica
|
US20040045056A1
(en)
*
|
1998-02-26 |
2004-03-04 |
Zhizheng Chen |
Transformation of Brassica
|
AUPP249298A0
(en)
*
|
1998-03-20 |
1998-04-23 |
Ag-Gene Australia Limited |
Synthetic genes and genetic constructs comprising same I
|
DK1624060T3
(en)
|
1998-03-20 |
2012-04-10 |
Commw Scient Ind Res Org |
Control of gene expression
|
US20040214330A1
(en)
*
|
1999-04-07 |
2004-10-28 |
Waterhouse Peter Michael |
Methods and means for obtaining modified phenotypes
|
US8598332B1
(en)
*
|
1998-04-08 |
2013-12-03 |
Bayer Cropscience N.V. |
Methods and means for obtaining modified phenotypes
|
EP3214177A3
(en)
*
|
1998-04-08 |
2017-11-22 |
Commonwealth Scientific and Industrial Research Organisation |
Methods and means for obtaining modified phenotypes
|
US20030228597A1
(en)
*
|
1998-04-13 |
2003-12-11 |
Cowsert Lex M. |
Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation
|
WO1999054459A2
(en)
*
|
1998-04-20 |
1999-10-28 |
Ribozyme Pharmaceuticals, Inc. |
Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
|
US7078224B1
(en)
*
|
1999-05-14 |
2006-07-18 |
Promega Corporation |
Cell concentration and lysate clearance using paramagnetic particles
|
US7019195B1
(en)
*
|
1998-05-26 |
2006-03-28 |
Syngenta Participations Ag |
Method for conferring resistance or tolerance aganist furovirus, potyvirus, tospovirus, and cucomovirus to plant cells
|
AR020078A1
(en)
*
|
1998-05-26 |
2002-04-10 |
Syngenta Participations Ag |
METHOD FOR CHANGING THE EXPRESSION OF AN OBJECTIVE GENE IN A PLANT CELL
|
US7005423B1
(en)
*
|
1999-07-02 |
2006-02-28 |
Devgen Nv |
Characterization of gene function using double stranded RNA inhibition
|
GB9827152D0
(en)
*
|
1998-07-03 |
1999-02-03 |
Devgen Nv |
Characterisation of gene function using double stranded rna inhibition
|
US20040242521A1
(en)
*
|
1999-10-25 |
2004-12-02 |
Board Of Regents, The University Of Texas System |
Thio-siRNA aptamers
|
US20060172925A1
(en)
*
|
1998-10-26 |
2006-08-03 |
Board Of Regents, The University Of Texas System |
Thio-siRNA aptamers
|
US6759574B1
(en)
|
1998-11-05 |
2004-07-06 |
The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University |
Plants having enhanced gall resistance and methods and compositions for producing same
|
US6939712B1
(en)
*
|
1998-12-29 |
2005-09-06 |
Impedagen, Llc |
Muting gene activity using a transgenic nucleic acid
|
WO2000044914A1
(en)
*
|
1999-01-28 |
2000-08-03 |
Medical College Of Georgia Research Institute, Inc. |
Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
|
AU2008202208C1
(en)
*
|
1999-01-30 |
2014-04-24 |
Alnylam Pharmaceuticals, Inc. |
Method and medicament for inhibiting the expression of a defined gene
|
DE19956568A1
(en)
*
|
1999-01-30 |
2000-08-17 |
Roland Kreutzer |
Method and medicament for inhibiting the expression of a given gene
|
US6987025B1
(en)
|
1999-02-11 |
2006-01-17 |
The Arizona Board Of Regents On Behalf Of The University Of Arizona |
Dwf4 polynucleotides, polypeptides and uses thereof
|
US7601494B2
(en)
|
1999-03-17 |
2009-10-13 |
The University Of North Carolina At Chapel Hill |
Method of screening candidate compounds for susceptibility to biliary excretion
|
CA2365901A1
(en)
*
|
1999-04-14 |
2000-10-19 |
Musc Foundation For Research Development |
Tissue-specific and pathogen-specific toxic agents and ribozymes
|
US20040138168A1
(en)
*
|
1999-04-21 |
2004-07-15 |
Wyeth |
Methods and compositions for inhibiting the function of polynucleotide sequences
|
CN1375004A
(en)
*
|
1999-04-21 |
2002-10-16 |
惠氏公司 |
Methods and compsotions for inhibiting the function of polynucleotide sequences
|
IL145538A0
(en)
*
|
1999-05-10 |
2002-06-30 |
Syngenta Participations Ag |
Regulation of viral gene expression
|
EP1180165A2
(en)
*
|
1999-05-27 |
2002-02-20 |
PHARMACIA & UPJOHN COMPANY |
A nematode drug screen for modulators of mammalian disorders
|
US7485715B2
(en)
|
1999-06-18 |
2009-02-03 |
Ceres, Inc. |
Sequence-determined DNA encoding AP2 domain polypeptides
|
US7479555B2
(en)
|
1999-07-21 |
2009-01-20 |
Ceres, Inc. |
Polynucleotides having a nucleotide sequence that encodes a polypeptide having MOV34 family activity
|
US20040002153A1
(en)
*
|
1999-07-21 |
2004-01-01 |
Monia Brett P. |
Modulation of PTEN expression via oligomeric compounds
|
EP1200575A4
(en)
|
1999-07-29 |
2008-03-05 |
Dana Farber Cancer Inst Inc |
Inducible cancer model to study the molecular basis of host tumor cell interactions in vivo
|
US6924109B2
(en)
*
|
1999-07-30 |
2005-08-02 |
Agy Therapeutics, Inc. |
High-throughput transcriptome and functional validation analysis
|
US8106098B2
(en)
*
|
1999-08-09 |
2012-01-31 |
The General Hospital Corporation |
Protein conjugates with a water-soluble biocompatible, biodegradable polymer
|
US6822086B1
(en)
*
|
1999-08-09 |
2004-11-23 |
The General Hospital Corporation |
Drug-carrier complexes and methods of use thereof
|
US6423885B1
(en)
|
1999-08-13 |
2002-07-23 |
Commonwealth Scientific And Industrial Research Organization (Csiro) |
Methods for obtaining modified phenotypes in plant cells
|
US7531718B2
(en)
|
1999-08-26 |
2009-05-12 |
Monsanto Technology, L.L.C. |
Nucleic acid sequences and methods of use for the production of plants with modified polyunsaturated fatty acids
|
US7067722B2
(en)
|
1999-08-26 |
2006-06-27 |
Monsanto Technology Llc |
Nucleic acid sequences and methods of use for the production of plants with modified polyunsaturated fatty acids
|
IL148374A0
(en)
*
|
1999-08-26 |
2002-09-12 |
Calgene Llc |
Plants with modified polyunsaturated fatty acids
|
US20040106567A1
(en)
*
|
1999-09-07 |
2004-06-03 |
Hagstrom James E. |
Intravascular delivery of non-viral nucleic acid
|
US20020006664A1
(en)
*
|
1999-09-17 |
2002-01-17 |
Sabatini David M. |
Arrayed transfection method and uses related thereto
|
AU1086501A
(en)
|
1999-10-15 |
2001-04-30 |
Carnegie Institution Of Washington |
Rna interference pathway genes as tools for targeted genetic interference
|
US20040157327A1
(en)
*
|
1999-10-22 |
2004-08-12 |
Wyeth |
Pablo, a polypeptide that interacts with BCL-XL, and uses related thereto
|
GB9925459D0
(en)
*
|
1999-10-27 |
1999-12-29 |
Plant Bioscience Ltd |
Gene silencing
|
US6326193B1
(en)
|
1999-11-05 |
2001-12-04 |
Cambria Biosciences, Llc |
Insect control agent
|
GB9927444D0
(en)
*
|
1999-11-19 |
2000-01-19 |
Cancer Res Campaign Tech |
Inhibiting gene expression
|
DE10160151A1
(en)
*
|
2001-01-09 |
2003-06-26 |
Ribopharma Ag |
Inhibiting expression of target gene, useful e.g. for inhibiting oncogenes, by administering double-stranded RNA complementary to the target and having an overhang
|
DE10100586C1
(en)
*
|
2001-01-09 |
2002-04-11 |
Ribopharma Ag |
Inhibiting gene expression in cells, useful for e.g. treating tumors, by introducing double-stranded complementary oligoRNA having unpaired terminal bases
|
US7829693B2
(en)
*
|
1999-11-24 |
2010-11-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a target gene
|
AU2625501A
(en)
*
|
1999-12-30 |
2001-07-16 |
Rutgers, The State University Of New Jersey |
Compositions and methods for gene silencing
|
CN101041079A
(en)
*
|
1999-12-30 |
2007-09-26 |
诺瓦提斯公司 |
Novel colloid synthetic vectors for gene therapy
|
US6531644B1
(en)
|
2000-01-14 |
2003-03-11 |
Exelixis, Inc. |
Methods for identifying anti-cancer drug targets
|
US7179796B2
(en)
|
2000-01-18 |
2007-02-20 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of PTP1B expression
|
US20020055479A1
(en)
*
|
2000-01-18 |
2002-05-09 |
Cowsert Lex M. |
Antisense modulation of PTP1B expression
|
US20080039414A1
(en)
*
|
2002-02-20 |
2008-02-14 |
Sima Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
US8202979B2
(en)
*
|
2002-02-20 |
2012-06-19 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
|
US20050233329A1
(en)
*
|
2002-02-20 |
2005-10-20 |
Sirna Therapeutics, Inc. |
Inhibition of gene expression using duplex forming oligonucleotides
|
US8273866B2
(en)
*
|
2002-02-20 |
2012-09-25 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA)
|
US7833992B2
(en)
*
|
2001-05-18 |
2010-11-16 |
Merck Sharpe & Dohme |
Conjugates and compositions for cellular delivery
|
US7491805B2
(en)
*
|
2001-05-18 |
2009-02-17 |
Sirna Therapeutics, Inc. |
Conjugates and compositions for cellular delivery
|
WO2002081628A2
(en)
*
|
2001-04-05 |
2002-10-17 |
Ribozyme Pharmaceuticals, Incorporated |
Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies
|
WO2003070918A2
(en)
|
2002-02-20 |
2003-08-28 |
Ribozyme Pharmaceuticals, Incorporated |
Rna interference by modified short interfering nucleic acid
|
US20050032733A1
(en)
*
|
2001-05-18 |
2005-02-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA)
|
AU3811101A
(en)
*
|
2000-02-11 |
2001-08-20 |
Lawrence Blatt |
Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
|
EP1272630A2
(en)
*
|
2000-03-16 |
2003-01-08 |
Genetica, Inc. |
Methods and compositions for rna interference
|
EP1728862A1
(en)
*
|
2000-03-16 |
2006-12-06 |
Genetica, Inc. |
Methods and compositions for RNA interference
|
US8202846B2
(en)
*
|
2000-03-16 |
2012-06-19 |
Cold Spring Harbor Laboratory |
Methods and compositions for RNA interference
|
US20030084471A1
(en)
*
|
2000-03-16 |
2003-05-01 |
David Beach |
Methods and compositions for RNA interference
|
WO2001070949A1
(en)
*
|
2000-03-17 |
2001-09-27 |
Benitec Australia Ltd |
Genetic silencing
|
EP2361981B2
(en)
†
|
2000-03-30 |
2019-01-23 |
The Whitehead Institute for Biomedical Research |
RNA sequence-specific mediators of RNA interference
|
NZ553687A
(en)
*
|
2000-03-30 |
2010-03-26 |
Whitehead Biomedical Inst |
RNA sequence-specific mediators of RNA interference
|
US7691991B2
(en)
|
2000-04-17 |
2010-04-06 |
Ceres, Inc. |
Sequence-determined DNA fragments encoding cytochrome P450 proteins
|
GB0012233D0
(en)
|
2000-05-19 |
2000-07-12 |
Devgen Nv |
Vector constructs
|
JP4901051B2
(en)
*
|
2000-05-30 |
2012-03-21 |
ジョンソン アンド ジョンソン リサーチ プロプライアトリー リミテッド |
Methods for mediating gene suppression by using factors that enhance RNAi
|
JP2002306183A
(en)
*
|
2000-06-02 |
2002-10-22 |
Mitsubishi Chemicals Corp |
Method for identifying gene function
|
AU2001275474A1
(en)
*
|
2000-06-12 |
2001-12-24 |
Akkadix Corporation |
Materials and methods for the control of nematodes
|
HUP0302320A3
(en)
|
2000-06-23 |
2005-11-28 |
Pioneer Hi Bred Int |
Recombinant constructs and their use in reducing gene expression
|
US7662791B2
(en)
|
2000-08-02 |
2010-02-16 |
University Of Southern California |
Gene silencing using mRNA-cDNA hybrids
|
US8044259B2
(en)
|
2000-08-03 |
2011-10-25 |
The Regents Of The University Of Michigan |
Determining the capability of a test compound to affect solid tumor stem cells
|
US6984522B2
(en)
|
2000-08-03 |
2006-01-10 |
Regents Of The University Of Michigan |
Isolation and use of solid tumor stem cells
|
CA2456008A1
(en)
*
|
2000-08-19 |
2002-02-28 |
Axordia Limited |
Stem cell differentiation
|
US7198924B2
(en)
|
2000-12-11 |
2007-04-03 |
Invitrogen Corporation |
Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
|
US20060247194A1
(en)
*
|
2000-08-30 |
2006-11-02 |
Sirna Therapeutics , Inc. |
Rna interference mediated treatment of alzheimer's disease using short interfering nucleic acid (sina)
|
US20050209179A1
(en)
*
|
2000-08-30 |
2005-09-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
|
US20080032942A1
(en)
|
2000-08-30 |
2008-02-07 |
Mcswiggen James |
RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
|
CA2422320A1
(en)
*
|
2000-09-14 |
2002-03-21 |
The Regents Of The University Of California |
Id-1 and id-2 genes and products as diagnostic and prognostic markers and therapeutic targets for treatment of breast cancer and other types of carcinoma
|
US20020165192A1
(en)
*
|
2000-09-19 |
2002-11-07 |
Kerr William G. |
Control of NK cell function and survival by modulation of ship activity
|
AU2001292753A1
(en)
*
|
2000-09-19 |
2002-04-02 |
University Of South Florida |
Control of nk cell function and survival by modulation of ship activity
|
US7691821B2
(en)
*
|
2001-09-19 |
2010-04-06 |
University Of South Florida |
Inhibition of SHIP to enhance stem cell harvest and transplantation
|
EP1332220B1
(en)
*
|
2000-10-12 |
2008-01-30 |
The University of Medicine and Dentistry of New Jersey |
Oligonucleotide - facilitated coalescence
|
US6777588B2
(en)
|
2000-10-31 |
2004-08-17 |
Peter Waterhouse |
Methods and means for producing barley yellow dwarf virus resistant cereal plants
|
US20020173478A1
(en)
*
|
2000-11-14 |
2002-11-21 |
The Trustees Of The University Of Pennsylvania |
Post-transcriptional gene silencing by RNAi in mammalian cells
|
CH695778A5
(en)
*
|
2000-11-29 |
2006-08-31 |
Hoffmann La Roche |
Inhibition of transcription of a target gene in a cell or in tissues.
|
EP1873259B1
(en)
|
2000-12-01 |
2012-01-25 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
RNA interference mediated by 21 and 22nt RNAs
|
CA2433680A1
(en)
*
|
2000-12-28 |
2002-08-01 |
Gregory M Arndt |
Double-stranded rna-mediated gene suppression
|
US7385046B2
(en)
|
2001-01-03 |
2008-06-10 |
Ceres, Inc. |
Sequence-determined DNA fragments encoding ethylene responsive element binding proteins
|
US8546143B2
(en)
|
2001-01-09 |
2013-10-01 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a target gene
|
US7767802B2
(en)
|
2001-01-09 |
2010-08-03 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
US7423142B2
(en)
*
|
2001-01-09 |
2008-09-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
EP1860199B1
(en)
|
2001-01-12 |
2014-03-05 |
Exelixis, Inc. |
Modulating insulin receptor signaling
|
JP2002208294A
(en)
*
|
2001-01-12 |
2002-07-26 |
Toshiba Corp |
Semiconductor memory having redundancy system
|
WO2002059294A1
(en)
|
2001-01-26 |
2002-08-01 |
Commonwealth Scientific And Industrial Research O Rganisation |
Methods and means for producing efficient silencing construct using recombinational cloning
|
US20020132257A1
(en)
*
|
2001-01-31 |
2002-09-19 |
Tony Giordano |
Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
|
WO2002062989A2
(en)
*
|
2001-02-08 |
2002-08-15 |
Sequitur, Inc. |
Methods of light activated release 0f ligands from endosomes
|
GB0104948D0
(en)
*
|
2001-02-28 |
2001-04-18 |
Novartis Res Foundation |
Novel methods
|
US7563618B2
(en)
*
|
2001-03-23 |
2009-07-21 |
Geron Corporation |
Oligonucleotide conjugates
|
US8034791B2
(en)
|
2001-04-06 |
2011-10-11 |
The University Of Chicago |
Activation of Egr-1 promoter by DNA damaging chemotherapeutics
|
US20050159379A1
(en)
*
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc |
RNA interference mediated inhibition of gastric inhibitory polypeptide (GIP) and gastric inhibitory polypeptide receptor (GIPR) gene expression using short interfering nucleic acid (siNA)
|
US20050176665A1
(en)
*
|
2001-05-18 |
2005-08-11 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of hairless (HR) gene expression using short interfering nucleic acid (siNA)
|
US20070049543A1
(en)
*
|
2001-05-18 |
2007-03-01 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of 11 beta-hydroxysteroid dehydrogenase-1 (11 beta-HSD-1) gene expression using short interfering nucleic acid siNA
|
US20050267058A1
(en)
*
|
2001-05-18 |
2005-12-01 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (sINA)
|
US20050196767A1
(en)
*
|
2001-05-18 |
2005-09-08 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acis (siNA)
|
US20050054596A1
(en)
*
|
2001-11-30 |
2005-03-10 |
Mcswiggen James |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20070270579A1
(en)
*
|
2001-05-18 |
2007-11-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
|
US20050153915A1
(en)
*
|
2001-05-18 |
2005-07-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of early growth response gene expression using short interfering nucleic acid (siNA)
|
US7109165B2
(en)
*
|
2001-05-18 |
2006-09-19 |
Sirna Therapeutics, Inc. |
Conjugates and compositions for cellular delivery
|
US20050164966A1
(en)
*
|
2001-05-18 |
2005-07-28 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of type 1 insulin-like growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20050080031A1
(en)
*
|
2001-05-18 |
2005-04-14 |
Sirna Therapeutics, Inc. |
Nucleic acid treatment of diseases or conditions related to levels of Ras, HER2 and HIV
|
US20050191618A1
(en)
*
|
2001-05-18 |
2005-09-01 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of human immunodeficiency virus (HIV) gene expression using short interfering nucleic acid (siNA)
|
US20050182009A1
(en)
*
|
2001-05-18 |
2005-08-18 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of NF-Kappa B / REL-A gene expression using short interfering nucleic acid (siNA)
|
US20050164968A1
(en)
*
|
2001-05-18 |
2005-07-28 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of ADAM33 gene expression using short interfering nucleic acid (siNA)
|
US20050014172A1
(en)
|
2002-02-20 |
2005-01-20 |
Ivan Richards |
RNA interference mediated inhibition of muscarinic cholinergic receptor gene expression using short interfering nucleic acid (siNA)
|
US20030175950A1
(en)
*
|
2001-05-29 |
2003-09-18 |
Mcswiggen James A. |
RNA interference mediated inhibition of HIV gene expression using short interfering RNA
|
US20060019913A1
(en)
*
|
2001-05-18 |
2006-01-26 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibtion of protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA)
|
WO2003070972A2
(en)
*
|
2002-02-20 |
2003-08-28 |
Sirna Therapeutics Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF CHROMOSOME TRANSLOCATION GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
WO2003072590A1
(en)
*
|
2002-02-20 |
2003-09-04 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of map kinase genes
|
US20040219671A1
(en)
*
|
2002-02-20 |
2004-11-04 |
Sirna Therapeutics, Inc. |
RNA interference mediated treatment of parkinson disease using short interfering nucleic acid (siNA)
|
US20050124567A1
(en)
*
|
2001-05-18 |
2005-06-09 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of TRPM7 gene expression using short interfering nucleic acid (siNA)
|
US20050137155A1
(en)
*
|
2001-05-18 |
2005-06-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated treatment of Parkinson disease using short interfering nucleic acid (siNA)
|
US20050148530A1
(en)
|
2002-02-20 |
2005-07-07 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20060142225A1
(en)
*
|
2001-05-18 |
2006-06-29 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of cyclin dependent kinase-2 (CDK2) gene expression using short interfering nucleic acid (siNA)
|
US9994853B2
(en)
|
2001-05-18 |
2018-06-12 |
Sirna Therapeutics, Inc. |
Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
|
US20080161256A1
(en)
*
|
2001-05-18 |
2008-07-03 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
|
US20050164224A1
(en)
*
|
2001-05-18 |
2005-07-28 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of cyclin D1 gene expression using short interfering nucleic acid (siNA)
|
US20050124566A1
(en)
*
|
2001-05-18 |
2005-06-09 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA)
|
US20050054598A1
(en)
*
|
2002-02-20 |
2005-03-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition hairless (HR) gene expression using short interfering nucleic acid (siNA)
|
US20050136436A1
(en)
*
|
2001-05-18 |
2005-06-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of G72 and D-amino acid oxidase (DAAO) gene expression using short interfering nucleic acid (siNA)
|
US20050124568A1
(en)
*
|
2001-05-18 |
2005-06-09 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of acetyl-CoA-carboxylase gene expression using short interfering nucleic acid (siNA)
|
US20050196765A1
(en)
*
|
2001-05-18 |
2005-09-08 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of checkpoint Kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA)
|
US20050282188A1
(en)
*
|
2001-05-18 |
2005-12-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
|
WO2003070897A2
(en)
*
|
2002-02-20 |
2003-08-28 |
Ribozyme Pharmaceuticals, Incorporated |
RNA INTERFERENCE MEDIATED INHIBITION OF TNF AND TNF RECEPTOR SUPERFAMILY GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US20060142226A1
(en)
*
|
2001-05-18 |
2006-06-29 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of cholesteryl ester transfer protein (CETP) gene expression using short interfering nucleic acid (siNA)
|
US20050079610A1
(en)
*
|
2001-05-18 |
2005-04-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of Fos gene expression using short interfering nucleic acid (siNA)
|
US20080188430A1
(en)
*
|
2001-05-18 |
2008-08-07 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA)
|
US20070042983A1
(en)
*
|
2001-05-18 |
2007-02-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
|
US20050176664A1
(en)
*
|
2001-05-18 |
2005-08-11 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering nucleic acid (siNA)
|
US20050227935A1
(en)
*
|
2001-05-18 |
2005-10-13 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of TNF and TNF receptor gene expression using short interfering nucleic acid (siNA)
|
US20070093437A1
(en)
*
|
2001-05-18 |
2007-04-26 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of xiap gene expression using short interfering nucleic acid (sina)
|
WO2002097114A2
(en)
*
|
2001-05-29 |
2002-12-05 |
Sirna Therapeutics, Inc. |
Nucleic acid treatment of diseases or conditions related to levels of ras, her2 and hiv
|
US20050182006A1
(en)
*
|
2001-05-18 |
2005-08-18 |
Sirna Therapeutics, Inc |
RNA interference mediated inhibition of protein kinase C alpha (PKC-alpha) gene expression using short interfering nucleic acid (siNA)
|
US20050256068A1
(en)
*
|
2001-05-18 |
2005-11-17 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of stearoyl-CoA desaturase (SCD) gene expression using short interfering nucleic acid (siNA)
|
US20050159380A1
(en)
*
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of angiopoietin gene expression using short interfering nucleic acid (siNA)
|
US20050130181A1
(en)
*
|
2001-05-18 |
2005-06-16 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of wingless gene expression using short interfering nucleic acid (siNA)
|
US20050233997A1
(en)
*
|
2001-05-18 |
2005-10-20 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
|
US20050176666A1
(en)
*
|
2001-05-18 |
2005-08-11 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of GPRA and AAA1 gene expression using short interfering nucleic acid (siNA)
|
US20050153914A1
(en)
*
|
2001-05-18 |
2005-07-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of MDR P-glycoprotein gene expression using short interfering nucleic acid (siNA)
|
US20040019001A1
(en)
*
|
2002-02-20 |
2004-01-29 |
Mcswiggen James A. |
RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA
|
US20090299045A1
(en)
*
|
2001-05-18 |
2009-12-03 |
Sirna Therapeutics, Inc. |
RNA Interference Mediated Inhibition Of Interleukin and Interleukin Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
US20060211642A1
(en)
*
|
2001-05-18 |
2006-09-21 |
Sirna Therapeutics, Inc. |
RNA inteference mediated inhibition of hepatitis C virus (HVC) gene expression using short interfering nucleic acid (siNA)
|
US20050233996A1
(en)
*
|
2002-02-20 |
2005-10-20 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of hairless (HR) gene expression using short interfering nucleic acid (siNA)
|
US20040006035A1
(en)
*
|
2001-05-29 |
2004-01-08 |
Dennis Macejak |
Nucleic acid mediated disruption of HIV fusogenic peptide interactions
|
US7517864B2
(en)
*
|
2001-05-18 |
2009-04-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20050187174A1
(en)
*
|
2001-05-18 |
2005-08-25 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA)
|
US20050170371A1
(en)
*
|
2001-05-18 |
2005-08-04 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of 5-alpha reductase and androgen receptor gene expression using short interfering nucleic acid (siNA)
|
US20050182007A1
(en)
*
|
2001-05-18 |
2005-08-18 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
|
US20050159382A1
(en)
*
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)
|
US20050164967A1
(en)
*
|
2001-05-18 |
2005-07-28 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of platelet-derived endothelial cell growth factor (ECGF1) gene expression using short interfering nucleic acid (siNA)
|
US20040198682A1
(en)
*
|
2001-11-30 |
2004-10-07 |
Mcswiggen James |
RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (siNA)
|
US20050233344A1
(en)
*
|
2001-05-18 |
2005-10-20 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of platelet derived growth factor (PDGF) and platelet derived growth factor receptor (PDGFR) gene expression using short interfering nucleic acid (siNA)
|
WO2003070917A2
(en)
*
|
2002-02-20 |
2003-08-28 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of myc and myb genes or genes of their respective pathways
|
US20050287128A1
(en)
*
|
2001-05-18 |
2005-12-29 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of TGF-beta and TGF-beta receptor gene expression using short interfering nucleic acid (siNA)
|
US20050191638A1
(en)
*
|
2002-02-20 |
2005-09-01 |
Sirna Therapeutics, Inc. |
RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
|
US20050119212A1
(en)
*
|
2001-05-18 |
2005-06-02 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of FAS and FASL gene expression using short interfering nucleic acid (siNA)
|
US20050203040A1
(en)
*
|
2001-05-18 |
2005-09-15 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA)
|
US20050209180A1
(en)
*
|
2001-05-18 |
2005-09-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA)
|
US20050159378A1
(en)
*
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
|
US20050143333A1
(en)
*
|
2001-05-18 |
2005-06-30 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
|
US20050222066A1
(en)
*
|
2001-05-18 |
2005-10-06 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20050288242A1
(en)
*
|
2001-05-18 |
2005-12-29 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of RAS gene expression using short interfering nucleic acid (siNA)
|
US20040209831A1
(en)
*
|
2002-02-20 |
2004-10-21 |
Mcswiggen James |
RNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (siNA)
|
US20050159376A1
(en)
*
|
2002-02-20 |
2005-07-21 |
Slrna Therapeutics, Inc. |
RNA interference mediated inhibition 5-alpha reductase and androgen receptor gene expression using short interfering nucleic acid (siNA)
|
EP2415486B1
(en)
|
2001-05-18 |
2017-02-22 |
Sirna Therapeutics, Inc. |
Conjugates and compositions for cellular delivery
|
US20060241075A1
(en)
*
|
2001-05-18 |
2006-10-26 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of desmoglein gene expression using short interfering nucleic acid (siNA)
|
US8008472B2
(en)
|
2001-05-29 |
2011-08-30 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of human immunodeficiency virus (HIV) gene expression using short interfering nucleic acid (siNA)
|
AU2002312241A1
(en)
|
2001-06-05 |
2002-12-16 |
Exelixis, Inc. |
B3galts as modifiers of the p53 pathway and methods of use
|
WO2003000861A2
(en)
*
|
2001-06-22 |
2003-01-03 |
The Regents Of The University Of California |
Eukaryotic genes involved in adult lifespan regulation
|
US20040126867A1
(en)
*
|
2001-07-06 |
2004-07-01 |
Crooke Stanley T. |
Human RNase III and compositions and uses thereof
|
ES2192945B1
(en)
*
|
2001-07-06 |
2005-03-01 |
Consejo Superior De Investigaciones Cientificas |
A METHOD TO INTERFER WITH VIRUS INFECTION IN PLANTS.
|
AUPR621501A0
(en)
|
2001-07-06 |
2001-08-02 |
Commonwealth Scientific And Industrial Research Organisation |
Delivery of ds rna
|
US7345025B2
(en)
*
|
2001-07-10 |
2008-03-18 |
Johnson & Johnson Research Pty. Limited |
Methods for genetic modification of hematopoietic progenitor cells and uses of the modified cells
|
WO2003006990A1
(en)
|
2001-07-12 |
2003-01-23 |
Exelixis, Inc. |
Modifiers of the p21 pathway and methods of use
|
CA2453183C
(en)
*
|
2001-07-12 |
2016-05-10 |
University Of Massachusetts |
In vivo production of small interfering rnas that mediate gene silencing
|
US8022272B2
(en)
|
2001-07-13 |
2011-09-20 |
Sungene Gmbh & Co. Kgaa |
Expression cassettes for transgenic expression of nucleic acids
|
US10590418B2
(en)
*
|
2001-07-23 |
2020-03-17 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for RNAi mediated inhibition of gene expression in mammals
|
EP1409506B1
(en)
|
2001-07-23 |
2012-05-09 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for rnai mediated inhibition of gene expression in mammals
|
US7612194B2
(en)
*
|
2001-07-24 |
2009-11-03 |
Monsanto Technology Llc |
Nucleic acid sequences from Diabrotica virgifera virgifera LeConte and uses thereof
|
GB0118223D0
(en)
*
|
2001-07-26 |
2001-09-19 |
Univ Sheffield |
Stem loop RNA
|
US20050037989A1
(en)
*
|
2001-08-27 |
2005-02-17 |
Lewis David L. |
Inhibition of gene function by delivery of polynucleotide-based gene expression inhibitors to mammalian cells in vivo
|
US20030198627A1
(en)
*
|
2001-09-01 |
2003-10-23 |
Gert-Jan Arts |
siRNA knockout assay method and constructs
|
US7456335B2
(en)
|
2001-09-03 |
2008-11-25 |
Basf Plant Science Gmbh |
Nucleic acid sequences and their use in methods for achieving pathogen resistance in plants
|
EP1424895B1
(en)
|
2001-09-13 |
2009-08-12 |
California Institute Of Technology |
Method for expression of small antiviral rna molecules within a cell
|
US7195916B2
(en)
*
|
2001-09-13 |
2007-03-27 |
California Institute Of Technology |
Method for expression of small antiviral RNA molecules within a cell
|
US7737124B2
(en)
|
2001-09-13 |
2010-06-15 |
California Institute Of Technology |
Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell
|
WO2003027265A2
(en)
|
2001-09-27 |
2003-04-03 |
University Of Delaware |
Composition and methods for enhancing oligonucleotide-directed nucleic acid sequence alteration
|
EP2390331B1
(en)
|
2001-09-28 |
2018-04-25 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
MicroRNA molecules
|
GB0123401D0
(en)
*
|
2001-09-28 |
2001-11-21 |
Novartis Forschungsstiftung |
Methods of inducing gene expression
|
DE10163098B4
(en)
|
2001-10-12 |
2005-06-02 |
Alnylam Europe Ag |
Method for inhibiting the replication of viruses
|
US7745418B2
(en)
|
2001-10-12 |
2010-06-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting viral replication
|
AU2002343527A1
(en)
*
|
2001-10-22 |
2003-05-06 |
University Of Rochester |
Telomerase interference
|
JP2005512976A
(en)
*
|
2001-10-26 |
2005-05-12 |
リボファーマ アーゲー |
Medicament for treating fibrotic diseases by RNA interference
|
JP2005506087A
(en)
*
|
2001-10-26 |
2005-03-03 |
リボファーマ アーゲー |
Use of double-stranded ribonucleic acid to treat infections caused by plus-strand RNA viruses
|
DE10230996A1
(en)
*
|
2001-10-26 |
2003-07-17 |
Ribopharma Ag |
Method for inhibiting viral replication, useful particularly for treating hepatitis C infection, by altering the 3'-untranslated region of the virus
|
DE10230997A1
(en)
*
|
2001-10-26 |
2003-07-17 |
Ribopharma Ag |
Drug to increase the effectiveness of a receptor-mediates apoptosis in drug that triggers tumor cells
|
AU2002368202B2
(en)
*
|
2001-11-02 |
2008-06-05 |
Insert Therapeutics, Inc |
Methods and compositions for therapeutic use of RNA interference
|
US20040063654A1
(en)
*
|
2001-11-02 |
2004-04-01 |
Davis Mark E. |
Methods and compositions for therapeutic use of RNA interference
|
IL161664A0
(en)
*
|
2001-11-05 |
2004-09-27 |
Janssen Pharmaceutica Nv |
METHOD FOR THE IN VITRO SYNTHESIS OF SHORT DOUBLE STRANDED RNAs
|
US20030150017A1
(en)
*
|
2001-11-07 |
2003-08-07 |
Mesa Jose Ramon Botella |
Method for facilitating pathogen resistance
|
US20030148519A1
(en)
*
|
2001-11-14 |
2003-08-07 |
Engelke David R. |
Intracellular expression and delivery of siRNAs in mammalian cells
|
IL162062A0
(en)
*
|
2001-11-19 |
2005-11-20 |
Proteologics Inc |
Methods for identifying and validating potential drug targets
|
WO2003044188A1
(en)
*
|
2001-11-21 |
2003-05-30 |
Mitsubishi Chemical Corporation |
Method of inhibiting gene expression
|
WO2003046173A1
(en)
*
|
2001-11-28 |
2003-06-05 |
Center For Advanced Science And Technology Incubation, Ltd. |
siRNA EXPRESSION SYSTEM AND PROCESS FOR PRODUCING FUNCTIONAL GENE-KNOCKDOWN CELLS AND THE LIKE USING THE SAME
|
US20050075304A1
(en)
*
|
2001-11-30 |
2005-04-07 |
Mcswiggen James |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20040138163A1
(en)
*
|
2002-05-29 |
2004-07-15 |
Mcswiggen James |
RNA interference mediated inhibition of vascular edothelial growth factor and vascular edothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20070203333A1
(en)
*
|
2001-11-30 |
2007-08-30 |
Mcswiggen James |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
GB0130199D0
(en)
*
|
2001-12-17 |
2002-02-06 |
Syngenta Mogen Bv |
New nematode feeding assay
|
US7294504B1
(en)
*
|
2001-12-27 |
2007-11-13 |
Allele Biotechnology & Pharmaceuticals, Inc. |
Methods and compositions for DNA mediated gene silencing
|
AU2008246266B2
(en)
*
|
2002-01-22 |
2012-09-06 |
Cold Spring Harbor Laboratory |
Methods and compositions for RNA interference
|
DE10202419A1
(en)
|
2002-01-22 |
2003-08-07 |
Ribopharma Ag |
Method of inhibiting expression of a target gene resulting from chromosome aberration
|
AU2012261651B2
(en)
*
|
2002-01-22 |
2015-09-24 |
Cold Spring Harbor Laboratory |
Methods and compositions for RNA interference
|
US20030166282A1
(en)
*
|
2002-02-01 |
2003-09-04 |
David Brown |
High potency siRNAS for reducing the expression of target genes
|
JP2005515780A
(en)
|
2002-02-01 |
2005-06-02 |
セクイター インコーポレイテッド |
Double stranded oligonucleotide
|
US20060009409A1
(en)
*
|
2002-02-01 |
2006-01-12 |
Woolf Tod M |
Double-stranded oligonucleotides
|
US20030203868A1
(en)
*
|
2002-02-06 |
2003-10-30 |
Bushman Frederic D. |
Inhibition of pathogen replication by RNA interference
|
US20050096289A1
(en)
*
|
2002-02-07 |
2005-05-05 |
Hans Prydz |
Methods and compositions for modulating tissue factor
|
US20050202428A1
(en)
*
|
2002-02-13 |
2005-09-15 |
Axordia Limited |
Pluripotential stem cells
|
JP2005527198A
(en)
|
2002-02-14 |
2005-09-15 |
シティ・オブ・ホープ |
Methods for producing interfering RNA molecules in mammalian cells and therapeutic uses of the interfering RNA molecules
|
US7935812B2
(en)
|
2002-02-20 |
2011-05-03 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA)
|
US7678897B2
(en)
|
2002-02-20 |
2010-03-16 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of platelet-derived endothelial cell growth factor (ECGF1) gene expression using short interfering nucleic acid (siNA)
|
US7928220B2
(en)
|
2002-02-20 |
2011-04-19 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of stromal cell-derived factor-1 (SDF-1) gene expression using short interfering nucleic acid (siNA)
|
US7667030B2
(en)
|
2002-02-20 |
2010-02-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
|
US9181551B2
(en)
|
2002-02-20 |
2015-11-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
US7893248B2
(en)
*
|
2002-02-20 |
2011-02-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
|
GB2397062B
(en)
|
2002-02-20 |
2005-06-15 |
Sirna Therapeutics Inc |
RNA interference mediated inhibition of hepatitis c virus (HCV) gene expression using short interfering nucleic acid (siNA)
|
EP1499631A4
(en)
*
|
2002-02-20 |
2006-01-25 |
Sirna Therapeutics Inc |
Rna interference mediated inhibition of tgf-beta and tgf-beta receptor gene expression using short interfering nucleic acid (sina)
|
US7667029B2
(en)
|
2002-02-20 |
2010-02-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of checkpoint kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA)
|
US7691999B2
(en)
|
2002-02-20 |
2010-04-06 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of NOGO and NOGO receptor gene expression using short interfering nucleic acid (siNA)
|
US8258288B2
(en)
|
2002-02-20 |
2012-09-04 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of respiratory syncytial virus (RSV) expression using short interfering nucleic acid (siNA)
|
US20090253774A1
(en)
|
2002-02-20 |
2009-10-08 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF PLATELET DERIVED GROWTH FACTOR (PDGF) AND PLATELET DERIVED GROWTH FACTOR RECEPTOR (PDGFR) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US20050222064A1
(en)
*
|
2002-02-20 |
2005-10-06 |
Sirna Therapeutics, Inc. |
Polycationic compositions for cellular delivery of polynucleotides
|
EP1432725A4
(en)
*
|
2002-02-20 |
2005-03-30 |
Sirna Therapeutics Inc |
RNA INTERFERENCE MEDIATED INHIBITION OF TELOMERASE GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US7683166B2
(en)
|
2002-02-20 |
2010-03-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA)
|
US7897753B2
(en)
|
2002-02-20 |
2011-03-01 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of XIAP gene expression using short interfering nucleic acid (siNA)
|
AU2003211058A1
(en)
*
|
2002-02-20 |
2003-09-09 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED TARGET DISCOVERY AND TARGET VALIDATION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US8067575B2
(en)
|
2002-02-20 |
2011-11-29 |
Merck, Sharp & Dohme Corp. |
RNA interference mediated inhibition of cyclin D1 gene expression using short interfering nucleic acid (siNA)
|
US20090137513A1
(en)
*
|
2002-02-20 |
2009-05-28 |
Sirna Therapeutics, Inc. |
RNA Interference Mediated Inhibition of Acetyl-CoA-Carboxylase Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
US9657294B2
(en)
|
2002-02-20 |
2017-05-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
US7897752B2
(en)
|
2002-02-20 |
2011-03-01 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of telomerase gene expression using short interfering nucleic acid (siNA)
|
US20090099117A1
(en)
|
2002-02-20 |
2009-04-16 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF MYOSTATIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US20090137510A1
(en)
*
|
2002-02-20 |
2009-05-28 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF NF-KAPPA B/ REL-A GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US8013143B2
(en)
|
2002-02-20 |
2011-09-06 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of CXCR4 gene expression using short interfering nucleic acid (siNA)
|
US7910724B2
(en)
|
2002-02-20 |
2011-03-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of Fos gene expression using short interfering nucleic acid (siNA)
|
US7897757B2
(en)
|
2002-02-20 |
2011-03-01 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA)
|
US20050137153A1
(en)
*
|
2002-02-20 |
2005-06-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of alpha-1 antitrypsin (AAT) gene expression using short interfering nucleic acid (siNA)
|
WO2003106476A1
(en)
*
|
2002-02-20 |
2003-12-24 |
Sirna Therapeutics, Inc |
Nucleic acid mediated inhibition of enterococcus infection and cytolysin toxin activity
|
US20050096284A1
(en)
*
|
2002-02-20 |
2005-05-05 |
Sirna Therapeutics, Inc. |
RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
|
US7928219B2
(en)
|
2002-02-20 |
2011-04-19 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (SINA)
|
AU2003207708A1
(en)
*
|
2002-02-20 |
2003-09-09 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of map kinase genes
|
US20090192105A1
(en)
|
2002-02-20 |
2009-07-30 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF INTERCELLULAR ADHESION MOLECULE (ICAM) GENE EXPRESSION USING SHORT INTERFERING NUCELIC ACID (siNA)
|
US7662952B2
(en)
*
|
2002-02-20 |
2010-02-16 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acid (siNA)
|
US7700760B2
(en)
|
2002-02-20 |
2010-04-20 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA)
|
US7928218B2
(en)
|
2002-02-20 |
2011-04-19 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)
|
US7683165B2
(en)
|
2002-02-20 |
2010-03-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA)
|
US20090253773A1
(en)
|
2002-02-20 |
2009-10-08 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF TNF AND TNF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US7795422B2
(en)
|
2002-02-20 |
2010-09-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA)
|
US20050176008A1
(en)
*
|
2002-02-22 |
2005-08-11 |
Mikio Suzuki |
Polynucleotide for target gene
|
CN100549171C
(en)
*
|
2002-02-22 |
2009-10-14 |
大塚制药株式会社 |
The target gene polynucleotide
|
AUPS078002A0
(en)
*
|
2002-02-27 |
2002-03-21 |
Unisearch Limited |
Dnazyme therapeutics
|
CA2476410C
(en)
|
2002-03-01 |
2013-09-24 |
Celltech R & D, Inc. |
Methods to increase or decrease bone density
|
US7274703B2
(en)
*
|
2002-03-11 |
2007-09-25 |
3Com Corporation |
Stackable network units with resiliency facility
|
CA2479187A1
(en)
*
|
2002-03-15 |
2003-09-25 |
Astral, Inc. |
Immunostimulatory double stranded rna and methods of inducing, enhancing or modulating the immune response
|
US20070037769A1
(en)
*
|
2003-03-14 |
2007-02-15 |
Multicell Immunotherapeutics, Inc. |
Compositions and methods to treat and control tumors by loading antigen presenting cells
|
EP2258712A3
(en)
|
2002-03-15 |
2011-05-04 |
Multicell Immunotherapeutics, Inc. |
Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs
|
AU2003221506A1
(en)
|
2002-03-19 |
2003-09-29 |
Novartis Ag |
Methods for the identification of compounds useful for the suppression of chronic neuropathic pain and compositions thereof
|
DE10212892A1
(en)
|
2002-03-20 |
2003-10-09 |
Basf Plant Science Gmbh |
Constructs and methods for regulating gene expression
|
DE10212893A1
(en)
*
|
2002-03-20 |
2003-10-16 |
Basf Plant Science Gmbh |
Process for increasing the oil content in plants
|
US7566813B2
(en)
|
2002-03-21 |
2009-07-28 |
Monsanto Technology, L.L.C. |
Nucleic acid constructs and methods for producing altered seed oil compositions
|
WO2003080802A2
(en)
*
|
2002-03-21 |
2003-10-02 |
Monsanto Technology Llc |
Nucleic acid constructs and methods for producing altered seed oil compositions
|
US7166771B2
(en)
|
2002-06-21 |
2007-01-23 |
Monsanto Technology Llc |
Coordinated decrease and increase of gene expression of more than one gene using transgenic constructs
|
DE60327618D1
(en)
*
|
2002-03-27 |
2009-06-25 |
Aegera Therapeutics Inc |
ANTISENSE NUCLEOBASIS AND ITS APPLICATIONS AGAINST IAP
|
US7541150B2
(en)
*
|
2002-04-08 |
2009-06-02 |
University Of Louisville Research Foundation, Inc |
Method for the diagnosis and prognosis of malignant diseases
|
US7357928B2
(en)
*
|
2002-04-08 |
2008-04-15 |
University Of Louisville Research Foundation, Inc. |
Method for the diagnosis and prognosis of malignant diseases
|
EP1352960A1
(en)
*
|
2002-04-12 |
2003-10-15 |
Viruvation B.V. |
Antiviral therapy on the basis of RNA interference
|
US20050222061A1
(en)
|
2002-04-18 |
2005-10-06 |
Schulte Ralf W |
Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye
|
US7226771B2
(en)
|
2002-04-19 |
2007-06-05 |
Diversa Corporation |
Phospholipases, nucleic acids encoding them and methods for making and using them
|
BR0309391A
(en)
|
2002-04-19 |
2005-10-25 |
Diversa Corp |
Phospholipases, nucleic acids encoding them and methods for preparing and using them
|
US20040180438A1
(en)
|
2002-04-26 |
2004-09-16 |
Pachuk Catherine J. |
Methods and compositions for silencing genes without inducing toxicity
|
AU2003228751A1
(en)
|
2002-05-01 |
2003-11-17 |
Cell Genesys, Inc. |
Lentiviral vector particles resistant to complement inactivation
|
US8137910B2
(en)
|
2002-05-03 |
2012-03-20 |
Duke University |
Method of regulating gene expression
|
US20060084617A1
(en)
|
2002-05-06 |
2006-04-20 |
Satishchandran C |
Methods for delivery of nucleic acids
|
US20030228691A1
(en)
*
|
2002-05-17 |
2003-12-11 |
Lewis David L. |
Processes for inhibiting gene expression using polynucleotides
|
US7351542B2
(en)
|
2002-05-20 |
2008-04-01 |
The Regents Of The University Of California |
Methods of modulating tubulin deacetylase activity
|
AU2003283951A1
(en)
|
2002-05-23 |
2004-03-03 |
Ceptyr, Inc. |
Modulation of biological signal transduction by rna interference
|
GB0212303D0
(en)
*
|
2002-05-28 |
2002-07-10 |
Isis Innovation |
Molecular targetting of IGF-1 receptor
|
US20040019008A1
(en)
*
|
2002-05-28 |
2004-01-29 |
Lewis David L. |
Compositions and processes using siRNA, amphipathic compounds and polycations
|
GB0212302D0
(en)
*
|
2002-05-28 |
2002-07-10 |
Isis Innovation |
Method of selecting targets for gene silencing by RNA interference
|
FR2840217B1
(en)
*
|
2002-06-03 |
2005-06-24 |
Oreal |
COSMETIC COMPOSITIONS COMPRISING AT LEAST ONE DOUBLE-STRANDED RNA OLIGONUCLEOTIDE (DSRNA) AND USES THEREOF
|
AUPS282602A0
(en)
|
2002-06-07 |
2002-06-27 |
Garvan Institute Of Medical Research |
Method of inhibiting cell proliferation
|
CA2388441A1
(en)
*
|
2002-06-10 |
2003-12-10 |
Wei-Ping Min |
Immunomodulation using rna interference
|
US20100075423A1
(en)
*
|
2002-06-12 |
2010-03-25 |
Life Technologies Corporation |
Methods and compositions relating to polypeptides with rnase iii domains that mediate rna interference
|
US20040033602A1
(en)
*
|
2002-06-12 |
2004-02-19 |
Ambion, Inc. |
Methods and compositions relating to polypeptides with RNase III domains that mediate RNA interference
|
US20040248094A1
(en)
*
|
2002-06-12 |
2004-12-09 |
Ford Lance P. |
Methods and compositions relating to labeled RNA molecules that reduce gene expression
|
CA2488916C
(en)
|
2002-06-14 |
2016-08-09 |
Brian Steer |
Xylanases, nucleic acids encoding them and methods for making and using them
|
AU2003251579B2
(en)
*
|
2002-06-21 |
2008-04-03 |
Monsanto Technology Llc |
Intron double stranded RNA constructs and uses thereof
|
US7704965B2
(en)
*
|
2002-06-26 |
2010-04-27 |
The Penn State Research Foundation |
Methods and materials for treating human papillomavirus infections
|
US20040132049A1
(en)
*
|
2002-06-26 |
2004-07-08 |
Bates Paula J. |
Method for the detection of apoptosis
|
BR0312580A
(en)
*
|
2002-07-10 |
2006-10-10 |
Univ Kansas State |
compositions and methods for controlling parasitic nematodes
|
US7655790B2
(en)
|
2002-07-12 |
2010-02-02 |
Sirna Therapeutics, Inc. |
Deprotection and purification of oligonucleotides and their derivatives
|
AU2003253992A1
(en)
*
|
2002-07-18 |
2004-02-09 |
Robert P. Bennett |
Viral vectors containing recombination sites
|
DE10233327A1
(en)
*
|
2002-07-22 |
2004-02-05 |
Basf Ag |
Process for achieving pathogen resistance in plants
|
US7148342B2
(en)
*
|
2002-07-24 |
2006-12-12 |
The Trustees Of The University Of Pennyslvania |
Compositions and methods for sirna inhibition of angiogenesis
|
US7399851B2
(en)
|
2002-07-25 |
2008-07-15 |
Dana Farber Cancer Institute, Inc. |
Composition and method for imaging cells
|
AU2003261231A1
(en)
*
|
2002-07-26 |
2004-02-16 |
Chiron Corporation |
Modified small interfering rna molecules and methods of use
|
EP1527183B1
(en)
|
2002-07-26 |
2008-08-20 |
BASF Plant Science GmbH |
Novel selection method
|
US20050239728A1
(en)
*
|
2002-07-31 |
2005-10-27 |
Pachuk Catherine J |
Double stranded rna structures and constructs, and methods for generating and using the same
|
US8389244B2
(en)
|
2002-08-01 |
2013-03-05 |
City Of Hope |
Methods and kits for synthesis of siRNA expression cassettes
|
US20080274989A1
(en)
*
|
2002-08-05 |
2008-11-06 |
University Of Iowa Research Foundation |
Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof
|
US20050042646A1
(en)
*
|
2002-08-05 |
2005-02-24 |
Davidson Beverly L. |
RNA interference suppresion of neurodegenerative diseases and methods of use thereof
|
US20040241854A1
(en)
*
|
2002-08-05 |
2004-12-02 |
Davidson Beverly L. |
siRNA-mediated gene silencing
|
US20040023390A1
(en)
*
|
2002-08-05 |
2004-02-05 |
Davidson Beverly L. |
SiRNA-mediated gene silencing with viral vectors
|
SI1857547T1
(en)
|
2002-08-05 |
2018-05-31 |
Silence Therapeutics Gmbh |
Further novel forms of interfering RNA molecules
|
US20050255086A1
(en)
*
|
2002-08-05 |
2005-11-17 |
Davidson Beverly L |
Nucleic acid silencing of Huntington's Disease gene
|
US20080176812A1
(en)
*
|
2002-08-05 |
2008-07-24 |
Davidson Beverly L |
Allele-specific silencing of disease genes
|
US20050106731A1
(en)
*
|
2002-08-05 |
2005-05-19 |
Davidson Beverly L. |
siRNA-mediated gene silencing with viral vectors
|
JP2005534696A
(en)
*
|
2002-08-06 |
2005-11-17 |
イントラディグム、コーポレイション |
In vivo down-regulation of target gene expression by introduction of interfering RNA
|
AU2003246349B2
(en)
|
2002-08-07 |
2011-02-03 |
Basf Plant Science Gmbh |
Nucleic acid sequences encoding proteins associated with abiotic stress response
|
US8729036B2
(en)
*
|
2002-08-07 |
2014-05-20 |
University Of Massachusetts |
Compositions for RNA interference and methods of use thereof
|
US20040029275A1
(en)
*
|
2002-08-10 |
2004-02-12 |
David Brown |
Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
|
CN1685063B
(en)
*
|
2002-08-12 |
2011-12-21 |
新英格兰生物实验室公司 |
Methods and compositions relating to gene silencing
|
AU2003264727A1
(en)
*
|
2002-09-04 |
2004-03-29 |
Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin |
Compositions and methods for tissue specific or inducible inhibition of gene expression
|
US7923547B2
(en)
|
2002-09-05 |
2011-04-12 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
US20080214437A1
(en)
*
|
2002-09-06 |
2008-09-04 |
Mohapatra Shyam S |
Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
|
US8071560B2
(en)
*
|
2004-02-17 |
2011-12-06 |
University Of South Florida |
Materials and methods for reducing inflammation by inhibition of the atrial natriuretic peptide receptor
|
WO2004022003A2
(en)
|
2002-09-06 |
2004-03-18 |
University Of South Florida |
Materials and methods for treatment of allergic diseases
|
US20080260744A1
(en)
|
2002-09-09 |
2008-10-23 |
Omeros Corporation |
G protein coupled receptors and uses thereof
|
AU2003267785C1
(en)
*
|
2002-09-13 |
2009-12-24 |
Replicor, Inc. |
Non-sequence complementary antiviral oligonucleotides
|
US20050196382A1
(en)
*
|
2002-09-13 |
2005-09-08 |
Replicor, Inc. |
Antiviral oligonucleotides targeting viral families
|
US8609831B2
(en)
*
|
2002-09-16 |
2013-12-17 |
University Of Southern California |
RNA-mediated gene modulation
|
US7476777B2
(en)
|
2002-09-17 |
2009-01-13 |
Ceres, Inc. |
Biological containment system
|
AU2003273336A1
(en)
*
|
2002-09-18 |
2004-04-08 |
Isis Pharmaceuticals, Inc. |
Efficient reduction of target rna's by single- and double-stranded oligomeric compounds
|
AU2003282877B9
(en)
|
2002-09-25 |
2011-05-12 |
University Of Massachusetts |
In Vivo gene silencing by chemically modified and stable siRNA
|
WO2004029215A2
(en)
*
|
2002-09-26 |
2004-04-08 |
The Regents Of The University Of California |
Conditional gene expression using rnai
|
US20060160759A1
(en)
*
|
2002-09-28 |
2006-07-20 |
Jianzhu Chen |
Influenza therapeutic
|
US20040242518A1
(en)
*
|
2002-09-28 |
2004-12-02 |
Massachusetts Institute Of Technology |
Influenza therapeutic
|
US20070224124A1
(en)
*
|
2002-09-30 |
2007-09-27 |
University Of South Florida |
Novel SH2containing inositol 5'-phosphatase isoform that partners with the Grb2 adapter protein
|
US20050059025A1
(en)
*
|
2002-10-07 |
2005-03-17 |
Five Giralda Farms |
Compositions, organisms and methodologies employing a novel human kinase
|
WO2005000194A2
(en)
*
|
2002-10-08 |
2005-01-06 |
Rinat Neuroscience Corp. |
Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
|
US9453251B2
(en)
|
2002-10-08 |
2016-09-27 |
Pfenex Inc. |
Expression of mammalian proteins in Pseudomonas fluorescens
|
AU2003285864C1
(en)
*
|
2002-10-08 |
2010-07-01 |
Rinat Neuroscience Corp. |
Methods for treating post-surgical pain by administering a nerve growth factor antagonist and compositions containing the same
|
BR0314614A
(en)
*
|
2002-10-10 |
2005-07-26 |
Wyeth Corp |
Compositions, organisms and methodologies employing a new human kinase
|
AU2003300027A1
(en)
*
|
2002-10-10 |
2004-05-04 |
Wyeth |
Compositions, organisms and methodologies employing a novel human kinase
|
AU2003301348A1
(en)
*
|
2002-10-18 |
2004-05-04 |
Wyeth |
Compositions and methods for diagnosing and treating autoimmune disease
|
CA2503491A1
(en)
*
|
2002-10-24 |
2004-05-06 |
Wyeth |
Calcineurin-like human phosphoesterase
|
EP1562970A4
(en)
*
|
2002-11-01 |
2006-04-12 |
Univ Pennsylvania |
COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF HIF-1 ALPHA
|
US7892793B2
(en)
*
|
2002-11-04 |
2011-02-22 |
University Of Massachusetts |
Allele-specific RNA interference
|
AU2003287505A1
(en)
|
2002-11-05 |
2004-06-03 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
US9150606B2
(en)
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
|
AU2003291753B2
(en)
|
2002-11-05 |
2010-07-08 |
Isis Pharmaceuticals, Inc. |
Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
|
US9150605B2
(en)
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
|
CA2505330A1
(en)
|
2002-11-05 |
2004-05-27 |
Isis Pharmaceuticals, Inc. |
Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
|
GB0225799D0
(en)
*
|
2002-11-05 |
2002-12-11 |
Novartis Forschungsstiftung |
Tel/etv6-mediated inhibition of cell proliferation
|
US7781575B2
(en)
|
2002-11-14 |
2010-08-24 |
Dharmacon, Inc. |
siRNA targeting tumor protein 53 (p53)
|
US7592442B2
(en)
*
|
2002-11-14 |
2009-09-22 |
Dharmacon, Inc. |
siRNA targeting ribonucleotide reductase M2 polypeptide (RRM2 or RNR-R2)
|
US8090542B2
(en)
*
|
2002-11-14 |
2012-01-03 |
Dharmacon Inc. |
Functional and hyperfunctional siRNA
|
US7691998B2
(en)
*
|
2002-11-14 |
2010-04-06 |
Dharmacon, Inc. |
siRNA targeting nucleoporin 62kDa (Nup62)
|
US9771586B2
(en)
|
2002-11-14 |
2017-09-26 |
Thermo Fisher Scientific Inc. |
RNAi targeting ZNF205
|
US20090227780A1
(en)
*
|
2002-11-14 |
2009-09-10 |
Dharmacon, Inc. |
siRNA targeting connexin 43
|
US9228186B2
(en)
|
2002-11-14 |
2016-01-05 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
US8198427B1
(en)
|
2002-11-14 |
2012-06-12 |
Dharmacon, Inc. |
SiRNA targeting catenin, beta-1 (CTNNB1)
|
US9719092B2
(en)
|
2002-11-14 |
2017-08-01 |
Thermo Fisher Scientific Inc. |
RNAi targeting CNTD2
|
US20100113307A1
(en)
*
|
2002-11-14 |
2010-05-06 |
Dharmacon, Inc. |
siRNA targeting vascular endothelial growth factor (VEGF)
|
US7612196B2
(en)
*
|
2002-11-14 |
2009-11-03 |
Dharmacon, Inc. |
siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)
|
US9719094B2
(en)
|
2002-11-14 |
2017-08-01 |
Thermo Fisher Scientific Inc. |
RNAi targeting SEC61G
|
US7619081B2
(en)
*
|
2002-11-14 |
2009-11-17 |
Dharmacon, Inc. |
siRNA targeting coatomer protein complex, subunit beta 2 (COPB2)
|
US20080268457A1
(en)
*
|
2002-11-14 |
2008-10-30 |
Dharmacon, Inc. |
siRNA targeting forkhead box P3 (FOXP3)
|
WO2006006948A2
(en)
*
|
2002-11-14 |
2006-01-19 |
Dharmacon, Inc. |
METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
|
US9879266B2
(en)
|
2002-11-14 |
2018-01-30 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
US9839649B2
(en)
|
2002-11-14 |
2017-12-12 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
US7951935B2
(en)
|
2002-11-14 |
2011-05-31 |
Dharmacon, Inc. |
siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC)
|
US7635770B2
(en)
*
|
2002-11-14 |
2009-12-22 |
Dharmacon, Inc. |
siRNA targeting protein kinase N-3 (PKN-3)
|
US7977471B2
(en)
*
|
2002-11-14 |
2011-07-12 |
Dharmacon, Inc. |
siRNA targeting TNFα
|
US10011836B2
(en)
|
2002-11-14 |
2018-07-03 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
US20040214198A1
(en)
*
|
2002-11-15 |
2004-10-28 |
University Of Massachusetts |
Allele-targeted RNA interference
|
CA2505416A1
(en)
*
|
2002-11-21 |
2004-06-10 |
Wyeth |
Methods for diagnosing rcc and other solid tumors
|
US7365186B2
(en)
*
|
2002-11-22 |
2008-04-29 |
Arborgen, Llc |
Vascular-preferred promoter sequences and uses thereof
|
AU2003298718A1
(en)
*
|
2002-11-22 |
2004-06-18 |
University Of Massachusetts |
Modulation of hiv replication by rna interference
|
CA2506617C
(en)
*
|
2002-11-24 |
2012-03-06 |
Daiichi Pharmaceutical Co., Ltd. |
Colon cancer metastasis inhibitor
|
EP2112229A3
(en)
|
2002-11-25 |
2009-12-02 |
Sequenom, Inc. |
Methods for identifying risk of breast cancer and treatments thereof
|
US7605249B2
(en)
*
|
2002-11-26 |
2009-10-20 |
Medtronic, Inc. |
Treatment of neurodegenerative disease through intracranial delivery of siRNA
|
US7217807B2
(en)
*
|
2002-11-26 |
2007-05-15 |
Rosetta Genomics Ltd |
Bioinformatically detectable group of novel HIV regulatory genes and uses thereof
|
US20050048641A1
(en)
*
|
2002-11-26 |
2005-03-03 |
Medtronic, Inc. |
System and method for delivering polynucleotides to the central nervous system
|
EP1576179B1
(en)
|
2002-11-27 |
2010-09-15 |
Irm Llc |
Methods and compositions for inducing apoptosis in cancer cells
|
US7297525B2
(en)
|
2002-11-27 |
2007-11-20 |
Wyeth |
Composition employing a novel human kinase
|
US20040110698A1
(en)
*
|
2002-12-10 |
2004-06-10 |
Kimron Veterinary Institute |
Oligonucleotides and methods using same for treating cox-ll associated diseases
|
JP2006509504A
(en)
*
|
2002-12-11 |
2006-03-23 |
ユニバーシティー オブ マサチューセッツ |
Method for introducing siRNA into adipocytes
|
EP2218779A1
(en)
|
2002-12-16 |
2010-08-18 |
Halozyme, Inc. |
Human chondroitinase glycoprotein (chasegp), process for preparing the same, and pharmaceutical compositions comprising thereof
|
US7078234B2
(en)
|
2002-12-18 |
2006-07-18 |
Monsanto Technology Llc |
Maize embryo-specific promoter compositions and methods for use thereof
|
US20040176293A1
(en)
*
|
2002-12-18 |
2004-09-09 |
Wyeth |
Methods for screening, treating and diagnosing inflammatory bowel disease and compositions thereof
|
CN1301263C
(en)
*
|
2002-12-18 |
2007-02-21 |
北京昭衍新药研究中心 |
Nucleotide sequence for anti HIV infection and preventing AIDS and use thereof
|
US7569364B2
(en)
*
|
2002-12-24 |
2009-08-04 |
Pfizer Inc. |
Anti-NGF antibodies and methods using same
|
US9498530B2
(en)
|
2002-12-24 |
2016-11-22 |
Rinat Neuroscience Corp. |
Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
|
NZ587852A
(en)
|
2002-12-24 |
2012-02-24 |
Rinat Neuroscience Corp |
Anti-NGF antibodies and methods using same
|
CN101018864A
(en)
|
2002-12-26 |
2007-08-15 |
先正达合作有限公司 |
Cell proliferation-related polypeptides and uses therefor
|
US20040248299A1
(en)
*
|
2002-12-27 |
2004-12-09 |
Sumedha Jayasena |
RNA interference
|
WO2004061423A2
(en)
*
|
2003-01-06 |
2004-07-22 |
Wyeth |
Compositions and methods for diagnosing and treating colon cancers
|
US20040220129A1
(en)
*
|
2003-01-16 |
2004-11-04 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for siRNA inhibition of ICAM-1
|
US8198077B2
(en)
*
|
2003-01-17 |
2012-06-12 |
Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. |
Inducible small RNA expression constructs for targeted gene silencing
|
JP3792655B2
(en)
*
|
2003-01-20 |
2006-07-05 |
日本電気株式会社 |
Novel oncogene, recombinant protein derived from the oncogene, and uses thereof
|
US20040147027A1
(en)
*
|
2003-01-28 |
2004-07-29 |
Troy Carol M. |
Complex for facilitating delivery of dsRNA into a cell and uses thereof
|
WO2004070062A2
(en)
*
|
2003-02-04 |
2004-08-19 |
Wyeth |
Compositions and methods for diagnosing and treating cancers
|
AU2004211949A1
(en)
*
|
2003-02-05 |
2004-08-26 |
University Of Massachusetts |
RNAi targeting of viruses
|
WO2004070025A2
(en)
*
|
2003-02-05 |
2004-08-19 |
Juan Saus |
Novel goodpasture antigen-binding protein isoforms and protein misfolded-mediated disorders
|
US20070104688A1
(en)
|
2003-02-13 |
2007-05-10 |
City Of Hope |
Small interfering RNA mediated transcriptional gene silencing in mammalian cells
|
US20040171118A1
(en)
*
|
2003-02-13 |
2004-09-02 |
City Of Hope |
Methods for directing DNA methylation in mammalian cells using homologous short double stranded RNAs
|
EP1592708A2
(en)
|
2003-02-14 |
2005-11-09 |
Sagres Discovery, Inc. |
Therapeutic gpcr targets in cancer
|
KR20050111598A
(en)
*
|
2003-02-19 |
2005-11-25 |
리나트 뉴로사이언스 코퍼레이션 |
Methods for treating pain by administering a nerve growth factor antagonist and an nsaid and compositions containing the same
|
WO2005017127A2
(en)
*
|
2003-02-21 |
2005-02-24 |
The Penn State Research Foundation |
Rna interference compositions and methods
|
US20040261149A1
(en)
*
|
2003-02-24 |
2004-12-23 |
Fauquet Claude M. |
siRNA-mediated inhibition of gene expression in plant cells
|
WO2004076639A2
(en)
*
|
2003-02-26 |
2004-09-10 |
Wyeth |
Use of gene expression profiling in the diagnosis and treatment of lupus nephritis and systemic lupus erythematosus
|
EP1599586B9
(en)
|
2003-02-28 |
2012-03-14 |
Oncotherapy Science, Inc. |
Rna-interference for znfn3a1-gene as a method for inhibiting cancer cell growth
|
US7645588B2
(en)
|
2003-03-04 |
2010-01-12 |
Calcimedica, Inc. |
Composition comprising a cell comprising a STIM1 protein and an agent that modulates intracellular calcium and methods of use
|
NZ542873A
(en)
|
2003-03-05 |
2008-07-31 |
Halozyme Inc |
Soluble, neutral-active hyaluronidase activity glycoprotein (sHASEGP) that is produced with high yield in a mammalian expression system by introducing nucleic acids that lack a narrow region encoding amino acids in the carboxy terminus of the human PH20 cDNA
|
NZ542665A
(en)
*
|
2003-03-05 |
2008-05-30 |
Senesco Technologies Inc |
Use of antisense oligonucleotides or siRNA to suppress expression of eIF-5A1
|
US7871607B2
(en)
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
EP1727898A4
(en)
*
|
2003-03-06 |
2009-11-04 |
Diversa Corp |
Amylases, nucleic acids encoding them and methods for making and using them
|
US20050164212A1
(en)
*
|
2003-03-06 |
2005-07-28 |
Todd Hauser |
Modulation of gene expression using DNA-RNA hybrids
|
EP3023498B1
(en)
|
2003-03-06 |
2018-11-28 |
BASF Enzymes LLC |
Amylases, nucleic acids encoding them and methods for making and using them
|
BRPI0408157B8
(en)
|
2003-03-07 |
2021-05-25 |
Dsm Food Specialties B V |
recombinant nucleic acid, recombinant polypeptide with lipase activity, transformed cell, methods employing them and composition
|
WO2004081200A2
(en)
*
|
2003-03-13 |
2004-09-23 |
University Of Utah Research Foundation |
Phospholipid scramblase 3
|
US8653252B2
(en)
|
2003-03-21 |
2014-02-18 |
Santaris Pharma A/S |
Short interfering RNA (siRNA) analogues
|
US20040248168A1
(en)
*
|
2003-03-25 |
2004-12-09 |
Wei Liu |
Novel brain-localized protein kinases homologous to homeodomain-interacting protein kinases
|
AU2004225480A1
(en)
*
|
2003-03-26 |
2004-10-14 |
Multicell Immunotherapeutics, Inc. |
Selected RNA motifs to include cell death and/or apoptosis
|
WO2004087903A2
(en)
*
|
2003-03-28 |
2004-10-14 |
Wyeth |
Novel proteins homologous to kinase suppressor of ras
|
EP2116606B1
(en)
|
2003-03-28 |
2012-12-19 |
Monsanto Technology, LLC |
Novel plant promoters for use in early seed development
|
WO2004087862A2
(en)
*
|
2003-04-01 |
2004-10-14 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Tak1-mediated inhibition of osteogenesis
|
EP1615670A4
(en)
|
2003-04-01 |
2006-12-13 |
Intradigm Corp |
Targets for tumor growth inhibition
|
EP1608733B1
(en)
*
|
2003-04-02 |
2011-12-07 |
Dharmacon, Inc. |
Modified polynucleotides for use in rna interference
|
US8158420B2
(en)
|
2003-04-04 |
2012-04-17 |
The Trustees Of Columbia University In The City Of New York |
Methods for inhibiting the differentation of proliferative telencephalic cells in vitro by addition of ATF5
|
ES2545639T3
(en)
|
2003-04-04 |
2015-09-14 |
Basf Enzymes Llc |
Pectate liases, nucleic acids that encode them and methods for their preparation and use
|
WO2004091515A2
(en)
*
|
2003-04-09 |
2004-10-28 |
Alnylam Pharmaceuticals, Inc. |
iRNA CONJUGATES
|
EP1615611B1
(en)
*
|
2003-04-09 |
2013-02-13 |
Alnylam Pharmaceuticals Inc. |
iRNA CONJUGATES
|
JP4912873B2
(en)
*
|
2003-04-09 |
2012-04-11 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
iRNA complex
|
US20070270360A1
(en)
*
|
2003-04-15 |
2007-11-22 |
Sirna Therapeutics, Inc. |
Rna Interference Mediated Inhibition of Severe Acute Respiratory Syndrome (Sars) Gene Expression Using Short Interfering Nucleic Acid
|
EP1469070A1
(en)
*
|
2003-04-15 |
2004-10-20 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Livin-specific siRNAs for the treatment of therapy-resistant tumors
|
JP2006523464A
(en)
*
|
2003-04-18 |
2006-10-19 |
ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア |
Compositions and methods for siRNA inhibition of angiopoietins 1, 2 and their receptor TIE2
|
IL155561A0
(en)
*
|
2003-04-24 |
2006-12-31 |
Yeda Res & Dev |
Oligonucleotides that block toll-like receptors
|
PL1623228T3
(en)
|
2003-04-29 |
2013-04-30 |
Biocrine Ab |
Apociii and the treatment and diagnosis of diabetes
|
WO2004098634A2
(en)
*
|
2003-04-30 |
2004-11-18 |
Government Of The United States Of America As Represented By The Sercretary Of The Department Of Health And Human Services National Institutes Of Health |
Protein arginine n-methyltransferase 2 (prmt-2)
|
EP1622572B1
(en)
|
2003-04-30 |
2017-12-20 |
Sirna Therapeutics, Inc. |
Conjugates and compositions for cellular delivery
|
EP1629283A2
(en)
*
|
2003-05-08 |
2006-03-01 |
Wyeth |
Protein kinase c zeta as a drug target for arthritis and other inflammatory diseases
|
US8067371B2
(en)
*
|
2003-05-09 |
2011-11-29 |
The Trustees Of Columbia University In The City Of New York |
RAGE G82S-related methods and compositions for treating inflammatory disorders
|
ATE516047T1
(en)
|
2003-05-09 |
2011-07-15 |
Diadexus Inc |
OVR110 ANTIBODY COMPOSITIONS AND METHODS OF USE
|
CA2523785A1
(en)
*
|
2003-05-09 |
2004-11-25 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Small interfering rna libraries and methods of synthesis and use
|
CN1780920B
(en)
*
|
2003-05-12 |
2012-03-28 |
波多玛克制药有限公司 |
Gene expression suppression agents
|
CA2525619A1
(en)
*
|
2003-05-16 |
2005-03-03 |
Rosetta Inpharmatics, Llc |
Methods and compositions for rna interference
|
US20070027099A1
(en)
*
|
2003-05-19 |
2007-02-01 |
Lin Marie C |
Gene therapy of HBV infection via adeno-associated viral vector mediated long term expression of small hairpin RNA (shRNA)
|
CA2526490C
(en)
|
2003-05-19 |
2014-03-04 |
The Trustees Of Columbia University In The City Of New York |
Compositions and methods for treating and preventing heart tissue degeneration, and uses thereof
|
WO2005001092A2
(en)
*
|
2003-05-20 |
2005-01-06 |
Wyeth |
Compositions and methods for diagnosing and treating cancers
|
JP4638876B2
(en)
*
|
2003-05-23 |
2011-02-23 |
ワイス |
GITR ligand, GITR ligand-related molecule and antibody and use thereof
|
US20050042641A1
(en)
*
|
2003-05-27 |
2005-02-24 |
Cold Spring Harbor Laboratory |
In vivo high throughput selection of RNAi probes
|
ATE449842T1
(en)
*
|
2003-05-28 |
2009-12-15 |
Takeda Pharmaceutical |
ANTI-BAMBI ANTIBODIES OR RNA FOR DIAGNOSIS AND THERAPY OF COLON OR LIVER CANCER
|
WO2005001110A2
(en)
*
|
2003-05-29 |
2005-01-06 |
The Salk Institute For Biological Studies |
Transcriptional regulation of gene expression by small double-stranded modulatory rna
|
WO2004111192A2
(en)
*
|
2003-05-29 |
2004-12-23 |
The Scripps Research Institute |
Targeted delivery to legumain-expressing cells
|
WO2004106511A1
(en)
|
2003-05-30 |
2004-12-09 |
Nippon Shinyaku Co., Ltd. |
OLIGO DOUBLE-STRANDED RNA INHIBITING THE EXPRESSION OF Bcl-2 AND MEDICINAL COMPOSITION CONTAINING THE SAME
|
AU2004248136B2
(en)
*
|
2003-06-02 |
2011-09-15 |
University Of Massachusetts |
Methods and compositions for controlling efficacy of RNA silencing
|
US7750144B2
(en)
|
2003-06-02 |
2010-07-06 |
University Of Massachusetts |
Methods and compositions for enhancing the efficacy and specificity of RNA silencing
|
DE602004029678D1
(en)
*
|
2003-06-02 |
2010-12-02 |
Univ Massachusetts |
METHOD AND COMPOSITIONS FOR IMPROVING THE EFFICIENCY AND SPECIFICITY OF FNAI
|
WO2005002507A2
(en)
|
2003-06-03 |
2005-01-13 |
Isis Pharmaceuticals, Inc. |
Modulation of survivin expression
|
WO2004106517A1
(en)
*
|
2003-06-03 |
2004-12-09 |
Benitec Australia Limited |
Double-stranded nucleic acid
|
JP4909072B2
(en)
*
|
2003-06-06 |
2012-04-04 |
アーバージェン インコーポレイテッド |
Transcription factor
|
KR20060031809A
(en)
|
2003-06-09 |
2006-04-13 |
더 리젠츠 오브 더 유니버시티 오브 미시간 |
Compositions and methods for treating and diagnosing cancer
|
DK2270162T3
(en)
|
2003-06-12 |
2019-01-21 |
Alnylam Pharmaceuticals Inc |
PRESERVED HBV AND HCV SEQUENCES USED FOR GEN-SILENCING
|
US20050039228A1
(en)
*
|
2003-06-19 |
2005-02-17 |
The Samuel Roberts Noble Foundation |
Methods and compositions for analysis of plant gene function
|
US20060241072A1
(en)
*
|
2003-06-20 |
2006-10-26 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds for use in gene modulation
|
EP1636385A4
(en)
*
|
2003-06-24 |
2010-06-02 |
Mirus Bio Corp |
Inhibition of gene function by delivery of polynucleotide-based gene expression inhibitors to mammalian cells in vivo
|
US20080131874A1
(en)
*
|
2003-06-24 |
2008-06-05 |
Amitava Mitra |
Method for efficient post-transcriptional gene silencing using intrinsic direct repeat sequences and utilization thereof in functional genomics
|
WO2005001062A2
(en)
*
|
2003-06-25 |
2005-01-06 |
Gencia Corporation |
Modified vectors for organelle transfection
|
JP5183064B2
(en)
*
|
2003-07-02 |
2013-04-17 |
エムユーエスシー ファウンデイション フォー リサーチ デべロップメント |
Specific and non-specific immunity induced by dsRNA in crustaceans and other invertebrates, and biological delivery vehicles used therein
|
EP2404929B1
(en)
|
2003-07-02 |
2014-06-18 |
BP Corporation North America Inc. |
Glucanases, nucleic acids encoding them and methods for making and using them
|
US20050019927A1
(en)
*
|
2003-07-13 |
2005-01-27 |
Markus Hildinger |
DECREASING GENE EXPRESSION IN A MAMMALIAN SUBJECT IN VIVO VIA AAV-MEDIATED RNAi EXPRESSION CASSETTE TRANSFER
|
US20050026290A1
(en)
*
|
2003-08-01 |
2005-02-03 |
Ciardi Joseph Anthony |
Inhibiting gene expression with dsRNA
|
EP1654368A2
(en)
|
2003-08-01 |
2006-05-10 |
BASF Plant Science GmbH |
Process for the production of fine chemicals
|
JP2007517763A
(en)
*
|
2003-08-01 |
2007-07-05 |
エイアンドジー ファーマスーティカル インコーポレイテッド |
Compositions and methods for restoring sensitivity to treatment with HER2 antagonists
|
US7888121B2
(en)
|
2003-08-08 |
2011-02-15 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
JP4555292B2
(en)
|
2003-08-08 |
2010-09-29 |
サンガモ バイオサイエンシズ インコーポレイテッド |
Methods and compositions for targeted cleavage and recombination
|
WO2005021714A2
(en)
|
2003-08-11 |
2005-03-10 |
Diversa Corporation |
Laccases, nucleic acids encoding them and methods for making and using them
|
EP1651674B1
(en)
|
2003-08-14 |
2010-09-29 |
Exelixis, Inc. |
Ups as modifiers of the beta catenin pathway and methods of use
|
IL157538A0
(en)
*
|
2003-08-21 |
2004-03-28 |
Bar Ilan Res & Dev Company Ltd |
Plant resistant to cytoplasm-feeding parasites
|
US20050112763A1
(en)
*
|
2003-08-21 |
2005-05-26 |
Cold Spring Harbor Laboratory |
RNAI-based modification of heterochromatin
|
CA2536026A1
(en)
*
|
2003-08-22 |
2005-05-06 |
Nucleonics Inc. |
Eukariotic expression systems for expression of inhibitory rna in multiple intracellular compartments
|
JP2007503803A
(en)
*
|
2003-08-28 |
2007-03-01 |
ノバルティス アクチエンゲゼルシャフト |
Interfering RNA duplexes with blunt ends and 3 'modifications
|
WO2005021767A1
(en)
*
|
2003-08-28 |
2005-03-10 |
Genpath Pharmaceuticals, Inc. |
Tumor-specific expression of reporter genes
|
US20070123480A1
(en)
*
|
2003-09-11 |
2007-05-31 |
Replicor Inc. |
Oligonucleotides targeting prion diseases
|
WO2005026322A2
(en)
*
|
2003-09-11 |
2005-03-24 |
Clontech Laboratories, Inc. |
siRNA ENCODING CONSTRUCTS AND METHODS FOR USING THE SAME
|
NZ546564A
(en)
*
|
2003-09-12 |
2010-02-26 |
Commw Scient Ind Res Org |
Modified gene-silencing nucleic acid molecules and uses thereof
|
ES2808561T3
(en)
*
|
2003-09-12 |
2021-03-01 |
Univ Massachusetts |
RNA interference for the treatment of gain-of-function disorders
|
US8680063B2
(en)
|
2003-09-12 |
2014-03-25 |
University Of Massachusetts |
RNA interference for the treatment of gain-of-function disorders
|
EP1682573B1
(en)
|
2003-09-15 |
2014-01-01 |
Cenix Bioscience GmbH |
The use of eukaryotic genes affecting cell cycle control or cell cycle progression for diagnosis and treatment of proliferattive diseases
|
CA2539300A1
(en)
*
|
2003-09-16 |
2005-03-24 |
Pharmacia Corporation |
Inhibitors of pace4 for the treatment of arthritis
|
JP2007505634A
(en)
*
|
2003-09-22 |
2007-03-15 |
ロゼッタ インファーマティクス エルエルシー |
Synthetic lethal screening using RNA interference
|
US20050282168A1
(en)
*
|
2003-09-29 |
2005-12-22 |
Wyeth |
Cell surface molecules as markers and therapeutic agents against kidney cancers
|
KR20060100370A
(en)
*
|
2003-09-30 |
2006-09-20 |
다카라 바이오 가부시키가이샤 |
Polypeptide having rnase iii activity
|
WO2005032486A2
(en)
*
|
2003-10-02 |
2005-04-14 |
Duke University |
A NOVEL SIRNA-BASED APPROACH TO TARGET THE HIF-α FACTOR FOR GENE THERAPY
|
WO2005038013A1
(en)
*
|
2003-10-07 |
2005-04-28 |
Isis Pharmaceuticals, Inc. |
Artisense oligonucleotides optimized for kidney targeting
|
US20060218673A9
(en)
*
|
2003-10-09 |
2006-09-28 |
E.I. Du Pont De Nemours And Company |
Gene silencing
|
CN1910293B
(en)
|
2003-10-23 |
2011-04-13 |
伊洛默格生物科学公司 |
Detection of mutations in a gene associated with resistance to viral infection, OASI
|
AU2004297533B2
(en)
|
2003-10-24 |
2010-04-29 |
Gencia Corporation |
Methods and compositions for delivering polynucleotides
|
US8133733B2
(en)
|
2003-10-24 |
2012-03-13 |
Gencia Corporation |
Nonviral vectors for delivering polynucleotides to target tissues
|
US8062891B2
(en)
*
|
2003-10-24 |
2011-11-22 |
Gencia Corporation |
Nonviral vectors for delivering polynucleotides to plants
|
US8507277B2
(en)
*
|
2003-10-24 |
2013-08-13 |
Gencia Corporation |
Nonviral vectors for delivering polynucleotides
|
US20090123468A1
(en)
*
|
2003-10-24 |
2009-05-14 |
Gencia Corporation |
Transducible polypeptides for modifying metabolism
|
US20090208478A1
(en)
*
|
2003-10-24 |
2009-08-20 |
Gencia Corporation |
Transducible polypeptides for modifying metabolism
|
US7962316B2
(en)
|
2003-10-27 |
2011-06-14 |
Merck Sharp & Dohme Corp. |
Method of designing siRNAs for gene silencing
|
US7553822B2
(en)
*
|
2003-10-30 |
2009-06-30 |
The United States Of America As Represented By The Department Of Health And Human Services |
Compositions and methods for inhibiting translation of a Mect1-MAML2 chimeric gene
|
US8012944B2
(en)
*
|
2003-10-30 |
2011-09-06 |
Pharmascience Inc. |
Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent
|
WO2005042782A1
(en)
*
|
2003-10-31 |
2005-05-12 |
The Trustees Of Columbia University In The City Of New York |
Methods for reducing seizure-induced neuronal damage
|
WO2005042722A2
(en)
*
|
2003-10-31 |
2005-05-12 |
University Of Florida Research Foundation, Inc. |
Materials and methods for improved sweet corn
|
US20050191653A1
(en)
*
|
2003-11-03 |
2005-09-01 |
Freier Susan M. |
Modulation of SGLT2 expression
|
US8227434B1
(en)
|
2003-11-04 |
2012-07-24 |
H. Lee Moffitt Cancer Center & Research Institute, Inc. |
Materials and methods for treating oncological disorders
|
GB2422607A
(en)
*
|
2003-11-10 |
2006-08-02 |
Univ Utah Res Found |
Improved methods and compositions for RNA interference
|
CA2546067A1
(en)
*
|
2003-11-14 |
2005-06-02 |
Yale University |
Fcyriia-specific nucleic acid interference
|
US7807646B1
(en)
*
|
2003-11-20 |
2010-10-05 |
University Of South Florida |
SHIP-deficiency to increase megakaryocyte progenitor production
|
US7763592B1
(en)
*
|
2003-11-20 |
2010-07-27 |
University Of South Florida |
SHIP-deficiency to increase megakaryocyte progenitor production
|
CN1972593A
(en)
*
|
2003-11-21 |
2007-05-30 |
雷维维科公司 |
Use of interfering RNA in the production of transgenic animals
|
WO2005054439A2
(en)
*
|
2003-12-01 |
2005-06-16 |
North Carolina State University |
Small interfering rna (sirna)-mediated heritable gene manipulation in plants
|
WO2005054438A2
(en)
*
|
2003-12-01 |
2005-06-16 |
Invitrogen Corporation |
Nucleic acid molecules containing recombination sites and methods of using the same
|
US8034789B2
(en)
|
2003-12-03 |
2011-10-11 |
Coda Therapeutics, Inc. |
Antisense compounds targeted to connexins and methods of use thereof
|
GB2423522A
(en)
*
|
2003-12-10 |
2006-08-30 |
Univ Utah Res Found |
Method for obtaining an enriched population of sirna-expressing cells
|
WO2005059157A2
(en)
*
|
2003-12-11 |
2005-06-30 |
The Board Of Trustees Of The Leland Stanford Junior University |
METHODS AND COMPOSITIONS FOR USE IN PREPARING HAIRPIN RNAs
|
JP4753130B2
(en)
*
|
2003-12-12 |
2011-08-24 |
独立行政法人産業技術総合研究所 |
Long interfering double-stranded RNA with reduced interferon response
|
US20050164970A1
(en)
*
|
2003-12-22 |
2005-07-28 |
University Of Kansas Medical Center |
Method for treating prostate cancer using siRNA duplex for androgen receptor
|
WO2005062937A2
(en)
*
|
2003-12-22 |
2005-07-14 |
University Of Massachusetts |
Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended sirna
|
US20060134787A1
(en)
|
2004-12-22 |
2006-06-22 |
University Of Massachusetts |
Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended siRNA
|
FR2872383B1
(en)
*
|
2004-07-02 |
2015-10-16 |
Bayer Cropscience Sa |
METHOD FOR MODIFYING GENE EXPRESSION OF PHYTOPATHOGENIC FUNGI
|
BRPI0416713B8
(en)
*
|
2003-12-23 |
2020-02-04 |
Bayer Sas |
methods of producing a plant or plant cell resistant to a phytopathogenic fungus, methods to inhibit or reduce the expression of a fungus gene and use of a construct
|
EP1701611B1
(en)
|
2003-12-24 |
2011-05-18 |
G2 Inflammation Pty Ltd |
Transgenic non-human mammal comprising a polynucleotide encoding human or humanized c5ar
|
US7700280B2
(en)
|
2003-12-31 |
2010-04-20 |
The Penn State Research Foundation |
Methods for assessing cisplatin resistance, disease progression, and treatment efficacy in ovarian cancer
|
WO2005069872A2
(en)
*
|
2004-01-15 |
2005-08-04 |
Washington University |
High throughput pharmaceutical screening using drosophila
|
US20080153764A1
(en)
*
|
2004-01-22 |
2008-06-26 |
The Cbr Institute For Biomedical Research, Inc. |
System and Methods For Short Rna Expression
|
WO2005090606A2
(en)
*
|
2004-01-23 |
2005-09-29 |
Dharmacon, Inc. |
Identification of toxic nucleotide sequences
|
WO2005072272A2
(en)
|
2004-01-23 |
2005-08-11 |
New England Biolabs, Inc. |
Compositions and methods for generating short double-stranded rna using mutated rnase iii
|
DK1713912T3
(en)
*
|
2004-01-30 |
2013-12-16 |
Santaris Pharma As |
Modified Short Interfering RNA (Modified siRNA)
|
EP1758998B1
(en)
*
|
2004-01-30 |
2010-12-15 |
Quark Pharmaceuticals, Inc. |
Oligoribonucleotides and methods of use thereof for treatment of fibrotic conditions and other diseases
|
ATE447024T1
(en)
*
|
2004-02-06 |
2009-11-15 |
Dharmacon Inc |
STABILIZED RNAS AS TRANSFECTION CONTROLS AND SILENCING REAGENTS
|
CA2555145A1
(en)
|
2004-02-06 |
2005-08-25 |
Wyeth |
Diagnosis and therapeutics for cancer
|
US20090280567A1
(en)
*
|
2004-02-06 |
2009-11-12 |
Dharmacon, Inc. |
Stabilized sirnas as transfection controls and silencing reagents
|
US20060075515A1
(en)
*
|
2004-08-11 |
2006-04-06 |
Luethy Michael H |
Enhanced zein reduction in transgenic corn seed
|
US7683237B2
(en)
*
|
2004-02-10 |
2010-03-23 |
Monsanto Technology Llc |
Maize seed with synergistically enhanced lysine content
|
AR047598A1
(en)
|
2004-02-10 |
2006-01-25 |
Monsanto Technology Llc |
TRANSGENIZED CORN SEED WITH GREATER AMINO ACID CONTENT
|
US7858769B2
(en)
|
2004-02-10 |
2010-12-28 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using multifunctional short interfering nucleic acid (multifunctional siNA)
|
US7855323B2
(en)
*
|
2004-02-10 |
2010-12-21 |
Monsanto Technology Llc |
Recombinant DNA for gene suppression
|
WO2005078848A2
(en)
|
2004-02-11 |
2005-08-25 |
University Of Tennessee Research Foundation |
Inhibition of tumor growth and invasion by anti-matrix metalloproteinase dnazymes
|
EP1766032B1
(en)
|
2004-02-13 |
2012-10-10 |
Monsanto Technology, LLC |
In vivo assembly of transcription units
|
WO2005094420A2
(en)
*
|
2004-02-17 |
2005-10-13 |
University Of South Florida |
Materials and methods for treatment of inflammatory and cell proliferation disorders
|
US7622301B2
(en)
*
|
2004-02-24 |
2009-11-24 |
Basf Plant Science Gmbh |
Compositions and methods using RNA interference for control of nematodes
|
WO2005082415A2
(en)
|
2004-02-25 |
2005-09-09 |
Dana Farber Cancer Institute, Inc. |
Inhibitors of insulin-like growth factor receptor-1 for inhibiting tumor cell growth
|
US20060003956A1
(en)
*
|
2004-03-03 |
2006-01-05 |
Casadome David O |
Materials and methods for the derepression of the E-cadherin promoter
|
US8569474B2
(en)
*
|
2004-03-09 |
2013-10-29 |
Isis Pharmaceuticals, Inc. |
Double stranded constructs comprising one or more short strands hybridized to a longer strand
|
EP1735009A4
(en)
|
2004-03-12 |
2011-03-30 |
Alnylam Pharmaceuticals Inc |
iRNA AGENTS TARGETING VEGF
|
US20070265220A1
(en)
|
2004-03-15 |
2007-11-15 |
City Of Hope |
Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
|
WO2005089287A2
(en)
*
|
2004-03-15 |
2005-09-29 |
City Of Hope |
Methods and compositions for the specific inhibition of gene expression by double-stranded rna
|
WO2005089443A2
(en)
*
|
2004-03-19 |
2005-09-29 |
The Penn State Research Foundation |
Combinatorial methods and compositions for treatment of melanoma
|
US7851452B2
(en)
*
|
2004-03-22 |
2010-12-14 |
The Trustees Of The University Of Pennsylvania |
Methods of use of bcl-6-derived nucleotides to induce apoptosis
|
ATE496142T1
(en)
*
|
2004-03-23 |
2011-02-15 |
Oncotherapy Science Inc |
METHOD FOR DIAGNOSING NON-SMALL CELL LUNG CANCER
|
EP1730534A2
(en)
|
2004-03-24 |
2006-12-13 |
Oncotherapy Science, Inc. |
Compositions and methods for treating lung cancer
|
DE602005023426D1
(en)
|
2004-03-25 |
2010-10-21 |
California Inst Of Techn |
Hybridization CHAIN REACTION
|
US20060041961A1
(en)
|
2004-03-25 |
2006-02-23 |
Abad Mark S |
Genes and uses for pant improvement
|
KR101147147B1
(en)
*
|
2004-04-01 |
2012-05-25 |
머크 샤프 앤드 돔 코포레이션 |
Modified polynucleotides for reducing off-target effects in rna interference
|
JP5223072B2
(en)
|
2004-04-02 |
2013-06-26 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
Methods and compositions for treating and preventing diseases associated with avβ5 integrin
|
PL1732949T3
(en)
|
2004-04-07 |
2010-06-30 |
Rinat Neuroscience Corp |
Methods for treating bone cancer pain by administering a nerve growth factor antagonist
|
EP1818405B1
(en)
|
2004-04-09 |
2015-06-03 |
Monsanto Technology, LLC |
Compositions and methods for control of insect infestations in plants
|
WO2005117938A2
(en)
*
|
2004-04-13 |
2005-12-15 |
Regents Of The University Of Minnesota |
Methods of treating ocular conditions
|
US20070031417A2
(en)
*
|
2004-04-14 |
2007-02-08 |
University Of Massachusetts |
Dicer interacting proteins and uses therefor
|
US20050233994A1
(en)
*
|
2004-04-16 |
2005-10-20 |
Ajamete Kaykas |
Methods and vectors for expressing siRNA
|
WO2006019430A2
(en)
*
|
2004-04-20 |
2006-02-23 |
Nastech Pharmaceutical Company Inc. |
Methods and compositions for enhancing delivery of double-stranded rna or a double-stranded hybrid nucleic acid to regulate gene expression in mammalian cells
|
CA2562673A1
(en)
*
|
2004-04-22 |
2005-11-03 |
Yissum Research Development Company Of The Hebrew University Of Jerusal Em |
Universal target sequences for sirna gene silencing
|
EP2357244A3
(en)
|
2004-04-22 |
2011-11-23 |
Commonwealth Scientific and Industrial Research Organisation |
Synthesis of long-chain polyunsaturated fatty acids by recombinant cells.
|
CA2557532A1
(en)
|
2004-04-23 |
2005-11-10 |
Angela M. Christiano |
Inhibition of hairless protein mrna
|
BRPI0510152A
(en)
|
2004-04-23 |
2007-10-02 |
Ceres Inc |
methods for modifying plant characteristics
|
US8076304B2
(en)
*
|
2004-04-26 |
2011-12-13 |
The Regents Of The University Of Colorado |
Methods and compositions for the diagnosis and treatment of cyclin A-1 associated conditions
|
ES2427177T3
(en)
|
2004-04-27 |
2013-10-29 |
Galapagos N.V. |
Methods, agents and tests for the detection of compounds to induce differentiation of undifferentiated mammalian cells to give rise to osteoblasts
|
US20060182783A1
(en)
*
|
2004-04-30 |
2006-08-17 |
Allergan, Inc. |
Sustained release intraocular drug delivery systems
|
US20060035815A1
(en)
*
|
2004-05-04 |
2006-02-16 |
Nastech Pharmaceutical Company Inc. |
Pharmaceutical compositions for delivery of ribonucleic acid to a cell
|
US20060040882A1
(en)
*
|
2004-05-04 |
2006-02-23 |
Lishan Chen |
Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
|
CA2566866A1
(en)
*
|
2004-05-11 |
2006-03-09 |
Wyeth |
Novel polynucleotides related to oligonucleotide arrays to monitor gene expression
|
US7605250B2
(en)
*
|
2004-05-12 |
2009-10-20 |
Dharmacon, Inc. |
siRNA targeting cAMP-specific phosphodiesterase 4D
|
WO2005113571A2
(en)
*
|
2004-05-13 |
2005-12-01 |
The University Of North Carolina At Chapel Hill |
Methods for the delivery of oligomeric compounds
|
US8563252B2
(en)
*
|
2004-05-14 |
2013-10-22 |
Rosetta Genomics Ltd. |
Methods for distinguishing between lung squamous carcinoma and other non small cell lung cancers
|
EP1784501B1
(en)
|
2004-05-14 |
2015-11-18 |
Rosetta Genomics Ltd |
VIRAL AND VIRUS ASSOCIATED MicroRNAS AND USES THEREOF
|
EP2325331A1
(en)
|
2004-05-14 |
2011-05-25 |
Rosetta Genomics Ltd |
MicroRNAs and Uses Thereof
|
US20050265927A1
(en)
*
|
2004-05-17 |
2005-12-01 |
Yale University |
Intranasal delivery of nucleic acid molecules
|
US7563885B1
(en)
*
|
2004-05-24 |
2009-07-21 |
Isis Pharmaceuticals, Inc. |
Modulation of Tudor-SN expression
|
US10508277B2
(en)
|
2004-05-24 |
2019-12-17 |
Sirna Therapeutics, Inc. |
Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
|
US7964196B2
(en)
*
|
2004-05-25 |
2011-06-21 |
Chimeros, Inc. |
Self-assembling nanoparticle drug delivery system
|
EP2290073A3
(en)
*
|
2004-05-28 |
2011-08-31 |
Asuragen, Inc. |
Methods and compositions involving microRNA
|
WO2005121372A2
(en)
*
|
2004-06-03 |
2005-12-22 |
Isis Pharmaceuticals, Inc. |
Double strand compositions comprising differentially modified strands for use in gene modulation
|
US8394947B2
(en)
*
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
US7858323B2
(en)
|
2004-06-09 |
2010-12-28 |
The Regents Of The University Of Michigan |
Phage microarray profiling of the humoral response to disease
|
US20060040876A1
(en)
|
2004-06-10 |
2006-02-23 |
Rong-Hwa Lin |
Modulation of peroxisome proliferator-activated receptors
|
CN103173282A
(en)
|
2004-06-16 |
2013-06-26 |
帝斯曼知识产权资产管理有限公司 |
Compositions and methods for enzymatic decolorization of chlorophyll
|
US20060156421A1
(en)
*
|
2004-06-18 |
2006-07-13 |
Cagan Ross L |
High throughput screening methods for anti-metastatic compounds
|
US20060010505A1
(en)
*
|
2004-06-18 |
2006-01-12 |
Washington University |
High throughput cancer pharmaceutical screening using drosophila
|
AU2005253776B8
(en)
|
2004-06-21 |
2012-02-02 |
King's College London |
Screening methods using c-Abl, Fyn and Syk in combination with tau protein
|
WO2006009575A1
(en)
|
2004-06-22 |
2006-01-26 |
The Board Of Trustees Of The University Of Illinois |
METHODS OF INHIBITING TUMOR CELL PROLIFERATION WITH FOXM1 siRNA
|
WO2006069610A2
(en)
|
2004-07-02 |
2006-07-06 |
Metanomics Gmbh |
Process for the production of fine chemicals
|
US8680062B2
(en)
|
2004-07-06 |
2014-03-25 |
Deliversir Ltd. |
System for delivering therapeutic agents into living cells and cells nuclei
|
US7968762B2
(en)
*
|
2004-07-13 |
2011-06-28 |
Van Andel Research Institute |
Immune-compromised transgenic mice expressing human hepatocyte growth factor (hHGF)
|
CA2571856A1
(en)
*
|
2004-07-20 |
2006-02-09 |
Wyeth |
Methods of identifying patients at risk of developing encephalitis following immunotherapy for alzheimer's disease
|
US20060024677A1
(en)
|
2004-07-20 |
2006-02-02 |
Morris David W |
Novel therapeutic targets in cancer
|
WO2007001324A2
(en)
|
2004-07-23 |
2007-01-04 |
The University Of North Carolina At Chapel Hill |
Methods and materials for determining pain sensitivity and predicting and treating related disorders
|
EP2412816B1
(en)
|
2004-07-26 |
2014-12-03 |
Pfenex Inc. |
Process for improved protein expression by strain engineering
|
DE102004036456A1
(en)
*
|
2004-07-28 |
2006-03-23 |
Basf Plant Science Gmbh |
Method for producing transgenic plants with increased pathogen resistance by changing the content and / or the activity of actin-depolymerizing factors
|
US20060075522A1
(en)
|
2004-07-31 |
2006-04-06 |
Jaclyn Cleveland |
Genes and uses for plant improvement
|
EP1781784A2
(en)
|
2004-08-02 |
2007-05-09 |
BASF Plant Science GmbH |
Method for isolation of transcription termination sequences
|
CA2576193A1
(en)
|
2004-08-03 |
2006-02-16 |
Biogen Idec Ma Inc. |
Taj in neuronal function
|
BRPI0514342A2
(en)
*
|
2004-08-13 |
2009-10-06 |
Basf Plant Science Gmbh |
double stranded rna molecule, grouping of double stranded rna molecules, transgenic plant, and methods for controlling a parasitic nematode's infection of a plant and for manufacturing a transgenic plant
|
AU2005277508B2
(en)
*
|
2004-08-16 |
2011-04-14 |
Quark Pharmaceuticals, Inc |
Therapeutic uses of inhibitors of RTP801
|
ATE518954T1
(en)
*
|
2004-08-18 |
2011-08-15 |
Lorus Therapeutics Inc |
SMALL INTERFERING RNA MOLECULES AGAINST RIBONUCLEOTIDE REDUCTASE AND THEIR USES
|
DE602005024015D1
(en)
|
2004-08-23 |
2010-11-18 |
Alnylam Pharmaceuticals Inc |
EXPRESSION CONSTRUCTS WITH SEVERAL RNA POLYMERASE III PROMOTERS
|
US20080222743A1
(en)
*
|
2004-08-25 |
2008-09-11 |
Avigenics, Inc. |
RNA interference and disease resistance in avians
|
US20090313712A1
(en)
*
|
2004-08-25 |
2009-12-17 |
Leandro Christmann |
RNA interference and disease resistance in avians
|
US20060046247A1
(en)
*
|
2004-08-25 |
2006-03-02 |
Rapp Jeffrey C |
Protecting avians from pathogens
|
US20060046248A1
(en)
*
|
2004-08-25 |
2006-03-02 |
Avigenics, Inc. |
RNA interference in avians
|
US7323310B2
(en)
*
|
2004-08-31 |
2008-01-29 |
Qiagen North American Holdings, Inc. |
Methods and compositions for RNA amplification and detection using an RNA-dependent RNA-polymerase
|
US7884086B2
(en)
*
|
2004-09-08 |
2011-02-08 |
Isis Pharmaceuticals, Inc. |
Conjugates for use in hepatocyte free uptake assays
|
US20060059585A1
(en)
|
2004-09-14 |
2006-03-16 |
Boris Jankowski |
Modulating plant sugar levels
|
US7595433B2
(en)
|
2004-09-14 |
2009-09-29 |
Ceres, Inc. |
Modulations of amino acid and sugar content in plants
|
FI20041204A0
(en)
|
2004-09-16 |
2004-09-16 |
Riikka Lund |
Methods for the utilization of new target genes associated with immune-mediated diseases
|
JP5085326B2
(en)
|
2004-09-18 |
2012-11-28 |
ユニバーシティ オブ メリーランド,ボルチモア |
Treatment agent targeting NCCa-ATP channel and method of use thereof
|
ATE486606T1
(en)
|
2004-09-18 |
2010-11-15 |
Univ Maryland |
THERAPEUTIC AGENTS FOR TARGETING THE NCCA ATP CHANNEL AND METHOD OF USE THEREOF
|
US7402428B2
(en)
*
|
2004-09-22 |
2008-07-22 |
Arborgen, Llc |
Modification of plant lignin content
|
US7799906B1
(en)
|
2004-09-22 |
2010-09-21 |
Arborgen, Llc |
Compositions and methods for modulating lignin of a plant
|
US7456338B2
(en)
*
|
2004-09-22 |
2008-11-25 |
Arborgen Llc |
Modification of plant lignin content
|
CA2579927A1
(en)
|
2004-09-24 |
2006-03-30 |
Basf Plant Science Gmbh |
Plant cells and plants with increased tolerance to environmental stress
|
CN102643818B
(en)
*
|
2004-09-28 |
2014-04-09 |
夸克制药公司 |
Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases
|
WO2006039399A2
(en)
*
|
2004-09-29 |
2006-04-13 |
University Of Rochester |
Staufen 1 (stau1) - mediated mrna decay
|
WO2006039582A2
(en)
*
|
2004-09-30 |
2006-04-13 |
The Regents Of The University Of California |
Compositions and methods for diagnosing and treating brain cancer and identifying neural stem cells
|
US8765704B1
(en)
|
2008-02-28 |
2014-07-01 |
Novartis Ag |
Modified small interfering RNA molecules and methods of use
|
CA2581651C
(en)
*
|
2004-10-01 |
2014-12-16 |
Novartis Vaccines And Diagnostics, Inc. |
Cholesterol-labelled modified rna
|
CN101056981A
(en)
*
|
2004-10-04 |
2007-10-17 |
德福根有限公司 |
Method for down-regulating gene expression in fungi
|
WO2006070227A2
(en)
*
|
2004-10-04 |
2006-07-06 |
Devgen Nv |
Method for down-regulating gene expression in fungi
|
US20060247197A1
(en)
|
2004-10-04 |
2006-11-02 |
Van De Craen Marc |
Method for down-regulating gene expression in fungi
|
EP1645633B1
(en)
|
2004-10-05 |
2011-09-21 |
SunGene GmbH |
Constitutive expression cassettes for regulation of plant expression
|
US8975471B2
(en)
*
|
2004-10-12 |
2015-03-10 |
The Rockefeller University |
MicroRNAs
|
WO2006044531A2
(en)
*
|
2004-10-13 |
2006-04-27 |
Isis Parmaceuticals, Inc. |
Antisense modulation of ptp1b expression
|
EP1799029B1
(en)
*
|
2004-10-13 |
2012-05-16 |
University Of Georgia Research Foundation, Inc. |
Nematode resistant transgenic plants
|
US7429692B2
(en)
|
2004-10-14 |
2008-09-30 |
Ceres, Inc. |
Sucrose synthase 3 promoter from rice and uses thereof
|
AU2005299492B2
(en)
|
2004-10-21 |
2011-09-01 |
Venganza, Inc. |
Methods and materials for conferring resistance to pests and pathogens of plants
|
US7790878B2
(en)
*
|
2004-10-22 |
2010-09-07 |
Alnylam Pharmaceuticals, Inc. |
RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof
|
US7592322B2
(en)
*
|
2004-10-22 |
2009-09-22 |
Alnylam Pharmaceuticals, Inc. |
RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof
|
US8772254B2
(en)
*
|
2004-10-25 |
2014-07-08 |
Devgen N.V. |
Method and constructs for delivering double stranded RNA to pest organisms
|
MX2007005069A
(en)
*
|
2004-10-27 |
2007-06-25 |
Schering Corp |
Compositions and methods for short interfering nucleic acid inhibition of nav1.8.
|
US9492400B2
(en)
*
|
2004-11-04 |
2016-11-15 |
Massachusetts Institute Of Technology |
Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
|
EP2302055B1
(en)
|
2004-11-12 |
2014-08-27 |
Asuragen, Inc. |
Methods and compositions involving miRNA and miRNA inhibitor molecules
|
WO2008073922A2
(en)
*
|
2006-12-08 |
2008-06-19 |
Asuragen, Inc. |
Functions and targets of let-7 micro rnas
|
CN101060849A
(en)
*
|
2004-11-17 |
2007-10-24 |
巴尔的摩马里兰大学 |
Highly branched HK peptides as effective carriers of siRNA
|
JP4851940B2
(en)
*
|
2004-11-19 |
2012-01-11 |
宮城県 |
Pharmaceutical composition for the treatment of cancer or diabetes
|
US7935811B2
(en)
*
|
2004-11-22 |
2011-05-03 |
Dharmacon, Inc. |
Apparatus and system having dry gene silencing compositions
|
US7923206B2
(en)
*
|
2004-11-22 |
2011-04-12 |
Dharmacon, Inc. |
Method of determining a cellular response to a biological agent
|
US7923207B2
(en)
|
2004-11-22 |
2011-04-12 |
Dharmacon, Inc. |
Apparatus and system having dry gene silencing pools
|
EP1662000B1
(en)
|
2004-11-25 |
2011-03-30 |
SunGene GmbH |
Expression cassettes for guard cell-preferential expression in plants
|
WO2006060454A2
(en)
*
|
2004-12-02 |
2006-06-08 |
B-Bridge International, Inc. |
Methods of designing small interfering rnas, antisense polynucleotides, and other hybridizing polynucleotides
|
EP1666599A3
(en)
|
2004-12-04 |
2006-07-12 |
SunGene GmbH |
Expression cassettes for mesophyll- and/or epidermis-preferential expression in plants
|
US7329797B2
(en)
|
2004-12-08 |
2008-02-12 |
Ceres, Inc. |
Modulating plant carbon levels
|
EP2163634A1
(en)
|
2004-12-08 |
2010-03-17 |
SunGene GmbH |
Expression cassettes for vascular tissue-preferential expression in plants
|
US9758790B2
(en)
|
2004-12-08 |
2017-09-12 |
Ceres, Inc. |
Modulating the level of components within plants
|
EP1669456A3
(en)
|
2004-12-11 |
2006-07-12 |
SunGene GmbH |
Expression cassettes for meristem-preferential expression in plants
|
AU2005316863A1
(en)
|
2004-12-16 |
2006-06-22 |
Ceres Inc. |
Modulating plant nitrogen levels
|
EP1974049A2
(en)
|
2004-12-17 |
2008-10-01 |
Metanomics GmbH |
Process for the control of production of fine chemicals
|
US20060200878A1
(en)
|
2004-12-21 |
2006-09-07 |
Linda Lutfiyya |
Recombinant DNA constructs and methods for controlling gene expression
|
US8404927B2
(en)
*
|
2004-12-21 |
2013-03-26 |
Monsanto Technology Llc |
Double-stranded RNA stabilized in planta
|
WO2006069253A2
(en)
*
|
2004-12-22 |
2006-06-29 |
Auckland Uniservices Limited |
Trefoil factors and methods of treating proliferation disorders using same
|
ATE507293T1
(en)
|
2004-12-22 |
2011-05-15 |
Alnylam Pharmaceuticals Inc |
CONSERVED HBV AND HCV SEQUENCES SUITABLE FOR GENE SILENCING
|
US7335760B2
(en)
|
2004-12-22 |
2008-02-26 |
Ceres, Inc. |
Nucleic acid sequences encoding zinc finger proteins
|
TWI386225B
(en)
*
|
2004-12-23 |
2013-02-21 |
Alcon Inc |
Rnai inhibition of ctgf for treatment of ocular disorders
|
TWI401316B
(en)
*
|
2004-12-23 |
2013-07-11 |
Alcon Inc |
Rnai inhibition of serum amyloid a for treatment of glaucoma
|
US20060142228A1
(en)
*
|
2004-12-23 |
2006-06-29 |
Ambion, Inc. |
Methods and compositions concerning siRNA's as mediators of RNA interference
|
MX2007007948A
(en)
|
2004-12-28 |
2007-09-11 |
Pioneer Hi Bred Int |
Improved grain quality through altered expression of seed proteins.
|
MX2007008065A
(en)
*
|
2004-12-30 |
2008-03-04 |
Todd M Hauser |
Compositions and methods for modulating gene expression using self-protected oligonucleotides.
|
US8252742B2
(en)
|
2004-12-30 |
2012-08-28 |
Hill's Pet Nutrition, Inc. |
Methods for enhancing the quality of life of a senior animal
|
US8137907B2
(en)
|
2005-01-03 |
2012-03-20 |
Cold Spring Harbor Laboratory |
Orthotopic and genetically tractable non-human animal model for liver cancer and the uses thereof
|
JP2008526883A
(en)
|
2005-01-07 |
2008-07-24 |
ディアデクサス インコーポレーテッド |
Ovr110 antibody compositions and methods of use
|
EP2487243A3
(en)
*
|
2005-01-07 |
2013-08-28 |
Alnylam Pharmaceuticals Inc. |
RNAI modulation of RSV and therapeutic uses thereof
|
EP2584033A1
(en)
|
2005-01-12 |
2013-04-24 |
Monsanto Technology LLC |
Genes and uses for plant improvement
|
MX2007008486A
(en)
|
2005-01-13 |
2008-02-15 |
Pioneer Hi Bred Int |
Maize cyclo1 gene and promoter.
|
US7554018B2
(en)
|
2005-01-14 |
2009-06-30 |
University Of Guelph |
Nitrogen-regulated sugar sensing gene and protein and modulation thereof
|
WO2006113679A2
(en)
*
|
2005-04-15 |
2006-10-26 |
Board Of Regents, The University Of Texas System |
Delivery of sirna by neutral lipid compositions
|
US7718625B2
(en)
*
|
2005-01-27 |
2010-05-18 |
University Of South Florida |
Polynucleotides targeted against the extended 5′-UTR region of argininosuccinate synthase and uses thereof
|
TW200639252A
(en)
*
|
2005-02-01 |
2006-11-16 |
Alcon Inc |
RNAi-mediated inhibition of ocular hypertension targets
|
CN108324923A
(en)
|
2005-02-03 |
2018-07-27 |
科达治疗有限公司 |
Anti- connection proteinate and its treatment use
|
EP2147977A1
(en)
|
2005-02-09 |
2010-01-27 |
BASF Plant Science GmbH |
Expression cassettes for regulation of expression in monocotyledonous plants
|
BRPI0606991A2
(en)
|
2005-02-14 |
2009-08-18 |
Wyeth Corp |
methods for screening test compounds capable of antagonizing il-17f signaling, to diagnose a disorder related to increased il-17f signaling in an individual, in vitro to inhibit at least one activity associated with il-21 signaling, in vitro to inhibit at least one activity associated with il-23 signaling, to purify the natural il-17a protein, and to isolate il-17a / il-17f heterodimers substantially free of il-17a homodimers and il-17f, use of a therapeutically effective amount of an il-17f signaling antagonist, pharmaceutical composition, vaccine adjuvant, isolated antibody, isolated il-17f and il-17a proteins, and il-17a / il-heterodimer. 17f
|
CA2597411C
(en)
|
2005-02-14 |
2014-08-12 |
University Of Iowa Research Foundation |
Use of complement factor h polymorphisms in treatment and diagnosis of age-related macular degeneration
|
EP1849011A2
(en)
*
|
2005-02-14 |
2007-10-31 |
University of Pittsburgh of the Commonwealth System of Higher Education |
Use of il-17f in diagnosis and therapy of airway inflammation
|
US20060211004A1
(en)
|
2005-02-15 |
2006-09-21 |
Ilsley Diane D |
Methods and compositions for determining non-specific cytotoxicity of a transfection agent
|
US8088976B2
(en)
|
2005-02-24 |
2012-01-03 |
Monsanto Technology Llc |
Methods for genetic control of plant pest infestation and compositions thereof
|
US8519225B2
(en)
|
2006-02-10 |
2013-08-27 |
Monsanto Technology Llc |
Identification and use of target genes for control of plant parasitic nematodes
|
US20090031440A1
(en)
|
2005-02-26 |
2009-01-29 |
Basf Plant Science Gmbh |
Expression Cassettes for Seed-Preferential Expression in Plants
|
EP2045327B8
(en)
|
2005-03-08 |
2012-03-14 |
BASF Plant Science GmbH |
Expression enhancing intron sequences
|
US7727721B2
(en)
*
|
2005-03-08 |
2010-06-01 |
California Institute Of Technology |
Hybridization chain reaction amplification for in situ imaging
|
BRPI0607985A2
(en)
|
2005-03-10 |
2009-10-27 |
Genentech Inc |
dscr1 modulator, treatment methods, side effect amelioration method and tumor growth inhibition method
|
EP2886658A1
(en)
|
2005-03-10 |
2015-06-24 |
BASF Enzymes LLC |
Lyase enzymes, nucleic acids encoding them and methods for making and using them
|
DE202005004135U1
(en)
*
|
2005-03-11 |
2005-05-19 |
Klocke Verpackungs-Service Gmbh |
Multi-component packaging with applicator
|
AU2006223131A1
(en)
*
|
2005-03-11 |
2006-09-21 |
Alcon, Inc. |
RNAi-mediated inhibition of frizzled related protein-1 for treatment of glaucoma
|
DE102005011648A1
(en)
*
|
2005-03-14 |
2006-09-21 |
IPK-Institut für Pflanzengenetik und Kulturpflanzenforschung |
A method of increasing fungal resistance in transgenic plants by host-induced suppression of gene expression in fungal pathogens
|
WO2006130201A1
(en)
*
|
2005-03-14 |
2006-12-07 |
Board Of Regents, The University Of Texas System |
Antigene oligomers inhibit transcription
|
BRPI0609140A2
(en)
|
2005-03-15 |
2010-02-17 |
Verenium Corp |
cellulases, nucleic acids that encode them and methods for their production and use
|
SI2567976T1
(en)
|
2005-03-23 |
2017-11-30 |
Genmab A/S |
Antibodies against CD38 for treatment of multiple myeloma
|
US20060223777A1
(en)
*
|
2005-03-29 |
2006-10-05 |
Dharmacon, Inc. |
Highly functional short hairpin RNA
|
JP4131271B2
(en)
*
|
2005-03-30 |
2008-08-13 |
ソニー株式会社 |
Information processing apparatus and method, and program
|
RU2533804C2
(en)
*
|
2005-03-31 |
2014-11-20 |
Ронен КАХАНА |
Producing poultry and other animals resistant to viral diseases
|
WO2006105361A2
(en)
|
2005-03-31 |
2006-10-05 |
Calando Pharmaceuticals, Inc. |
Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
|
EP2062591A1
(en)
|
2005-04-07 |
2009-05-27 |
Novartis Vaccines and Diagnostics, Inc. |
CACNA1E in cancer diagnosis detection and treatment
|
EP1871911A2
(en)
|
2005-04-07 |
2008-01-02 |
Chiron Corporation |
Cancer-related genes (prlr)
|
US20060234973A1
(en)
*
|
2005-04-14 |
2006-10-19 |
Kevin Fitzgerald |
Transcription factor RNA interference reagents and methods of use thereof
|
WO2006112879A2
(en)
*
|
2005-04-15 |
2006-10-26 |
The Trustees Of The University Of Pennsylvania |
Hunk, a snf1-related kinase essential for mammary tumor metastasis
|
EP1873240B1
(en)
|
2005-04-15 |
2011-12-28 |
National University Corporation Tottori University |
hTERT GENE EXPRESSION REGULATORY GENE
|
WO2006113743A2
(en)
*
|
2005-04-18 |
2006-10-26 |
Massachusetts Institute Of Technology |
Compositions and methods for rna interference with sialidase expression and uses thereof
|
US20060269556A1
(en)
*
|
2005-04-18 |
2006-11-30 |
Karl Nocka |
Mast cell activation using siglec 6 antibodies
|
US8034994B2
(en)
|
2005-04-19 |
2011-10-11 |
Basf Plant Science Gmbh |
Starchy-endosperm and/or germinating embryo-specific expression in mono-cotyledonous plants
|
BRPI0608829A2
(en)
|
2005-04-19 |
2011-03-15 |
Basf Plant Science Gmbh |
method for transgenic expression with enhanced specificity in a plant, use of a chimeric nucleic acid construct, chimeric ribonucleotide sequence, expression construct, expression vector, nonhuman organism or transformed cell, transformed seed, and pharmaceutical preparation
|
BRPI0614070A2
(en)
|
2005-05-10 |
2018-07-31 |
Basf Plant Science Gmbh |
expression cassettes, isolated nucleotide sequence, synthetic transcriptional regulatory sequence, methods for providing a synthetic transcriptional regulatory nucleotide sequence, and an expression cassette, vector, non-human organism or transgenic host cell (a), and, cell of plant or transgenic plant
|
WO2006124726A2
(en)
*
|
2005-05-12 |
2006-11-23 |
The General Hospital Corporation |
Novel biotinylated compositions
|
EP1888052A2
(en)
|
2005-05-12 |
2008-02-20 |
Wisconsin Alumni Research Foundation |
Blockade of pin1 prevents cytokine production by activated immune cells
|
FR2885808B1
(en)
|
2005-05-19 |
2007-07-06 |
Oreal |
VECTORIZATION OF DSRNA BY CATIONIC PARTICLES AND TOPICAL USE.
|
WO2007001684A2
(en)
*
|
2005-05-19 |
2007-01-04 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Inhibiting dna polymerase beta to enhance efficacy of anticancer agents
|
WO2006129204A2
(en)
|
2005-05-31 |
2006-12-07 |
Devgen Nv |
Rnai for control of insects and arachnids
|
EP1896587A2
(en)
|
2005-05-31 |
2008-03-12 |
Cold Spring Harbor Laboratory |
METHODS FOR PRODUCING MICRORNAs
|
CN101213300B
(en)
|
2005-06-01 |
2013-01-23 |
聚加转染股份有限公司 |
Oligonucleotides for RNA interference and biological applications thereof
|
US20070020660A1
(en)
*
|
2005-06-06 |
2007-01-25 |
Burczynski Michael E |
Expression profiles of peripheral blood mononuclear cells for inflammatory bowel diseases
|
WO2006132606A1
(en)
*
|
2005-06-09 |
2006-12-14 |
Agency For Science, Technology And Research |
Hepatic stellate cell specific promoter and uses thereof
|
US20070299029A1
(en)
*
|
2005-06-09 |
2007-12-27 |
Agency For Science, Technology And Research |
Hepatic stellate cell specific promoter and uses thereof
|
US20070014776A1
(en)
*
|
2005-06-09 |
2007-01-18 |
Gimeno Ruth E |
Identification of adiponutrin-related proteins as esterases and methods of use for the same
|
US20100266574A1
(en)
*
|
2005-06-10 |
2010-10-21 |
Orna Mor |
Oligoribonucleotides and Methods of Use Thereof for Treatment of Fibrotic Conditions and Other Diseases
|
US8124111B2
(en)
*
|
2005-06-10 |
2012-02-28 |
Children's Hospital & Research Center At Oakland |
Immunomodulation by altering sphingosine 1-phosphate lyase (SPL) activity
|
CA2612021A1
(en)
*
|
2005-06-13 |
2006-12-28 |
The Regents Of The University Of Michigan |
Compositions and methods for treating and diagnosing cancer
|
ES2267390B1
(en)
*
|
2005-06-16 |
2008-03-16 |
Universidad Politecnica De Valencia |
INSULATION AND CHARACTERIZATION OF MUTANT CSB3-1 OF THALIAN ARABIDOPSIS, AND ITS USE AS A REGULATOR OF THE RESISTANCE IN PLANTS TO DISEASES PRODUCED BY BIOTROPHIC PATHOGENS.
|
WO2006136596A2
(en)
|
2005-06-23 |
2006-12-28 |
Basf Plant Science Gmbh |
Improved methods for the production of stably transformed, fertile zea mays plants
|
US20080280843A1
(en)
|
2006-05-24 |
2008-11-13 |
Van Bilsen Paul |
Methods and kits for linking polymorphic sequences to expanded repeat mutations
|
WO2007005613A2
(en)
*
|
2005-07-01 |
2007-01-11 |
Promega Corporation |
Network of buoyant particles for biomolecule purification
|
EP1915448B1
(en)
*
|
2005-07-07 |
2013-09-04 |
Yissum Research Development Company, of The Hebrew University of Jerusalem |
Nucleic acid agents for downregulating h19, and methods of using same
|
WO2007011702A2
(en)
|
2005-07-15 |
2007-01-25 |
The University Of North Carolina At Chapel Hill |
Use of egfr inhibitors to prevent or treat obesity
|
EP1913149A4
(en)
*
|
2005-07-26 |
2009-08-05 |
Sangamo Biosciences Inc |
Targeted integration and expression of exogenous nucleic acid sequences
|
EP1907580A2
(en)
*
|
2005-07-28 |
2008-04-09 |
Oncotherapy Science, Inc. |
Method for diagnosing and treating renal cell carcinoma
|
US20090176725A1
(en)
*
|
2005-08-17 |
2009-07-09 |
Sirna Therapeutics Inc. |
Chemically modified short interfering nucleic acid molecules that mediate rna interference
|
CN101277614A
(en)
|
2005-08-18 |
2008-10-01 |
阿塞莱洛克斯公司 |
Methods for bone treatment by modulating an arachidonic acid metabolic or signaling pathway
|
US20070161591A1
(en)
|
2005-08-18 |
2007-07-12 |
University Of Massachusetts |
Methods and compositions for treating neurological disease
|
TW200801201A
(en)
*
|
2005-08-23 |
2008-01-01 |
Illumigen Biosciences Inc |
Detection of mutations in a gene associated with resistance to viral infection, OAS2 or OAS3
|
WO2007025231A2
(en)
*
|
2005-08-26 |
2007-03-01 |
The Trustees Of The University Of Pennsylvania |
Methods using snail transcriptional repressor
|
WO2007028147A2
(en)
*
|
2005-09-01 |
2007-03-08 |
Philadelphia Health & Education Corporation D.B.A. Drexel University College Of Medicin |
Identification of a prostatic intraepithelial neoplasia (pin)-specific gene and protein (pin-1) useful as a diagnostic treatment for prostate cancer
|
AU2006285606A1
(en)
|
2005-09-01 |
2007-03-08 |
Suntory Holdings Limited |
Tryptophan transporter gene and use thereof
|
US20090018097A1
(en)
*
|
2005-09-02 |
2009-01-15 |
Mdrna, Inc |
Modification of double-stranded ribonucleic acid molecules
|
US8222028B2
(en)
|
2005-09-08 |
2012-07-17 |
Chromatin, Inc. |
Plants modified with mini-chromosomes
|
CA2814598A1
(en)
|
2005-09-12 |
2007-03-22 |
The Regents Of The University Of Michigan |
Recurrent gene fusions in prostate cancer
|
KR20080082956A
(en)
|
2005-09-15 |
2008-09-12 |
노보솜 아게 |
Improvements in or relating to amphoteric liposomes
|
AU2006292362B2
(en)
|
2005-09-16 |
2013-02-14 |
Monsanto Technology Llc |
Methods for genetic control of insect infestations in plants and compositions thereof
|
ES2545093T3
(en)
|
2005-09-16 |
2015-09-08 |
Devgen N.V. |
Transgenic plant-based methods for plant pests using RNAi
|
EP2372363A1
(en)
|
2005-09-20 |
2011-10-05 |
OSI Pharmaceuticals, Inc. |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1
|
CN101268194A
(en)
|
2005-09-20 |
2008-09-17 |
巴斯福植物科学有限公司 |
Methods for controlling gene expression using ta-siRNA
|
CA2660661A1
(en)
|
2005-09-26 |
2007-04-05 |
The Trustees Of Columbia University In The City Of New York |
Side population cells in cardiac repair
|
AU2006297173A1
(en)
*
|
2005-09-29 |
2007-04-12 |
Viral Logic Systems Technology Corp. |
Immunomodulatory compositions and uses therefor
|
UA102367C2
(en)
*
|
2005-10-03 |
2013-07-10 |
Монсанто Текнолоджи Ллс |
Transgenic corn seed with increased lysine content
|
EP1931806B1
(en)
|
2005-10-07 |
2011-10-05 |
California Institute Of Technology |
Pkr activation via hybridization chain reaction
|
EP1934348B1
(en)
*
|
2005-10-11 |
2018-05-02 |
Ben-Gurion University Of The Negev Research And Development Authority |
Compositions for silencing the expression of vdac1 and uses thereof
|
WO2007047706A2
(en)
|
2005-10-17 |
2007-04-26 |
Children's Hospital |
Methods and compositions for regulating gene expression
|
US7794951B2
(en)
*
|
2005-10-18 |
2010-09-14 |
University Of Massachusetts Medical School |
SREBP2gc transcription factors and uses thereof
|
CA2626304C
(en)
|
2005-10-20 |
2015-07-14 |
Commonwealth Scientific And Industrial Research Organisation |
Cereals with altered dormancy
|
US20080274469A1
(en)
|
2005-10-21 |
2008-11-06 |
The Regents Of The University Of California |
C-Kit Oncogene Mutations in Melanoma
|
ATE536373T1
(en)
*
|
2005-10-21 |
2011-12-15 |
Genzyme Corp |
ANTIBODIES-BASED THERAPEUTIC PRODUCTS WITH INCREASED ADCC ACTIVITY
|
US7723314B1
(en)
|
2005-10-28 |
2010-05-25 |
Transderm, Inc. |
Methods and compositions for treating pachyonychia congenita
|
WO2007051045A2
(en)
|
2005-10-28 |
2007-05-03 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of huntingtin gene
|
US7723112B2
(en)
|
2005-10-31 |
2010-05-25 |
The Regents Of The University Of Michigan |
Compositions and methods for treating and diagnosing cancer
|
HUE031122T2
(en)
|
2005-10-31 |
2017-07-28 |
Oncomed Pharm Inc |
Compositions and methods for treating cancer based on human fzd receptors
|
US7723477B2
(en)
*
|
2005-10-31 |
2010-05-25 |
Oncomed Pharmaceuticals, Inc. |
Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
|
EP1942948A4
(en)
|
2005-11-04 |
2010-03-03 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for inhibiting expression of nav1.8 gene
|
EP1948806A2
(en)
|
2005-11-08 |
2008-07-30 |
BASF Plant Science GmbH |
Use of armadillo repeat (arm1) polynucleotides for obtaining pathogen resistance in plants
|
ATE510545T1
(en)
|
2005-11-09 |
2011-06-15 |
Alnylam Pharmaceuticals Inc |
COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF FACTOR V LEIDEN MUTATION GENE
|
CN100447243C
(en)
*
|
2005-11-15 |
2008-12-31 |
中国人民解放军第四军医大学 |
HBV specificity interference target point gene and its siRNA and application in anti HBV infecting thereof
|
DK2641970T3
(en)
|
2005-11-17 |
2015-02-02 |
Univ Texas |
Modulation of gene expression by oligomers targeted to chromosomal DNA
|
US8916530B2
(en)
*
|
2005-11-18 |
2014-12-23 |
Gradalis, Inc. |
Individualized cancer therapy
|
US8603991B2
(en)
|
2005-11-18 |
2013-12-10 |
Gradalis, Inc. |
Individualized cancer therapy
|
WO2007060240A2
(en)
*
|
2005-11-25 |
2007-05-31 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Method for demonstrating presence or absence of markers (eef1a1 or mark3 )associated with the presence and/or the chemosensitivity of tumors
|
CN101374856A
(en)
*
|
2005-11-29 |
2009-02-25 |
斯克里普斯研究学院 |
Inhibiting tumor cell invasion, metastasis and angiogenesis
|
JP4737531B2
(en)
|
2005-12-05 |
2011-08-03 |
サントリーホールディングス株式会社 |
Method for producing ceramide using transformed yeast
|
EP1974024A2
(en)
|
2005-12-09 |
2008-10-01 |
BASF Plant Science GmbH |
Nucleic acid molecules encoding polypeptides involved in regulation of sugar and lipid metabolism and methods of use viii
|
WO2007067733A2
(en)
*
|
2005-12-09 |
2007-06-14 |
Massachusetts Institute Of Technology |
Compositions and methods to monitor rna delivery to cells
|
US8030034B2
(en)
|
2005-12-09 |
2011-10-04 |
Promega Corporation |
Nucleic acid purification with a binding matrix
|
US9267937B2
(en)
*
|
2005-12-15 |
2016-02-23 |
Massachusetts Institute Of Technology |
System for screening particles
|
BRPI0706368A2
(en)
|
2006-01-06 |
2011-03-22 |
Univ Georgia |
composition, vector, method for providing resistance to a plant's nematode cyst, fusion protein, method for inhibiting biological activity, isolated nucleic acid
|
JP5474356B2
(en)
|
2006-01-12 |
2014-04-16 |
デブジェン エヌブイ |
Method for controlling pests using RNAi
|
ES2464315T3
(en)
*
|
2006-01-12 |
2014-06-02 |
Basf Plant Science Gmbh |
Use of stomatin polynucleotides (STM1) to achieve resistance to pathogens in plants
|
JP5474355B2
(en)
|
2006-01-12 |
2014-04-16 |
デブジェン エヌブイ |
Genetically modified plant system method for plant pests using RNAi
|
US8906876B2
(en)
|
2006-01-12 |
2014-12-09 |
Devgen Nv |
Methods for controlling pests using RNAi
|
US20090060921A1
(en)
*
|
2006-01-17 |
2009-03-05 |
Biolex Therapeutics, Inc. |
Glycan-optimized anti-cd20 antibodies
|
EP1973940A2
(en)
|
2006-01-17 |
2008-10-01 |
Biolex Therapeutics, Inc. |
Compositions and methods for humanization and optimization of n-glycans in plants
|
CN100562342C
(en)
*
|
2006-01-17 |
2009-11-25 |
奥林格斯技术有限公司 |
The oligonucleotide drug of control influenza infection
|
US7825099B2
(en)
*
|
2006-01-20 |
2010-11-02 |
Quark Pharmaceuticals, Inc. |
Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
|
UY30097A1
(en)
|
2006-01-20 |
2007-08-31 |
Atugen Ag |
THERAPEUTIC USES OF RTP801 INHIBITORS
|
US8222482B2
(en)
|
2006-01-26 |
2012-07-17 |
Ceres, Inc. |
Modulating plant oil levels
|
JP2009524419A
(en)
*
|
2006-01-27 |
2009-07-02 |
サンタリス ファーマ アー/エス |
LNA modified phosphorothiolated oligonucleotides
|
BRPI0707276B1
(en)
|
2006-01-27 |
2021-08-31 |
Biogen Ma Inc |
NOGO RECEPTOR ANTAGONIST FUSION POLYPEPTIDE
|
WO2007092314A2
(en)
|
2006-02-02 |
2007-08-16 |
Verenium Corporation |
Esterases and related nucleic acids and methods
|
US20080022423A1
(en)
*
|
2006-02-03 |
2008-01-24 |
Monsanto Technology Llc |
IN PLANTA RNAi CONTROL OF FUNGI
|
DK2450439T3
(en)
|
2006-02-10 |
2014-02-10 |
Verenium Corp |
Cellulose-degrading enzymes, nucleic acids encoding them, and methods of preparing and utilizing them
|
CN101421406B
(en)
|
2006-02-13 |
2016-08-31 |
孟山都技术有限公司 |
For producing nucleic acid construct and the method that the seed oil of change forms
|
CA2836368C
(en)
|
2006-02-13 |
2020-04-07 |
Monsanto Technology Llc |
Method for managing crop pest resistance
|
US8043839B2
(en)
|
2006-02-14 |
2011-10-25 |
Verenium Corporation |
Xylanases, nucleic acids encoding them and methods for making and using them
|
US20070293657A1
(en)
*
|
2006-02-17 |
2007-12-20 |
Nastech Pharmaceutical Company Inc. |
Complexes and methods of forming complexes of ribonucleic acids and peptides
|
AU2006338876B2
(en)
|
2006-02-24 |
2011-08-04 |
Suntory Holdings Limited |
Ammonia transporter gene and use thereof
|
JP2009165352A
(en)
*
|
2006-02-24 |
2009-07-30 |
Suntory Liquors Ltd |
ACYL-CoA:ETHANOL O-ACYLTRANSFERASE/ESTERASE GENE AND USE THEREOF
|
WO2007120989A2
(en)
|
2006-02-24 |
2007-10-25 |
Ceres, Inc. |
Shade regulatory regions
|
EP1869072B1
(en)
|
2006-02-24 |
2012-10-03 |
Suntory Holdings Limited |
Gene encoding protein responsible for flocculation property of yeast and use thereof
|
WO2007099694A1
(en)
|
2006-02-24 |
2007-09-07 |
Suntory Limited |
Gene encoding protein responsible for flocculation property of yeast and use thereof
|
WO2007097093A1
(en)
*
|
2006-02-27 |
2007-08-30 |
Suntory Limited |
Branched amino acid transporter gene and use thereof
|
JPWO2007097095A1
(en)
*
|
2006-02-27 |
2009-07-09 |
サントリーホールディングス株式会社 |
Aromatic amino acid transporter gene and use thereof
|
WO2007103485A2
(en)
*
|
2006-03-08 |
2007-09-13 |
Promega Corporation |
Small rna purification
|
US7910566B2
(en)
*
|
2006-03-09 |
2011-03-22 |
Quark Pharmaceuticals Inc. |
Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA
|
US20100068172A1
(en)
*
|
2006-03-16 |
2010-03-18 |
Devgen N.V. |
Nematode Control
|
EP1999257B1
(en)
|
2006-03-20 |
2011-06-22 |
Novozymes, Inc. |
Polypeptides having endoglucanase activity and polynucleotides encoding same
|
WO2007107162A2
(en)
*
|
2006-03-23 |
2007-09-27 |
Santaris Pharma A/S |
Small internally segmented interfering rna
|
FR2898908A1
(en)
|
2006-03-24 |
2007-09-28 |
Agronomique Inst Nat Rech |
Process, useful to prepare differentiated avian cells from avian stem cells grown in culture medium, comprises induction of stem cells differentiation by inhibiting expression/activity of gene expressed in the stem cells e.g. Nanog gene
|
WO2007115201A2
(en)
|
2006-03-30 |
2007-10-11 |
Novozymes, Inc. |
Polypeptides having endoglucanase activity and polynucleotides encoding same
|
WO2007123777A2
(en)
|
2006-03-30 |
2007-11-01 |
Duke University |
Inhibition of hif-1 activation for anti-tumor and anti-inflammatory responses
|
KR20170061189A
(en)
|
2006-03-31 |
2017-06-02 |
알닐람 파마슈티칼스 인코포레이티드 |
DsRNA for inhibiting expression of Eg5 gene
|
JP2009534309A
(en)
|
2006-03-31 |
2009-09-24 |
マサチューセッツ インスティテュート オブ テクノロジー |
System for targeted delivery of therapeutic agents
|
CA2644273A1
(en)
|
2006-04-05 |
2008-03-27 |
Metanomics Gmbh |
Process for the production of a fine chemical
|
EP2010226B1
(en)
|
2006-04-07 |
2014-01-15 |
The Research Foundation of State University of New York |
Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
|
US9044461B2
(en)
|
2006-04-07 |
2015-06-02 |
The Research Foundation Of State University Of New York |
Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
|
CA2648581A1
(en)
*
|
2006-04-07 |
2008-09-12 |
Chimeros, Inc. |
Compositions and methods for treating b- cell malignancies
|
US7625874B2
(en)
*
|
2006-04-11 |
2009-12-01 |
The Regents Of The University Of California |
Compositions and methods for treating diseases associated with T-box and N-Myc
|
US20100055116A1
(en)
*
|
2006-04-13 |
2010-03-04 |
Liou Hsiou-Chi |
Methods and Compositions for Targeting c-Rel
|
AU2007238636A1
(en)
|
2006-04-13 |
2007-10-25 |
Novartis Vaccines & Diagnostics, Inc. |
Methods of treating, diagnosing or detecting cancer
|
CA2647685A1
(en)
*
|
2006-04-19 |
2007-11-01 |
Wyeth |
Short interfering rna duplexes targeting an ires sequence and uses thereof
|
US20080070268A1
(en)
*
|
2006-04-21 |
2008-03-20 |
Wyeth |
Differential expression profiling analysis of cell culture phenotypes and the uses thereof
|
GB0608838D0
(en)
|
2006-05-04 |
2006-06-14 |
Novartis Ag |
Organic compounds
|
US20070281900A1
(en)
*
|
2006-05-05 |
2007-12-06 |
Nastech Pharmaceutical Company Inc. |
COMPOSITIONS AND METHODS FOR LIPID AND POLYPEPTIDE BASED siRNA INTRACELLULAR DELIVERY
|
PL2032134T3
(en)
|
2006-05-09 |
2015-11-30 |
Genzyme Corp |
Methods of treating fatty liver disease comprising inhibiting glucosphingolipid synthesis
|
NZ587616A
(en)
|
2006-05-11 |
2012-03-30 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for inhibiting expression of the pcsk9 gene
|
GB0609498D0
(en)
*
|
2006-05-12 |
2006-06-21 |
Oncomethylome Sciences S A |
Novel methylation marker
|
JP5630998B2
(en)
|
2006-05-15 |
2014-11-26 |
マサチューセッツ インスティテュート オブ テクノロジー |
Polymers for functional particles
|
JPWO2007132867A1
(en)
|
2006-05-15 |
2009-09-24 |
杉本 芳一 |
Preventive and therapeutic agents for cancer
|
CA2652377C
(en)
|
2006-05-16 |
2014-04-22 |
Monsanto Technology Llc |
Use of non-agrobacterium bacterial species for plant transformation
|
WO2007137117A2
(en)
*
|
2006-05-17 |
2007-11-29 |
Massachusetts Institute Of Technology |
Aptamer-directed drug delivery
|
US20070286863A1
(en)
*
|
2006-05-17 |
2007-12-13 |
Christopher Sinal |
CMKLR regulation of adipogenesis and adipocyte metabolic function
|
US20070269892A1
(en)
*
|
2006-05-18 |
2007-11-22 |
Nastech Pharmaceutical Company Inc. |
FORMULATIONS FOR INTRACELLULAR DELIVERY dsRNA
|
CN101489566B
(en)
|
2006-05-19 |
2012-04-18 |
阿尔尼拉姆医药品有限公司 |
Rnai modulation of aha and therapeutic uses thereof
|
EP2018426B1
(en)
|
2006-05-19 |
2013-05-15 |
Alcon Research, Ltd. |
Rnai-mediated inhibition of tumor necrosis factor alpha-related conditions
|
CA2653451C
(en)
|
2006-05-22 |
2015-12-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of ikk-b gene
|
US9273356B2
(en)
|
2006-05-24 |
2016-03-01 |
Medtronic, Inc. |
Methods and kits for linking polymorphic sequences to expanded repeat mutations
|
US20070275923A1
(en)
*
|
2006-05-25 |
2007-11-29 |
Nastech Pharmaceutical Company Inc. |
CATIONIC PEPTIDES FOR siRNA INTRACELLULAR DELIVERY
|
AU2007267864A1
(en)
*
|
2006-05-25 |
2007-12-06 |
Wyeth |
Expression of the cysteine protease legumain in vascular and inflammatory diseases
|
WO2007140599A1
(en)
|
2006-06-05 |
2007-12-13 |
Cancer Care Ontario |
Assessment of risk for colorectal cancer
|
US9315818B2
(en)
|
2006-06-07 |
2016-04-19 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Plant expression constructs and methods of utilizing same
|
EP2026843A4
(en)
*
|
2006-06-09 |
2011-06-22 |
Quark Pharmaceuticals Inc |
Therapeutic uses of inhibitors of rtp801l
|
EP2029746B1
(en)
*
|
2006-06-12 |
2012-07-04 |
Exegenics, Inc., D/b/a Opko Health, Inc. |
Compositions and methods for sirna inhibition of angiogenesis
|
AU2007258233B2
(en)
|
2006-06-13 |
2012-11-22 |
The Rockefeller University |
Novel therapeutic and diagnostic products and methods
|
US9200275B2
(en)
*
|
2006-06-14 |
2015-12-01 |
Merck Sharp & Dohme Corp. |
Methods and compositions for regulating cell cycle progression
|
WO2007149493A2
(en)
*
|
2006-06-22 |
2007-12-27 |
Immugen Inc |
Restoration of hearing loss
|
WO2007150030A2
(en)
|
2006-06-23 |
2007-12-27 |
Massachusetts Institute Of Technology |
Microfluidic synthesis of organic nanoparticles
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
JP2010500867A
(en)
|
2006-06-30 |
2010-01-14 |
ロゼッタ ジノミクス リミテッド |
Nucleic acid detection method
|
US8097596B2
(en)
*
|
2006-06-30 |
2012-01-17 |
Lakewood-Amedex, Inc. |
Compositions and methods for the treatment of muscle wasting
|
US20130191941A1
(en)
|
2006-07-05 |
2013-07-25 |
Shing Kwok |
Modulating light response pathways in plants, increasing light-related tolerances in plants, and increasing biomass in plants
|
EP2046110A4
(en)
|
2006-07-07 |
2010-10-27 |
Univ Washington State |
Genes encoding chavicol/eugenol synthase from the creosote bush larrea tridentata
|
AU2007314477B2
(en)
|
2006-07-11 |
2012-03-29 |
Rutgers, The State University Of New Jersey |
MG53 compositions and methods of use
|
WO2008006169A1
(en)
|
2006-07-12 |
2008-01-17 |
Commonwealth Scientific And Industrial Research Organisation |
Polynucleotides and methods for enhancing salinity tolerance in plants
|
EP2479284B1
(en)
|
2006-07-13 |
2017-09-20 |
University of Iowa Research Foundation |
Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration
|
WO2008014426A2
(en)
|
2006-07-28 |
2008-01-31 |
Children's Memorial Hospital |
Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
|
PL380335A1
(en)
*
|
2006-07-31 |
2008-02-04 |
Instytut Chemii Bioorganicznej Pan W Poznaniu |
Sequence of double-stranded ATN-RNA, intervention using interference RNA (iRnAi) as well as application of sequence of double-stranded ATN-RNA in brain tumour treatment
|
EP2444413A1
(en)
|
2006-08-04 |
2012-04-25 |
Verenium Corporation |
Methods for oil or gas well drilling, washing and/or fracturing
|
UA106193C2
(en)
|
2006-08-11 |
2014-08-11 |
ДАУ АГРОСАЙЕНСИЗ ЕлЕлСи |
Homological recombination mediated by zinc finger nucleases
|
EP1886685A1
(en)
|
2006-08-11 |
2008-02-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
|
US9580515B2
(en)
|
2006-08-21 |
2017-02-28 |
Zensun (Shanghai) Science & Technology, Co., Ltd. |
Neukinase, a downstream protein of neuregulin
|
WO2008025711A2
(en)
*
|
2006-08-30 |
2008-03-06 |
Basf Plant Science Gmbh |
Method for increasing resistance to pathogens in transgenic plants
|
CN104232680B
(en)
|
2006-08-31 |
2021-04-27 |
孟山都技术有限公司 |
Method for rapid transformation of monocot plants
|
US7872118B2
(en)
*
|
2006-09-08 |
2011-01-18 |
Opko Ophthalmics, Llc |
siRNA and methods of manufacture
|
US20080261216A1
(en)
*
|
2006-09-08 |
2008-10-23 |
The Regents Of The University Of Michigan |
HERV Group II Viruses In Lymphoma And Cancer
|
EP2062597A4
(en)
|
2006-09-15 |
2010-03-03 |
Univ Tokai |
Preventive or remedy for er-negative and her2-negative breast cancer and method of screening the same
|
JP5431940B2
(en)
|
2006-09-18 |
2014-03-05 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
RNAi regulation of SCAP and its therapeutic use
|
WO2008036776A2
(en)
*
|
2006-09-19 |
2008-03-27 |
Asuragen, Inc. |
Mir-15, mir-26, mir -31,mir -145, mir-147, mir-188, mir-215, mir-216 mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention
|
EP2076599A2
(en)
*
|
2006-09-19 |
2009-07-08 |
Asuragen, Inc. |
Mir-200 regulated genes and pathways as targets for therapeutic intervention
|
CA2663001A1
(en)
|
2006-09-21 |
2008-03-27 |
Verenium Corporation |
Phospholipases, nucleic acids encoding them and methods for making and using them
|
WO2008036933A2
(en)
|
2006-09-21 |
2008-03-27 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the hamp gene
|
EP2617818B1
(en)
|
2006-09-21 |
2016-03-23 |
BASF Enzymes LLC |
Phytases, nucleic acids encoding them and methods for making and using them
|
EP2081949B1
(en)
*
|
2006-09-22 |
2014-12-10 |
GE Healthcare Dharmacon, Inc. |
Tripartite oligonucleotide complexes and methods for gene silencing by rna interference
|
ES2531391T3
(en)
|
2006-10-06 |
2015-03-13 |
Basf Plant Science Gmbh |
Delta-5 desaturases and procedure for the preparation of polyunsaturated fatty acids in non-human transgenic organisms
|
ES2633352T3
(en)
|
2006-10-12 |
2017-09-20 |
Monsanto Technology Llc |
plant microRNA and procedures for their use
|
AU2007306556B2
(en)
|
2006-10-13 |
2014-04-10 |
Marina Biotech, Inc. |
Improvements in or relating to amphoteric liposomes
|
WO2008049078A1
(en)
|
2006-10-18 |
2008-04-24 |
Nastech Pharmaceutical Company Inc. |
Nicked or gapped nucleic acid molecules and uses thereof
|
WO2008066626A2
(en)
|
2006-10-25 |
2008-06-05 |
The Rockefeller University |
METHODS FOR THE TREATMENT OF Aβ RELATED DISORDERS AND COMPOSITIONS THEREFOR
|
JP2010507387A
(en)
*
|
2006-10-25 |
2010-03-11 |
クアーク・ファーマスーティカルス、インコーポレイテッド |
Novel siRNA and method of using the same
|
US8362322B2
(en)
|
2006-10-27 |
2013-01-29 |
Ceres, Inc. |
Modulating lignin in plants
|
CA2667971C
(en)
|
2006-11-01 |
2017-04-18 |
Gary Weisinger |
Adipocyte-specific constructs and methods for inhibiting platelet-type 12 lipoxygenase expression
|
EP2548438B1
(en)
|
2006-11-08 |
2015-08-05 |
Veritas Bio, LLC |
In vivo delivery of double stranded RNA to a target cell
|
US8252526B2
(en)
|
2006-11-09 |
2012-08-28 |
Gradalis, Inc. |
ShRNA molecules and methods of use thereof
|
US8906874B2
(en)
|
2006-11-09 |
2014-12-09 |
Gradalis, Inc. |
Bi-functional shRNA targeting Stathmin 1 and uses thereof
|
US8758998B2
(en)
|
2006-11-09 |
2014-06-24 |
Gradalis, Inc. |
Construction of bifunctional short hairpin RNA
|
ES2397637T3
(en)
|
2006-11-10 |
2013-03-08 |
Massachusetts Institute Of Technology |
PAK inhibitors for use in the treatment of neurodevelopmental disorders
|
KR20150072458A
(en)
|
2006-11-15 |
2015-06-29 |
코다 테라퓨틱스, 인크. |
Improved methods and compositions for wound healing
|
US20100303723A1
(en)
*
|
2006-11-20 |
2010-12-02 |
Massachusetts Institute Of Technology |
Drug delivery systems using fc fragments
|
WO2008064128A2
(en)
|
2006-11-22 |
2008-05-29 |
Ceres, Inc. |
Broadly expressing regulatory regions
|
EP2104513B1
(en)
|
2006-11-27 |
2015-05-20 |
diaDexus, Inc. |
Ovr110 antibody compositions and methods of use
|
EP2101813B1
(en)
|
2006-11-27 |
2014-04-02 |
Patrys Limited |
Novel glycosylated peptide target in neoplastic cells
|
ATE533838T1
(en)
|
2006-11-29 |
2011-12-15 |
Novozymes Inc |
METHOD FOR IMPROVED INTRODUCTION OF DNA INTO BACTERIAL CELLS
|
EP2099818A2
(en)
|
2006-11-29 |
2009-09-16 |
Novozymes Inc. |
Bacillus licheniformis chromosome
|
CN101195821A
(en)
*
|
2006-12-04 |
2008-06-11 |
中国科学院上海生命科学研究院 |
Method for improving insect resistance of plant by using RNAi technique
|
US8481506B2
(en)
*
|
2006-12-05 |
2013-07-09 |
Rosetta Genomics, Ltd. |
Nucleic acids involved in viral infection
|
CA2671294A1
(en)
*
|
2006-12-08 |
2008-06-19 |
Asuragen, Inc. |
Mir-21 regulated genes and pathways as targets for therapeutic intervention
|
CN101622350A
(en)
*
|
2006-12-08 |
2010-01-06 |
奥斯瑞根公司 |
miR-126 regulated genes and pathways as targets for therapeutic intervention
|
WO2008067840A1
(en)
|
2006-12-08 |
2008-06-12 |
Swetree Technologies Ab |
Plants having improved growth characteristics and method for making the same
|
CA2671850A1
(en)
*
|
2006-12-08 |
2008-06-19 |
Massachusetts Institute Of Technology |
Delivery of nanoparticles and/or agents to cells
|
BRPI0720048A8
(en)
|
2006-12-14 |
2023-02-07 |
Dow Agrosciences Llc |
OPTIMIZED NON-CANONIC ZINC FINGER PROTEINS
|
MX2009006782A
(en)
|
2006-12-21 |
2009-09-21 |
Verenium Corp |
Amylases and glucoamylases, nucleic acids encoding them and methods for making and using them.
|
EP2913341A1
(en)
|
2006-12-22 |
2015-09-02 |
University of Utah Research Foundation |
Method of detecting ocular diseases and pathologic conditions and treatment of same
|
WO2008077547A1
(en)
*
|
2006-12-22 |
2008-07-03 |
F. Hoffmann-La Roche Ag |
Shrna-mediated inhibition of expression of alpha-1. 6-fucosyltransferase
|
EP3103451A1
(en)
|
2007-01-12 |
2016-12-14 |
University of Maryland, Baltimore |
Targetting ncca-atp channel for organ protection following ischemic episode
|
DK2202314T3
(en)
|
2007-01-15 |
2014-06-16 |
Basf Plant Science Gmbh |
Use of Subtilisin (RNR9) Polynucleotides to Achieve Pathogen Resistance in Plants
|
WO2008087641A2
(en)
*
|
2007-01-16 |
2008-07-24 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
H19 silencing nucleic acid agents for treating rheumatoid arthritis
|
US20100204300A1
(en)
*
|
2007-01-17 |
2010-08-12 |
Stephen Mark Tompkins |
Anti-viral methods and compositions
|
US8148147B2
(en)
|
2007-01-24 |
2012-04-03 |
The Regents Of The University Of Michigan |
Compositions and methods for treating and diagnosing pancreatic cancer
|
CN101641010A
(en)
|
2007-01-26 |
2010-02-03 |
路易斯维尔大学研究基金会公司 |
Be used as the modification of the allochthon component of vaccine
|
US8389486B2
(en)
*
|
2007-01-26 |
2013-03-05 |
Rosetta Genomics, Ltd |
Methods for treating hematopoietic malignancies
|
WO2008094937A2
(en)
*
|
2007-01-29 |
2008-08-07 |
Joslin Diabetes Center, Inc. |
Methods of modulating angiogenesis
|
NZ598285A
(en)
|
2007-01-30 |
2013-10-25 |
Syngenta Participations Ag |
Enzymes for the treatment of lignocellulosics, nucleic acids encoding them and methods for making and using them
|
EP2124522B1
(en)
|
2007-02-05 |
2011-11-16 |
National University of Singapore |
Putative cytokinin receptor and methods for use thereof
|
EP2111451A1
(en)
|
2007-02-06 |
2009-10-28 |
BASF Plant Science GmbH |
Compositions and methods using rna interference for control of nematodes
|
CA2674562A1
(en)
|
2007-02-08 |
2008-08-14 |
Basf Plant Science Gmbh |
Compositions and methods using rna interference of opr3-like gene for control of nematodes
|
MX2009007766A
(en)
|
2007-02-09 |
2009-07-30 |
Basf Plant Science Gmbh |
Compositions and methods using rna interference of cdpk-like for control of nematodes.
|
WO2008098165A2
(en)
*
|
2007-02-09 |
2008-08-14 |
Massachusetts Institute Of Technology |
Oscillating cell culture bioreactor
|
DE102007008596B4
(en)
|
2007-02-15 |
2010-09-02 |
Friedrich-Schiller-Universität Jena |
Biologically active molecules based on PNA and siRNA, methods for their cell-specific activation and application kit for administration
|
CN101631868B
(en)
|
2007-02-16 |
2016-02-10 |
巴斯福植物科学有限公司 |
For regulating the nucleotide sequence of embryo-specific expression in monocotyledons
|
EP2510941A3
(en)
|
2007-02-20 |
2013-01-23 |
Merrimack Pharmaceuticals, Inc. |
Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
|
CN101646769A
(en)
|
2007-02-20 |
2010-02-10 |
孟山都技术公司 |
Invertebrate micrornas
|
JP2010518880A
(en)
*
|
2007-02-26 |
2010-06-03 |
クアーク・ファーマスーティカルス、インコーポレイテッド |
Inhibitors of RTP801 and their use in the treatment of diseases
|
WO2008104974A2
(en)
*
|
2007-02-27 |
2008-09-04 |
Rosetta Genomics Ltd. |
Composition and methods for modulating cell proliferation and cell death
|
US9006206B2
(en)
|
2007-02-27 |
2015-04-14 |
Rosetta Genomics Ltd. |
Composition and methods for modulating cell proliferation and cell death
|
US20100292301A1
(en)
*
|
2007-02-28 |
2010-11-18 |
Elena Feinstein |
Novel sirna structures
|
US9340601B2
(en)
*
|
2007-03-01 |
2016-05-17 |
The Board Of Trustees Of The Leland Stanford Junior University |
Splice variants of the EGF receptor
|
WO2008106658A2
(en)
*
|
2007-03-01 |
2008-09-04 |
California Institute Of Technology |
TRIGGERED RNAi
|
WO2008109432A2
(en)
*
|
2007-03-02 |
2008-09-12 |
The Board Of Regents Of The University Of Texas System |
Therapeutic targeting of interleukins using sirna in neutral liposomes
|
EP2243834A1
(en)
|
2007-03-05 |
2010-10-27 |
Cancer Care Ontario |
Assessment of risk for colorectal cancer
|
US8080648B1
(en)
|
2007-03-09 |
2011-12-20 |
The United States Of America, As Represented By The Secretary Of Agriculture |
Pesticidal double stranded RNA composition and method of use thereof
|
CA2680600A1
(en)
*
|
2007-03-12 |
2008-09-18 |
Antigen Express, Inc. |
Li-rnai involved li suppression in cancer immunotherapy
|
EP2125898B1
(en)
|
2007-03-14 |
2013-05-15 |
Novartis AG |
Apcdd1 inhibitors for treating, diagnosing or detecting cancer
|
ES2538217T3
(en)
|
2007-03-21 |
2015-06-18 |
Brookhaven Science Associates, Llc |
Combined fork antisense compositions and methods to modulate expression
|
US7812002B2
(en)
*
|
2007-03-21 |
2010-10-12 |
Quark Pharmaceuticals, Inc. |
Oligoribonucleotide inhibitors of NRF2 and methods of use thereof for treatment of cancer
|
PE20090064A1
(en)
|
2007-03-26 |
2009-03-02 |
Novartis Ag |
DOUBLE-CHAIN RIBONUCLEIC ACID TO INHIBIT THE EXPRESSION OF THE HUMAN E6AP GENE AND THE PHARMACEUTICAL COMPOSITION THAT INCLUDES IT
|
JP5705535B2
(en)
|
2007-03-26 |
2015-04-22 |
アメリカ合衆国 |
Methods for regulating embryonic stem cell differentiation
|
US20100273172A1
(en)
|
2007-03-27 |
2010-10-28 |
Rosetta Genomics Ltd. |
Micrornas expression signature for determination of tumors origin
|
WO2012070037A2
(en)
|
2010-11-22 |
2012-05-31 |
Rosetta Genomics Ltd. |
Methods and materials for classification of tissue of origin of tumor samples
|
CL2008000883A1
(en)
*
|
2007-03-28 |
2008-10-03 |
Wyeth6 3 |
METHOD OF DETECTION OF CAPABLE COMPOUNDS TO ANTAGONIZE THE SIGNALING OF IL-17F / IL-17A; COMPOUND IDENTIFIED BY SUCH METHOD; USE OF A QUANTITY OF AN IL-17F / IL-17A SENALIZATION ANTAGONIST, PHARMACEUTICAL COMPOSITION UNDERSTANDING
|
CA2682161A1
(en)
|
2007-03-29 |
2008-10-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a gene from ebola virus
|
EP1985295A1
(en)
*
|
2007-04-04 |
2008-10-29 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Selective inhibitors of CB2 receptor expression and/or activity for the treatment of obesity and obesity-related disorders
|
WO2008124634A1
(en)
|
2007-04-04 |
2008-10-16 |
Massachusetts Institute Of Technology |
Polymer-encapsulated reverse micelles
|
WO2008124632A1
(en)
|
2007-04-04 |
2008-10-16 |
Massachusetts Institute Of Technology |
Amphiphilic compound assisted nanoparticles for targeted delivery
|
AU2008236566A1
(en)
*
|
2007-04-09 |
2008-10-16 |
Chimeros, Inc. |
Self-assembling nanoparticle drug delivery system
|
EP2147013A4
(en)
*
|
2007-04-16 |
2012-03-07 |
Modgene Llc |
Methods and compositions for diagnosis and treatment of depression and anxiety
|
CA2682135A1
(en)
*
|
2007-04-17 |
2008-10-30 |
Baxter International Inc. |
Nucleic acid microparticles for pulmonary delivery
|
CA2584934A1
(en)
|
2007-04-17 |
2008-10-17 |
University Of Guelph |
Nitrogen-regulated sugar sensing gene and protein and modulation thereof
|
US9156865B2
(en)
|
2007-04-23 |
2015-10-13 |
Deliversir Ltd |
System for delivering therapeutic agents into living cells and cells nuclei
|
EP2144633B1
(en)
|
2007-04-23 |
2014-07-16 |
Deliversir Ltd |
A system for delivering therapeutic agents into living cells and cells nuclei
|
US9556210B2
(en)
|
2007-04-23 |
2017-01-31 |
Sabag-Rfa Ltd. |
System for delivering therapeutic agents into living cells and cells nuclei
|
EP2152903A2
(en)
|
2007-04-26 |
2010-02-17 |
Ludwig Institute for Cancer Research, Ltd. |
Methods for diagnosing and treating astrocytomas
|
US9580719B2
(en)
|
2007-04-27 |
2017-02-28 |
Pfenex, Inc. |
Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
|
CN103555735B
(en)
|
2007-04-27 |
2016-03-09 |
加利福尼亚大学董事会 |
Plant CO 2sensor, encode their nucleic acid and manufacture and their method of use
|
CA2685326A1
(en)
|
2007-04-27 |
2008-11-06 |
Dow Global Technologies Inc. |
Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
|
US11078262B2
(en)
|
2007-04-30 |
2021-08-03 |
Allergan, Inc. |
High viscosity macromolecular compositions for treating ocular conditions
|
WO2008143774A2
(en)
*
|
2007-05-01 |
2008-11-27 |
University Of Massachusetts |
Methods and compositions for locating snp heterozygosity for allele specific diagnosis and therapy
|
WO2008137771A2
(en)
*
|
2007-05-02 |
2008-11-13 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF CYCLIC NUCLEOTIDE TYPE 4 PHOSPHODIESTERASE ( PDE4B) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
WO2008137115A1
(en)
|
2007-05-03 |
2008-11-13 |
The Brigham And Women's Hospital, Inc. |
Multipotent stem cells and uses thereof
|
EP2492346A3
(en)
|
2007-05-04 |
2013-03-27 |
BASF Plant Science GmbH |
Seed enhancement by combinations of pyruvate kinases
|
EP3434259A1
(en)
|
2007-05-04 |
2019-01-30 |
Marina Biotech, Inc. |
Amino acid lipids and uses thereof
|
US20100251392A1
(en)
*
|
2007-05-04 |
2010-09-30 |
Abbott Laboratories |
Methods for assessing the delivery of exogenous agents
|
US20100115635A1
(en)
*
|
2007-05-04 |
2010-05-06 |
Abbott Laboratories |
Methods for Assessing the Delivery of Exogenous Agents
|
EP2155910A4
(en)
*
|
2007-05-08 |
2010-06-02 |
Univ Duke |
Compositions and methods for characterizing and regulating olfactory sensation
|
CN105748480A
(en)
|
2007-05-11 |
2016-07-13 |
宾夕法尼亚大学理事会 |
Methods of treatment of skin ulcers
|
EA200971050A1
(en)
|
2007-05-11 |
2010-06-30 |
Томас Джефферсон Юниверсити |
METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS
|
WO2008143786A1
(en)
*
|
2007-05-14 |
2008-11-27 |
The Rockefeller University |
Production of artificial micrornas using synthetic microrna precursors
|
EP1992699A1
(en)
*
|
2007-05-15 |
2008-11-19 |
Genoplante-Valor |
Method for increasing the resistance of a plant to endoparasitic nematodes
|
EP2155770B1
(en)
|
2007-05-16 |
2013-10-16 |
California Institute of Technology |
A versatile nucleic acid hairpin motif for programming biomolecular self-assembly pathways
|
CN104480112B
(en)
|
2007-05-22 |
2018-06-12 |
阿克丘勒斯治疗公司 |
For the UNA oligomer for the treatment of
|
US20090232893A1
(en)
*
|
2007-05-22 |
2009-09-17 |
Bader Andreas G |
miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
|
US20090131354A1
(en)
*
|
2007-05-22 |
2009-05-21 |
Bader Andreas G |
miR-126 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
|
AR066642A1
(en)
|
2007-05-22 |
2009-09-02 |
Basf Plant Gmbh |
VEGETABLE CELLS AND PLANTS WITH HIGHER TOLERANCE AND / OR RESISTANCE TO ENVIRONMENTAL STRESS AND HIGHER PRODUCTION OF BIOMASS PRODUCED BY SILENCING OF GENES
|
EP2390335A3
(en)
|
2007-05-23 |
2012-03-21 |
Syngenta Participations AG |
Polynucleotide markers
|
CA2688417C
(en)
|
2007-05-24 |
2017-04-25 |
Calcimedica, Inc. |
Calcium channel proteins and uses thereof
|
EP2572712A3
(en)
|
2007-06-01 |
2013-11-20 |
The Trustees Of Princeton University |
Treatment of viral infections by modulation of host cell metabolic pathways
|
WO2008154333A2
(en)
*
|
2007-06-08 |
2008-12-18 |
Asuragen, Inc. |
Mir-34 regulated genes and pathways as targets for therapeutic intervention
|
WO2008152636A2
(en)
*
|
2007-06-15 |
2008-12-18 |
Quark Pharmaceuticals, Inc. |
Compositions and methods for inhibiting nadph oxidase expression
|
EP2164863A4
(en)
|
2007-06-15 |
2010-07-28 |
Univ Arkansas |
Methods of delivery of molecules to cells using a ricin subunit and compositions relating to same
|
WO2008157299A2
(en)
*
|
2007-06-15 |
2008-12-24 |
Wyeth |
Differential expression profiling analysis of cell culture phenotypes and uses thereof
|
US8097422B2
(en)
|
2007-06-20 |
2012-01-17 |
Salk Institute For Biological Studies |
Kir channel modulators
|
DE102007029471A1
(en)
|
2007-06-20 |
2008-12-24 |
Novosom Ag |
New optional cationic sterols
|
EP2167107B1
(en)
|
2007-06-22 |
2016-12-14 |
University of Maryland, Baltimore |
Inhibitors of ncca-atp channels for therapy
|
DK2170403T3
(en)
*
|
2007-06-27 |
2014-06-16 |
Quark Pharmaceuticals Inc |
Compositions and Methods for Inhibiting the Expression of Proapoptotic Genes
|
US10745701B2
(en)
|
2007-06-28 |
2020-08-18 |
The Trustees Of Princeton University |
Methods of identifying and treating poor-prognosis cancers
|
US20090324596A1
(en)
*
|
2008-06-30 |
2009-12-31 |
The Trustees Of Princeton University |
Methods of identifying and treating poor-prognosis cancers
|
CA2728575A1
(en)
*
|
2007-06-29 |
2009-01-08 |
Boston Biomedical, Inc. |
Enabling the use of long dsrna for gene targeting in mammalian and other selected animal cells
|
US20090087431A1
(en)
*
|
2007-07-02 |
2009-04-02 |
Wyeth |
Methods of treating bone disorders with modulators of axl
|
CA2692478A1
(en)
|
2007-07-03 |
2009-01-08 |
Kyorin Pharmaceutical Co., Ltd. |
Treatment of influenza
|
EP2316943B1
(en)
|
2007-07-05 |
2013-06-19 |
Novartis AG |
DSRNA for treating viral infection
|
US20110015249A1
(en)
*
|
2007-07-06 |
2011-01-20 |
Intradigm Corporation |
Methods and compositions for treatment of cancer and other angiogenesis-related diseases
|
EP3018216B1
(en)
|
2007-07-06 |
2018-09-12 |
The Regents Of The University Of Michigan |
Recurrent gene fusions in prostate cancer
|
BRPI0814685A2
(en)
|
2007-07-10 |
2019-09-24 |
Neurin Pharmaceuticals 1991 Ltd |
splicing variants of cd44 in neurodegenerative diseases
|
US9689031B2
(en)
|
2007-07-14 |
2017-06-27 |
Ionian Technologies, Inc. |
Nicking and extension amplification reaction for the exponential amplification of nucleic acids
|
WO2009012263A2
(en)
|
2007-07-18 |
2009-01-22 |
The Trustees Of Columbia University In The City Of New York |
Tissue-specific micrornas and compositions and uses thereof
|
JP5624884B2
(en)
|
2007-08-02 |
2014-11-12 |
ノビミューンエスアー |
Anti-RANTES antibodies and methods of use thereof
|
US20090044296A1
(en)
*
|
2007-08-07 |
2009-02-12 |
Cornell Research Foundation, Inc. |
Hrpn interactors and uses thereof
|
NZ583466A
(en)
|
2007-08-13 |
2012-09-28 |
Commw Scient Ind Res Org |
Barley with low levels of hordein, methods of producing food with low levels of hordein and methods of treating coeliac's disease
|
EP2185706B1
(en)
|
2007-08-14 |
2017-09-27 |
Commonwealth Scientific and Industrial Research Organisation |
Improved gene silencing methods
|
EP2179292B1
(en)
|
2007-08-16 |
2012-11-28 |
The Regents of the University of Michigan |
Metabolomic profiling of prostate cancer
|
CA2697363A1
(en)
|
2007-08-23 |
2009-03-05 |
The Board Of Trustees Of The Leland Stanford Junior University |
Modulation of synaptogenesis
|
JP2010536388A
(en)
|
2007-08-30 |
2010-12-02 |
ザ ウォルター アンド エリザ ホール インスティテュート オブ メディカル リサーチ |
Dendritic cell markers and uses thereof
|
WO2009033027A2
(en)
*
|
2007-09-05 |
2009-03-12 |
Medtronic, Inc. |
Suppression of scn9a gene expression and/or function for the treatment of pain
|
US8361714B2
(en)
*
|
2007-09-14 |
2013-01-29 |
Asuragen, Inc. |
Micrornas differentially expressed in cervical cancer and uses thereof
|
WO2009039300A2
(en)
*
|
2007-09-18 |
2009-03-26 |
Intradigm Corporation |
Compositions comprising hif-1 alpha sirna and methods of use thereof
|
EP2190995A2
(en)
*
|
2007-09-18 |
2010-06-02 |
Intradigm Corporation |
Compositions comprising k-ras sirna and methods of use
|
JP5723154B2
(en)
|
2007-09-19 |
2015-05-27 |
アプライド バイオシステムズ リミテッド ライアビリティー カンパニー |
SiRNA sequence-independent modification format for reducing the influence of off-target phenotype in RNAi and its stabilized form
|
BRPI0817560B1
(en)
|
2007-09-27 |
2022-09-20 |
Dow Agrosciences Llc |
ENGINEERED ZINC FINGER PROTEINS (ZFP) TARGETING 5-ENOLPIRUVYL SHIKYMATE-3-PHOSPHATE SYNTHASE, ZINC FINGER NUCLEASE (ZFN) GENES, VECTOR, AS WELL AS METHODS FOR INTRODUCTION OF A TRANSGENE INTO A CELL GENOME PLANT, TO EXPRESS THE PRODUCT OF A TRANSGENE IN A PLANT CELL, FOR DELETION OF AN EPSPS GENE SEQUENCE FROM AN EPSPS GENE LOCU IN THE GENOME OF A PLANT CELL, AND TO MODULATE EXPRESSION OF AN EPSPS GENE
|
CN103898110A
(en)
*
|
2007-10-03 |
2014-07-02 |
夸克制药公司 |
Novel sirna structures
|
US8486680B2
(en)
|
2007-10-03 |
2013-07-16 |
Bp Corporation North America Inc. |
Xylanases, nucleic acids encoding them and methods for making and using them
|
EP2205746A4
(en)
*
|
2007-10-04 |
2010-12-22 |
Univ Texas |
Modulating gene expression with agrna and gapmers targeting antisense transcripts
|
WO2009045536A2
(en)
*
|
2007-10-05 |
2009-04-09 |
The University Of North Carolina At Chapel Hill |
Receptor targeted oligonucleotides
|
EP2630967A1
(en)
|
2007-10-12 |
2013-08-28 |
Massachusetts Institute of Technology |
Vaccine nanotechnology
|
CA2702494A1
(en)
|
2007-10-19 |
2009-04-23 |
The Regents Of The University Of California |
Compositions and methods for ameliorating cns inflammation, psychosis, delirium, ptsd or ptss
|
PE20091163A1
(en)
|
2007-11-01 |
2009-08-09 |
Wyeth Corp |
ANTIBODIES FOR GDF8
|
US8097712B2
(en)
*
|
2007-11-07 |
2012-01-17 |
Beelogics Inc. |
Compositions for conferring tolerance to viral disease in social insects, and the use thereof
|
CA2705488C
(en)
|
2007-11-12 |
2018-01-16 |
Curtis C. Harris |
Therapeutic applications of p53 isoforms in regenerative medicine, aging and cancer
|
EP2065037A1
(en)
|
2007-11-27 |
2009-06-03 |
DKFZ Deutsches Krebsforschungszentrum |
Means and methods for treating or preventing brain tumors based on the nuclear receptor tailless (Tlx)
|
AR069440A1
(en)
|
2007-11-27 |
2010-01-20 |
Commw Scient Ind Res Org |
PLANTS WITH MODIFIED ALMIDON METABOLISM AND VEGETABLE NUCLEIC ACID MOLECULES CODING INTERVENING ENZYMES
|
WO2009070805A2
(en)
*
|
2007-12-01 |
2009-06-04 |
Asuragen, Inc. |
Mir-124 regulated genes and pathways as targets for therapeutic intervention
|
US7968525B1
(en)
|
2007-12-03 |
2011-06-28 |
University Of Florida Research Foundation, Inc. |
Use of RNA interference to validate new termiticide target sites and a method of termite control
|
WO2009073709A1
(en)
|
2007-12-06 |
2009-06-11 |
Novozymes A/S |
Polypeptides having acetylxylan esterase activity and polynucleotides encoding same
|
EP2617828B1
(en)
|
2007-12-10 |
2014-09-24 |
Alnylam Pharmaceuticals Inc. |
Compositions and methods for inhibiting expression of factor VII gene
|
US20100204305A1
(en)
*
|
2007-12-11 |
2010-08-12 |
Lorus Therapeutics Inc. |
Small interfering rna molecules against ribonucleotide reductase and uses thereof
|
US20110105584A1
(en)
*
|
2007-12-12 |
2011-05-05 |
Elena Feinstein |
Rtp80il sirna compounds and methods of use thereof
|
US8614311B2
(en)
|
2007-12-12 |
2013-12-24 |
Quark Pharmaceuticals, Inc. |
RTP801L siRNA compounds and methods of use thereof
|
WO2009076679A2
(en)
*
|
2007-12-13 |
2009-06-18 |
Alnylam Pharmaceuticals Inc. |
Methods and compositions for prevention or treatment of rsv infection
|
US20110041215A1
(en)
*
|
2007-12-17 |
2011-02-17 |
Basf Plant Science Gmbh |
Lipid Metabolism Protein And Uses Thereof I (BZIP Transcription Factor)
|
KR20100105849A
(en)
|
2007-12-19 |
2010-09-30 |
노보자임스 에이/에스 |
Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same
|
EP2072528A1
(en)
|
2007-12-19 |
2009-06-24 |
Labeit, Mr. Siegfried |
A host cell deficient for MuRF1 and MuRF2
|
US20100293665A1
(en)
|
2007-12-21 |
2010-11-18 |
Basf Plant Science Gmbh |
Plants With Increased Yield (KO NUE)
|
AU2008343756A1
(en)
*
|
2007-12-21 |
2009-07-09 |
Coda Therapeutics, Inc. |
Use of anti-connexin polypeptide agent in combination with anti-connexin polynucleotide agent for the treatment of fibrotic conditions
|
EP2237786A2
(en)
|
2007-12-21 |
2010-10-13 |
Coda Therapeutics, Inc. |
Use of inhibitors of connexin43 for treatment of fibrotic conditions
|
WO2009086215A2
(en)
*
|
2007-12-21 |
2009-07-09 |
Wyeth |
Pathway analysis of cell culture phenotypes and uses thereof
|
JP2011507506A
(en)
|
2007-12-21 |
2011-03-10 |
ケイヘーネ・エヌ・ブイ |
Trichome-specific promoter
|
AU2008343754A1
(en)
*
|
2007-12-21 |
2009-07-09 |
Coda Therapeutics, Inc. |
Use of anti-connexin polynucleotides for the treatment of surgical adhesions
|
WO2009086156A2
(en)
*
|
2007-12-21 |
2009-07-09 |
Asuragen, Inc. |
Mir-10 regulated genes and pathways as targets for therapeutic intervention
|
AU2008344053B2
(en)
|
2007-12-28 |
2014-03-27 |
Swetree Technologies Ab |
Woody plants having improved growth charateristics and method for making the same using transcription factors
|
US20090226914A1
(en)
*
|
2007-12-31 |
2009-09-10 |
Bates Paula J |
Methods and products to target, capture and characterize stem cells
|
US8709772B2
(en)
|
2008-01-03 |
2014-04-29 |
Verenium Corporation |
Transferases and oxidoreductases, nucleic acids encoding them and methods for making and using them
|
CA2710922A1
(en)
|
2008-01-03 |
2009-07-16 |
Verenium Corporation |
Isomerases, nucleic acids encoding them and methods for making and using them
|
WO2009097077A2
(en)
*
|
2008-01-07 |
2009-08-06 |
Coda Therapeutics, Inc. |
Wound healing compositions and treatments
|
TW200930398A
(en)
*
|
2008-01-11 |
2009-07-16 |
Univ Chang Gung |
RNAi sequence, inhibitor, and inhibition method that specifically inhibits expression of 78-kDA glucose-regulated protein
|
EP2242854A4
(en)
*
|
2008-01-15 |
2012-08-15 |
Quark Pharmaceuticals Inc |
Sirna compounds and methods of use thereof
|
MX356866B
(en)
|
2008-01-25 |
2018-06-18 |
Multivir Inc |
P53 biomarkers.
|
US8580503B2
(en)
*
|
2008-01-27 |
2013-11-12 |
Rosetta Genomics Ltd. |
Methods and compositions for diagnosing complications of pregnancy
|
CA2714144A1
(en)
|
2008-02-05 |
2009-08-13 |
Pioneer Hi-Bred International, Inc. |
Maize leaf- and stalk-preferred promoter
|
US20090263803A1
(en)
*
|
2008-02-08 |
2009-10-22 |
Sylvie Beaudenon |
Mirnas differentially expressed in lymph nodes from cancer patients
|
US8188060B2
(en)
|
2008-02-11 |
2012-05-29 |
Dharmacon, Inc. |
Duplex oligonucleotides with enhanced functionality in gene regulation
|
JP5697993B2
(en)
|
2008-02-11 |
2015-04-08 |
アールエックスアイ ファーマシューティカルズ コーポレーション |
Modified RNAi polynucleotides and uses thereof
|
DE102009043743B4
(en)
|
2009-03-13 |
2016-10-13 |
Friedrich-Schiller-Universität Jena |
Cell-specific molecules based on siRNA as well as application kits for their production and use
|
US8497364B2
(en)
*
|
2008-02-27 |
2013-07-30 |
California Institute Of Technology |
Triggered RNAi
|
KR101397407B1
(en)
|
2008-03-05 |
2014-06-19 |
알닐람 파마슈티칼스 인코포레이티드 |
Compositions and methods for inhibiting expression of Eg5 and VEGF genes
|
US20090233297A1
(en)
*
|
2008-03-06 |
2009-09-17 |
Elizabeth Mambo |
Microrna markers for recurrence of colorectal cancer
|
WO2009114726A1
(en)
*
|
2008-03-12 |
2009-09-17 |
Intradigm Corporation |
Compositions comprising notch1 sirna and methods of use thereof
|
JP2011517404A
(en)
*
|
2008-03-20 |
2011-06-09 |
クォーク・ファーマシューティカルズ・インク |
Novel siRNA compound for inhibiting RTP801
|
EP2271757A2
(en)
*
|
2008-03-26 |
2011-01-12 |
Asuragen, INC. |
Compositions and methods related to mir-16 and therapy of prostate cancer
|
BRPI0911332A2
(en)
|
2008-04-04 |
2019-09-24 |
Calando Pharmaceuticals Inc |
compositions and use of epas1 inhibitors
|
WO2009126726A1
(en)
*
|
2008-04-08 |
2009-10-15 |
Asuragen, Inc |
Methods and compositions for diagnosing and modulating human papillomavirus (hpv)
|
AU2009234229B2
(en)
|
2008-04-10 |
2014-06-19 |
Monsanto Technology Llc |
Methods and compositions for root knot nematode control
|
US8802923B2
(en)
|
2008-04-10 |
2014-08-12 |
A.B. Seeds Ltd. |
Compositions and methods for enhancing oil content in plants
|
EP2281050B1
(en)
|
2008-04-14 |
2014-04-02 |
Sangamo BioSciences, Inc. |
Linear donor constructs for targeted integration
|
US8278287B2
(en)
*
|
2008-04-15 |
2012-10-02 |
Quark Pharmaceuticals Inc. |
siRNA compounds for inhibiting NRF2
|
GB0807018D0
(en)
|
2008-04-17 |
2008-05-21 |
Fusion Antibodies Ltd |
Antibodies and treatment
|
US8518884B2
(en)
|
2008-04-25 |
2013-08-27 |
Northwestern University |
Methods for treating atrial or ventricular arrhythmias by administering a G-protein alpha inhibitor
|
EP2990487A1
(en)
|
2008-05-08 |
2016-03-02 |
Asuragen, INC. |
Compositions and methods related to mirna modulation of neovascularization or angiogenesis
|
US20090291073A1
(en)
*
|
2008-05-20 |
2009-11-26 |
Ward Keith W |
Compositions Comprising PKC-theta and Methods for Treating or Controlling Ophthalmic Disorders Using Same
|
US20100021904A1
(en)
*
|
2008-05-21 |
2010-01-28 |
Pierce Niles A |
Shielded cross-linking probes
|
US8241854B2
(en)
*
|
2008-05-22 |
2012-08-14 |
California Institute Of Technology |
Triggered RNAi
|
US20100021901A1
(en)
*
|
2008-05-22 |
2010-01-28 |
Peng Yin |
Compositions and methods for detecting analytes
|
WO2009143391A2
(en)
*
|
2008-05-22 |
2009-11-26 |
Isis Pharmaceuticals, Inc |
Methods for modulation expression of creb
|
AU2009256243A1
(en)
|
2008-06-04 |
2009-12-10 |
The Board Of Regents Of The University Of Texas System |
Modulation of gene expression through endogenous small RNA targeting of gene promoters
|
US8431692B2
(en)
|
2008-06-06 |
2013-04-30 |
Quark Pharmaceuticals, Inc. |
Compositions and methods for treatment of ear disorders
|
SG10201510586PA
(en)
|
2008-06-30 |
2016-01-28 |
Mesoblast Inc |
Treatment of Eye Diseases And Excessive Neovascularization Using A Combined Therapy
|
US8815818B2
(en)
|
2008-07-18 |
2014-08-26 |
Rxi Pharmaceuticals Corporation |
Phagocytic cell delivery of RNAI
|
WO2010023877A1
(en)
|
2008-08-27 |
2010-03-04 |
Oncotherapy Science, Inc. |
Prmt1 for target genes of cancer therapy and diagnosis
|
US8198062B2
(en)
|
2008-08-29 |
2012-06-12 |
Dsm Ip Assets B.V. |
Hydrolases, nucleic acids encoding them and methods for making and using them
|
US8357503B2
(en)
|
2008-08-29 |
2013-01-22 |
Bunge Oils, Inc. |
Hydrolases, nucleic acids encoding them and methods for making and using them
|
US8153391B2
(en)
|
2008-08-29 |
2012-04-10 |
Bunge Oils, Inc. |
Hydrolases, nucleic acids encoding them and methods for making and using them
|
EP2331690B1
(en)
|
2008-09-02 |
2016-01-13 |
Alnylam Pharmaceuticals Inc. |
Compositions and methods for inhibiting expression of mutant egfr gene
|
JP5773872B2
(en)
|
2008-09-10 |
2015-09-02 |
ユニバーシティー オブ ブラッドフォードUniversity Of Bradford |
Compositions and methods
|
CA2734922C
(en)
|
2008-09-15 |
2020-01-14 |
Laetitia Malphettes |
Compositions comprising polynucleotides comprising hybrid osmo-responsive transcriptional regulatory elements and methods for producing a protein under conditions of hyperosmolarity
|
EP2719380A3
(en)
|
2008-09-16 |
2014-07-30 |
University of Maryland, Baltimore |
SUR1 inhibitors for therapy
|
EP2165710A1
(en)
|
2008-09-19 |
2010-03-24 |
Institut Curie |
Tyrosine kinase receptor Tyro3 as a therapeutic target in the treatment of a bladder tumor
|
AU2009293658A1
(en)
|
2008-09-22 |
2010-03-25 |
James Cardia |
Reduced size self-delivering RNAi compounds
|
EP3109321B1
(en)
|
2008-09-25 |
2019-05-01 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene
|
AU2009296246B2
(en)
|
2008-09-26 |
2015-07-30 |
Oncomed Pharmaceuticals, Inc. |
Frizzled-binding agents and uses thereof
|
MX2011003297A
(en)
*
|
2008-09-29 |
2011-04-21 |
Monsanto Technology Llc |
Soybean transgenic event mon87705 and methods for detection thereof.
|
US8298794B2
(en)
|
2008-10-09 |
2012-10-30 |
Ceres, Inc. |
Cinnamyl-alcohol dehydrogenases
|
WO2010042933A2
(en)
|
2008-10-10 |
2010-04-15 |
Northwestern University |
Inhibition and treatment of prostate cancer metastasis
|
US8343497B2
(en)
|
2008-10-12 |
2013-01-01 |
The Brigham And Women's Hospital, Inc. |
Targeting of antigen presenting cells with immunonanotherapeutics
|
US8277812B2
(en)
*
|
2008-10-12 |
2012-10-02 |
Massachusetts Institute Of Technology |
Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
|
US8343498B2
(en)
|
2008-10-12 |
2013-01-01 |
Massachusetts Institute Of Technology |
Adjuvant incorporation in immunonanotherapeutics
|
US8591905B2
(en)
|
2008-10-12 |
2013-11-26 |
The Brigham And Women's Hospital, Inc. |
Nicotine immunonanotherapeutics
|
JP2012505887A
(en)
*
|
2008-10-16 |
2012-03-08 |
サイトニックス コーポレイション |
Biomarkers and methods for detection and treatment of spinal cord and joint pain
|
EP2902013A1
(en)
|
2008-10-16 |
2015-08-05 |
Marina Biotech, Inc. |
Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics
|
IL281434B2
(en)
|
2008-10-20 |
2023-09-01 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for inhabiting expression of transthyretin
|
US20100168205A1
(en)
*
|
2008-10-23 |
2010-07-01 |
Alnylam Pharmaceuticals, Inc. |
Methods and Compositions for Prevention or Treatment of RSV Infection Using Modified Duplex RNA Molecules
|
US8691514B2
(en)
|
2008-10-31 |
2014-04-08 |
Japan Science And Technology Agency |
Method for selective control of helper T cell function
|
UY32220A
(en)
|
2008-11-03 |
2010-06-30 |
Swetree Technologies Ab |
VEGETABLE MATERIAL, PLANTS AND METHOD TO PRODUCE THE PLANT CONTAINING ALTERED PROPERTIES OF LIGNINA
|
US9289475B2
(en)
|
2008-11-06 |
2016-03-22 |
The Johns Hopkins University |
Treatment of chronic inflammatory respiratory disorders
|
WO2010054328A2
(en)
|
2008-11-07 |
2010-05-14 |
Research Development Foundation |
Compositions and methods for the inhibition of cripto/grp78 complex formation and signaling
|
CA2742986C
(en)
*
|
2008-11-07 |
2015-03-31 |
Triact Therapeutics, Inc. |
Use of catecholic butane derivatives in cancer therapy
|
EP2687609B1
(en)
|
2008-11-10 |
2017-01-04 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Method for treating solid tumor
|
US20100132059A1
(en)
*
|
2008-11-10 |
2010-05-27 |
Wyeth Llc |
Temperature-induced polynucleotides and uses therefor
|
US20100179213A1
(en)
*
|
2008-11-11 |
2010-07-15 |
Mirna Therapeutics, Inc. |
Methods and Compositions Involving miRNAs In Cancer Stem Cells
|
CA2780482A1
(en)
|
2008-11-17 |
2010-05-10 |
Anil K. Sood |
Hdl particles for delivery of nucleic acids
|
US9074211B2
(en)
|
2008-11-19 |
2015-07-07 |
Rxi Pharmaceuticals Corporation |
Inhibition of MAP4K4 through RNAI
|
ES2667812T3
(en)
|
2008-11-20 |
2018-05-14 |
Novozymes Inc. |
Polypeptides having amylolytic enhancing activity and polynucleotides encoding them
|
CA2745111A1
(en)
|
2008-12-03 |
2010-06-10 |
Research Development Foundation |
Modulation of olfml-3 mediated angiogenesis
|
KR20110097915A
(en)
|
2008-12-03 |
2011-08-31 |
마리나 바이오테크, 인크. |
Usirna complexes
|
EP2373788A1
(en)
|
2008-12-04 |
2011-10-12 |
Novozymes Inc. |
Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same
|
EP2361306A1
(en)
|
2008-12-04 |
2011-08-31 |
OPKO Ophthalmics, LLC |
Compositions and methods for selective inhibition of pro-angiogenic vegf isoforms
|
US8497075B2
(en)
|
2008-12-09 |
2013-07-30 |
Novartis Ag |
Methods of identifying a modulator that inhibits the binding between Epstein-Barr virus induced receptor 2 and cholesterol derived ligands
|
CA2746514C
(en)
|
2008-12-10 |
2018-11-27 |
Alnylam Pharmaceuticals, Inc. |
Gnaq targeted dsrna compositions and methods for inhibiting expression
|
EP2198879A1
(en)
|
2008-12-11 |
2010-06-23 |
Institut Curie |
CD74 modulator agent for regulating dendritic cell migration and device for studying the motility capacity of a cell
|
AU2009326129B2
(en)
|
2008-12-12 |
2016-05-12 |
Basf Plant Science Gmbh |
Desaturases and process for the production of polyunsaturated fatty acids in transgenic organisms
|
WO2010068650A1
(en)
|
2008-12-12 |
2010-06-17 |
Novozymes, Inc. |
Polypeptides having lipase activity and polynucleotides encoding same
|
WO2010068800A1
(en)
|
2008-12-12 |
2010-06-17 |
Novozymes, Inc. |
Polypeptides having aspartic endopeptidase activity and polynucleotides encoding same
|
US20110269206A1
(en)
|
2008-12-15 |
2011-11-03 |
Novozymes, Inc |
Polypeptides Having Catalase Activity And Polynucleotides Encoding Same
|
WO2010074955A1
(en)
|
2008-12-16 |
2010-07-01 |
Novozymes, Inc. |
Polypeptides having carboxypeptidase activity and polynucleotides encoding same
|
US20110271407A1
(en)
|
2008-12-16 |
2011-11-03 |
Novozymes, Inc. |
Polypeptides Having Alpha-Mannosidase Activity And Polynucleotides Encoding Same
|
EP2370175A2
(en)
*
|
2008-12-16 |
2011-10-05 |
Bristol-Myers Squibb Company |
Methods of inhibiting quiescent tumor proliferation
|
EP2370575B1
(en)
|
2008-12-17 |
2017-11-01 |
Dow AgroSciences LLC |
Targeted integration into the zp15 locus
|
WO2010080129A2
(en)
|
2008-12-18 |
2010-07-15 |
Dicerna Pharmaceuticals, Inc. |
Extended dicer substrate agents and methods for the specific inhibition of gene expression
|
US20110288155A1
(en)
|
2008-12-18 |
2011-11-24 |
Elena Feinstein |
Sirna compounds and methods of use thereof
|
JP2012513464A
(en)
|
2008-12-23 |
2012-06-14 |
ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク |
Phosphodiesterase inhibitors and uses thereof
|
WO2010074783A1
(en)
|
2008-12-23 |
2010-07-01 |
The Trustees Of Columbia University In The City Of New York |
Phosphodiesterase inhibitors and uses thereof
|
EP2201982A1
(en)
|
2008-12-24 |
2010-06-30 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Histamine H4 receptor antagonists for the treatment of vestibular disorders
|
US9493774B2
(en)
|
2009-01-05 |
2016-11-15 |
Rxi Pharmaceuticals Corporation |
Inhibition of PCSK9 through RNAi
|
AU2010203474B2
(en)
*
|
2009-01-08 |
2015-11-19 |
Northwestern University |
Inhibition of bacterial protein production by polyvalent oligonucleotide modified nanoparticle conjugates
|
WO2010081001A2
(en)
|
2009-01-09 |
2010-07-15 |
The Regents Of The University Of Michigan |
Recurrent gene fusions in cancer
|
CN102388134A
(en)
|
2009-01-28 |
2012-03-21 |
诺维信股份有限公司 |
Polypeptides having beta-glucosidase activity and polynucleotides encoding same
|
WO2010088463A2
(en)
|
2009-01-30 |
2010-08-05 |
Novozymes, Inc. |
Polypeptides having expansin activity and polynucleotides encoding same
|
US8309530B2
(en)
*
|
2009-02-04 |
2012-11-13 |
Washington State University |
Compositions and methods for modulating ghrelin-mediated conditions
|
WO2010090762A1
(en)
|
2009-02-04 |
2010-08-12 |
Rxi Pharmaceuticals Corporation |
Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
|
EP2395996A1
(en)
|
2009-02-13 |
2011-12-21 |
Indiana University Research and Technology Corporation |
Compounds and methods for inhibiting mmp2 and mmp9
|
CA2750991C
(en)
|
2009-02-13 |
2019-09-10 |
The Regents Of The University Of California |
Control of plant stress tolerance, water use efficiency and gene expression using novel aba receptor proteins and synthetic agonists
|
WO2010099139A2
(en)
|
2009-02-25 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Combination anti-cancer therapy
|
US20120041051A1
(en)
|
2009-02-26 |
2012-02-16 |
Kevin Fitzgerald |
Compositions And Methods For Inhibiting Expression Of MIG-12 Gene
|
US20110171124A1
(en)
|
2009-02-26 |
2011-07-14 |
Osi Pharmaceuticals, Inc. |
In situ methods for monitoring the EMT status of tumor cells in vivo
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
US8642834B2
(en)
|
2009-02-27 |
2014-02-04 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
US8465912B2
(en)
|
2009-02-27 |
2013-06-18 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
AU2010223967B2
(en)
|
2009-03-12 |
2015-07-30 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
|
WO2010107952A2
(en)
|
2009-03-19 |
2010-09-23 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
BRPI1009271A8
(en)
|
2009-03-19 |
2016-02-10 |
Merck Sharp & Dohme |
DOUBLE-STRAND SHORT INTERFERING NUCLEIC ACID MOLECULE, PHARMACEUTICAL COMPOSITION, AND, METHOD FOR TREATMENT A HUMAN INDIVIDUAL SUFFERING FROM A CONDITION THAT IS MEDIATED BY THE ACTION, OR LOSS OF ACTION, OF BACH1
|
JP2012520685A
(en)
|
2009-03-19 |
2012-09-10 |
メルク・シャープ・エンド・ドーム・コーポレイション |
RNA interference-mediated inhibition of GATA binding protein 3 (GATA3) gene expression using small interfering nucleic acids (siNA)
|
US20120035247A1
(en)
|
2009-03-19 |
2012-02-09 |
Merck Sharp & Dohme Corp. |
RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 6 (STAT6) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
US8748493B2
(en)
|
2009-03-20 |
2014-06-10 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Inhibitors of cathepsin S for prevention or treatment of obesity-associated disorders
|
WO2010106163A1
(en)
|
2009-03-20 |
2010-09-23 |
Basf Plant Science Company Gmbh |
Nematode-resistant transgenic plants
|
EP2408904B1
(en)
|
2009-03-20 |
2017-10-18 |
Mesoblast, Inc. |
Production of reprogrammed pluripotent cells
|
US20110045080A1
(en)
*
|
2009-03-24 |
2011-02-24 |
William Marsh Rice University |
Single-Walled Carbon Nanotube/Bioactive Substance Complexes and Methods Related Thereto
|
WO2010111464A1
(en)
|
2009-03-27 |
2010-09-30 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
EP2411019A2
(en)
|
2009-03-27 |
2012-02-01 |
Merck Sharp&Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
KR20110138223A
(en)
|
2009-03-27 |
2011-12-26 |
머크 샤프 앤드 돔 코포레이션 |
Rna interference mediated inhibition of the intercellular adhesion molecule 1 (icam-1) gene expression using short interfering nucleic acid (sina)
|
US20120022143A1
(en)
|
2009-03-27 |
2012-01-26 |
Merck Sharp & Dohme Corp |
RNA Interference Mediated Inhibition of the Thymic Stromal Lymphopoietin (TSLP) Gene Expression Using Short Interfering Nucliec Acid (siNA)
|
US20120004281A1
(en)
|
2009-03-27 |
2012-01-05 |
Merck Sharp & Dohme Corp |
RNA Interference Mediated Inhibition of the Nerve Growth Factor Beta Chain (NGFB) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
US20100257634A1
(en)
*
|
2009-04-03 |
2010-10-07 |
Venganza Inc. |
Bioassay for gene silencing constructs
|
PL3199165T3
(en)
*
|
2009-04-03 |
2022-09-05 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of kras by asymmetric double-stranded rna
|
WO2010115874A1
(en)
|
2009-04-07 |
2010-10-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment and the diagnosis ofpulmonary arterial hypertension
|
US20100297127A1
(en)
|
2009-04-08 |
2010-11-25 |
Ghilardi Nico P |
Use of il-27 antagonists to treat lupus
|
WO2010120874A2
(en)
|
2009-04-14 |
2010-10-21 |
Chimeros, Inc. |
Chimeric therapeutics, compositions, and methods for using same
|
US8283332B2
(en)
|
2009-04-17 |
2012-10-09 |
University Of Louisville Research Foundation, Inc. |
PFKFB4 inhibitors and methods of using the same
|
CN102686244A
(en)
*
|
2009-04-21 |
2012-09-19 |
西莱克塔生物科技公司 |
Immunonanotherapeutics providing a Th1-biased response
|
US10519458B2
(en)
|
2009-04-22 |
2019-12-31 |
Basf Plant Science Company Gmbh |
Whole seed specific promoter
|
US8815586B2
(en)
*
|
2009-04-24 |
2014-08-26 |
The Board Of Regents Of The University Of Texas System |
Modulation of gene expression using oligomers that target gene regions downstream of 3′ untranslated regions
|
EP2243828A1
(en)
|
2009-04-24 |
2010-10-27 |
DKFZ Deutsches Krebsforschungszentrum |
Use of mixed lineage like kinase polypeptides (MLKL polypeptides) in cancer therapy
|
CA2760883A1
(en)
|
2009-05-05 |
2010-11-11 |
Beeologics Inc. |
Prevention and treatment of nosema disease in bees
|
MY186558A
(en)
*
|
2009-05-13 |
2021-07-27 |
Malaysian Palm Oil Board |
A constitutive promoter from oil palm type 2
|
US8207138B2
(en)
|
2009-05-19 |
2012-06-26 |
Medtronic, Inc. |
Methods and devices for improved efficiency of RNA delivery to cells
|
US20100298697A1
(en)
*
|
2009-05-19 |
2010-11-25 |
Medtronic, Inc. |
Method and devices for improved efficiency of rna delivery to cells
|
ES2432618T3
(en)
|
2009-05-20 |
2013-12-04 |
Inserm (Institut National De La Santé Et De La Recherche Medicale) |
Serotonin 5-HT3 receptor antagonists for use in the treatment or prevention of a pathology of the inner ear with vestibular deficit
|
ES2664599T3
(en)
|
2009-05-20 |
2018-04-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Serotonin 5-HT3 receptor antagonists for use in the treatment of lesion vestibular disorders
|
EP2432499A2
(en)
|
2009-05-20 |
2012-03-28 |
Schering Corporation |
Modulation of pilr receptors to treat microbial infections
|
CA2763283C
(en)
|
2009-05-21 |
2021-01-12 |
Verenium Corporation |
Phytases, nucleic acids encoding them and methods for making and using them
|
ES2804764T3
(en)
|
2009-06-01 |
2021-02-09 |
Halo Bio Rnai Therapeutics Inc |
Polynucleotides for multivalent RNA interference, compositions and methods of use thereof
|
EP2438163B1
(en)
|
2009-06-02 |
2015-01-21 |
Novozymes Inc. |
Polypeptides having cellobiohydrolase activity and polynucleotides encoding same
|
US9187757B2
(en)
|
2009-06-05 |
2015-11-17 |
University Of Florida Research Foundation, Inc. |
Isolation and targeted suppression of lignin biosynthetic genes
|
EP2258858A1
(en)
|
2009-06-05 |
2010-12-08 |
Universitätsklinikum Freiburg |
Transgenic LSD1 animal model for cancer
|
BRPI1010843A2
(en)
|
2009-06-08 |
2015-09-08 |
Nunhems Bv |
drought tolerant plants
|
CA2765034A1
(en)
|
2009-06-09 |
2010-12-23 |
Pioneer Hi-Bred International, Inc. |
Early endosperm promoter and methods of use
|
CN102458366B
(en)
|
2009-06-15 |
2015-02-11 |
阿尔尼拉姆医药品有限公司 |
Lipid formulated DSRNA targeting the PCSK9 gene
|
EP2266550A1
(en)
|
2009-06-15 |
2010-12-29 |
Institut Curie |
Antagonists of ß-catenin for preventing and/or treating neurodegenerative disorders
|
WO2010147992A1
(en)
|
2009-06-15 |
2010-12-23 |
Alnylam Pharmaceuticals, Inc. |
Methods for increasing efficacy of lipid formulated sirna
|
US20100323018A1
(en)
*
|
2009-06-17 |
2010-12-23 |
Massachusetts Institute Of Technology |
Branched DNA/RNA monomers and uses thereof
|
US20100324124A1
(en)
*
|
2009-06-17 |
2010-12-23 |
Massachusetts Institute Of Technology |
Compositions and methods relating to DNA-based particles
|
US20120142609A1
(en)
|
2009-06-26 |
2012-06-07 |
Abdoulaye Sene |
Non human animal models for increased retinal vascular permeability
|
CA2764073A1
(en)
|
2009-06-30 |
2011-01-20 |
E. I. Du Pont De Nemours And Company |
Plant seeds with altered storage compound levels, related constructs and methods involving genes encoding cytosolic pyrophosphatase
|
CA2767169A1
(en)
|
2009-07-07 |
2011-01-13 |
Novozymes, Inc. |
Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same
|
CN104744310A
(en)
|
2009-07-09 |
2015-07-01 |
玛瑞纳生物技术有限公司 |
Amphoteric liposomes comprising imino lipids
|
US8921657B2
(en)
|
2009-07-10 |
2014-12-30 |
Basf Plant Science Company Gmbh |
Expression cassettes for endosperm-specific expression in plants
|
US20120107243A1
(en)
|
2009-07-14 |
2012-05-03 |
Mayo Foundation For Medical Education And Research |
Peptide-mediated non-covalent delivery of active agents across the blood-brain barrier
|
HUE033312T2
(en)
|
2009-07-20 |
2017-11-28 |
Bristol Myers Squibb Co |
Combination of an anti-CTLA4 antibody with etoposide for the synergistic treatment of proliferative diseases
|
WO2011011412A2
(en)
|
2009-07-20 |
2011-01-27 |
Ceres, Inc. |
Transgenic plants having increased biomass
|
US9409983B2
(en)
|
2009-07-23 |
2016-08-09 |
The Board Of Trustess Of The University Of Illinois |
Methods and compositions involving PBEF inhibitors for lung inflammation conditions and diseases
|
IN2012DN00303A
(en)
|
2009-07-24 |
2015-05-08 |
Univ California |
|
WO2011014458A1
(en)
|
2009-07-28 |
2011-02-03 |
Novozymes, Inc. |
Polypeptides having phytase activity and polynucleotides encoding same
|
NZ598457A
(en)
*
|
2009-08-03 |
2014-06-27 |
Recombinetics Inc |
Methods and compositions for targeted gene modification
|
CA2806295A1
(en)
|
2009-08-03 |
2011-02-10 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating insects
|
AP3574A
(en)
|
2009-08-14 |
2016-02-08 |
Alnylam Pharmaceuticals Inc |
Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
|
US8822144B2
(en)
|
2009-08-19 |
2014-09-02 |
Rosetta Genomics Ltd. |
Compositions and methods for prognosis and treatment of prostate cancer
|
US20120258093A1
(en)
|
2009-08-20 |
2012-10-11 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
|
CN102481311A
(en)
|
2009-08-21 |
2012-05-30 |
比欧洛吉科斯公司 |
Preventing and curing beneficial insect diseases via plant transcribed molecules
|
US8222397B2
(en)
*
|
2009-08-28 |
2012-07-17 |
Promega Corporation |
Methods of optimal purification of nucleic acids and kit for use in performing such methods
|
US8039613B2
(en)
|
2009-08-28 |
2011-10-18 |
Promega Corporation |
Methods of purifying a nucleic acid and formulation and kit for use in performing such methods
|
WO2011028880A2
(en)
|
2009-09-04 |
2011-03-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods for enhancing genome stability and telomere elongation in embryonic stem cells
|
ES2655079T3
(en)
|
2009-09-10 |
2018-02-16 |
Merck Sharp & Dohme Corp. |
Use of IL-33 antagonists to treat fibrotic diseases
|
WO2011032100A1
(en)
|
2009-09-11 |
2011-03-17 |
Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Inhibitors of kshv vil6 and human il6
|
AU2010291985B2
(en)
|
2009-09-14 |
2016-05-05 |
The Regents Of The University Of Colorado |
Modulation of yeast-based immunotherapy products and responses
|
EP3269804B1
(en)
|
2009-09-17 |
2020-11-11 |
Novozymes, Inc. |
Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same
|
CN102712916B
(en)
|
2009-09-18 |
2015-11-25 |
诺维信股份有限公司 |
There are the polypeptide of beta-glucosidase activity and the polynucleotide of this polypeptide of coding
|
WO2011036118A1
(en)
*
|
2009-09-22 |
2011-03-31 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating cancer by modulating mex-3
|
CA2775347A1
(en)
|
2009-09-29 |
2011-04-07 |
Novozymes A/S |
Polypeptides having xylanase activity and polynucleotides encoding same
|
BR112012006982B1
(en)
|
2009-09-29 |
2021-12-21 |
Novozymes, Inc. |
TRANSGENIC MICROBIAL HOST CELL, METHODS FOR PRODUCING A POLYPEPTIDE, FOR PRODUCING A MUTANT OF A PRECURSOR CELL, FOR INHIBITING THE EXPRESSION OF A POLYPEPTIDE, FOR PRODUCING A PROTEIN, FOR DEGRADING OR CONVERTING A CELLULOSIC MATERIAL, FOR PRODUCING A FERMENTATION PRODUCT, FOR FERMENTING A CELLULOSIC MATERIAL, NUCLEIC ACID CONSTRUCTIONS, EXPRESSION VECTOR, ISOLATED POLYPEPTIDE HAVING CELLULOLYTIC ENHANCEMENT ACTIVITY, ISOLATED POLYNUCLEOTIDE ENCODING THE SAME, AND, DETERGENT COMPOSITION
|
US8586829B2
(en)
|
2009-09-30 |
2013-11-19 |
Novozymes A/S |
Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same
|
ES2551141T3
(en)
|
2009-09-30 |
2015-11-16 |
Novozymes Inc. |
Thermoascus crustaceus derived polypeptides with cellulolytic augmentation activity and polynucleotides encoding them
|
US20150025122A1
(en)
|
2009-10-12 |
2015-01-22 |
Larry J. Smith |
Methods and Compositions for Modulating Gene Expression Using Oligonucleotide Based Drugs Administered in vivo or in vitro
|
US8962584B2
(en)
|
2009-10-14 |
2015-02-24 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. |
Compositions for controlling Varroa mites in bees
|
UA109884C2
(en)
|
2009-10-16 |
2015-10-26 |
|
A POLYPEPTIDE THAT HAS THE ACTIVITY OF THE PHOSPHATIDYLINOSYTOL-SPECIFIC PHOSPHOLIPASE C, NUCLEIC ACID, AND METHOD OF METHOD
|
UA111708C2
(en)
|
2009-10-16 |
2016-06-10 |
Бандж Ойлз, Інк. |
METHOD OF OIL REFINING
|
EP2490696A1
(en)
|
2009-10-20 |
2012-08-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of disorders of glucose homeostasis
|
IN2012DN03073A
(en)
|
2009-10-26 |
2015-07-31 |
Pioneer Hi Bred Int |
|
CA2776336A1
(en)
|
2009-10-29 |
2011-05-19 |
Novozymes, Inc. |
Polypeptides having cellobiohydrolase activity and polynucleotides encoding same
|
US9799416B2
(en)
*
|
2009-11-06 |
2017-10-24 |
Terrapower, Llc |
Methods and systems for migrating fuel assemblies in a nuclear fission reactor
|
EP2496693B1
(en)
|
2009-11-06 |
2017-10-25 |
Novozymes, Inc. |
Polypeptides having cellobiohydrolase activity and polynucleotides encoding same
|
EP2501398A1
(en)
|
2009-11-06 |
2012-09-26 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical composition for the treatment of atherosclerosis
|
CN104694517B
(en)
|
2009-11-06 |
2019-06-28 |
诺维信股份有限公司 |
Polypeptide with xylanase activity and the polynucleotides for encoding the polypeptide
|
US8901097B2
(en)
|
2009-11-08 |
2014-12-02 |
Quark Pharmaceuticals, Inc. |
Methods for delivery of siRNA to the spinal cord and therapies arising therefrom
|
EP2322927A1
(en)
|
2009-11-16 |
2011-05-18 |
Deutsches Krebsforschungszentrum |
Compounds inhibiting CD95 signaling for the treatment of pancreatic cancer
|
EP2501414B1
(en)
|
2009-11-17 |
2018-01-10 |
The Trustees Of The University Of Pennsylvania |
Smndelta7 degron: novel compositions and methods of use
|
EP2322619A1
(en)
|
2009-11-17 |
2011-05-18 |
Deutsches Krebsforschungszentrum |
Inhibitors of centrosomal clustering
|
EP3037435B1
(en)
|
2009-11-17 |
2019-08-07 |
MUSC Foundation for Research Development |
Human monoclonal antibodies to human nucleolin
|
NZ599237A
(en)
|
2009-11-26 |
2014-03-28 |
Quark Pharmaceuticals Inc |
Sirna compounds comprising terminal substitutions
|
EP2505660B1
(en)
|
2009-11-27 |
2014-05-21 |
Japan Science And Technology Agency |
Method for screening of therapeutic agent for hyperlipemia
|
EP2507375A4
(en)
|
2009-12-03 |
2013-04-24 |
Basf Plant Science Co Gmbh |
Expression cassettes for embryo-specific expression in plants
|
AU2010328295B2
(en)
|
2009-12-07 |
2015-09-10 |
The Johns Hopkins University |
SR-BI as a predictor of human female infertility and responsiveness to treatment
|
WO2011072091A1
(en)
|
2009-12-09 |
2011-06-16 |
Quark Pharmaceuticals, Inc. |
Methods and compositions for treating diseases, disorders or injury of the cns
|
KR101692063B1
(en)
|
2009-12-09 |
2017-01-03 |
닛토덴코 가부시키가이샤 |
MODULATION OF hsp47 EXPRESSION
|
US20120283190A1
(en)
|
2009-12-09 |
2012-11-08 |
Institut National de la Santé et de la Recherche Medicale (INSERM) |
Endothelin inhibitors for the treatment of rapidly progressive glomerulonephritis
|
WO2011069953A1
(en)
|
2009-12-09 |
2011-06-16 |
Basf Plant Science Company Gmbh |
Methods for increasing the resistance of plants to fungi by silencing the fungal smt1-gene
|
US10640457B2
(en)
|
2009-12-10 |
2020-05-05 |
The Trustees Of Columbia University In The City Of New York |
Histone acetyltransferase activators and uses thereof
|
ES2764999T3
(en)
|
2009-12-10 |
2020-06-05 |
Univ Columbia |
Histone acetyltransferase activators and uses thereof
|
US8691227B2
(en)
|
2009-12-17 |
2014-04-08 |
Merck Sharp & Dohme Corp. |
Methods of treating multiple sclerosis, rheumatoid arthritis and inflammatory bowel disease using agonists antibodies to PILR-α
|
JP5819848B2
(en)
*
|
2009-12-18 |
2015-11-24 |
アローヘッド リサーチ コーポレイション |
Organic composition for treating HSF1-related diseases
|
CA2785492C
(en)
|
2009-12-23 |
2018-07-24 |
Novartis Ag |
Lipids, lipid compositions, and methods of using them
|
CN108295087B
(en)
|
2009-12-23 |
2021-01-15 |
格兰达利斯有限公司 |
Furin-knockdown and GM-CSF-enhanced (FANG) cancer vaccines
|
US9157084B2
(en)
|
2009-12-23 |
2015-10-13 |
Gradalis, Inc. |
Furin-knockdown bi-functional RNA
|
WO2011080261A1
(en)
|
2009-12-28 |
2011-07-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for improved cardiomyogenic differentiation of pluripotent cells
|
WO2011082106A1
(en)
|
2009-12-29 |
2011-07-07 |
Hill's Pet Nutrition, Inc. |
Compositions including ginger for the amelioration or prevention of inflammatory conditions
|
EP2521782B1
(en)
|
2010-01-05 |
2019-04-10 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Flt3 receptor antagonists for the treatment or the prevention of pain disorders
|
WO2011084193A1
(en)
|
2010-01-07 |
2011-07-14 |
Quark Pharmaceuticals, Inc. |
Oligonucleotide compounds comprising non-nucleotide overhangs
|
TWI535445B
(en)
|
2010-01-12 |
2016-06-01 |
安可美德藥物股份有限公司 |
Wnt antagonists and methods of treatment and screening
|
DE102010004957A1
(en)
|
2010-01-14 |
2011-07-21 |
Universitätsklinikum Jena, 07743 |
Biologically active molecules for influencing virus, bacterial, parasite-infected cells and / or tumor cells and methods for their use
|
CA2786956C
(en)
|
2010-01-15 |
2018-07-10 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Compounds for the treatment of autism
|
EP2529033B1
(en)
|
2010-01-26 |
2017-05-24 |
National Jewish Health |
Methods for risk prediction, diagnosis, prognosis of pulmonary disorders
|
WO2011100058A1
(en)
|
2010-02-09 |
2011-08-18 |
Sangamo Biosciences, Inc. |
Targeted genomic modification with partially single-stranded donor molecules
|
JP2013519869A
(en)
|
2010-02-10 |
2013-05-30 |
ノバルティス アーゲー |
Methods and compounds for muscle growth
|
BR112012019609A2
(en)
|
2010-02-23 |
2019-09-24 |
Basf Plant Science Gmbh |
isolated expression vector, plants, transgenic method for producing a transgenic plant and method for conferring nematode resistance in a plant
|
WO2011109572A2
(en)
|
2010-03-03 |
2011-09-09 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
US20110217309A1
(en)
|
2010-03-03 |
2011-09-08 |
Buck Elizabeth A |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
EP2860254A1
(en)
|
2010-03-03 |
2015-04-15 |
E. I. du Pont de Nemours and Company |
Plant seeds with altered storage compound levels, related constructs and methods involving genes encoding oxidoreductase motif polypeptides
|
NZ601784A
(en)
|
2010-03-08 |
2014-08-29 |
Monsanto Technology Llc |
Polynucleotide molecules for gene regulation in plants
|
WO2011116209A2
(en)
|
2010-03-17 |
2011-09-22 |
The Regents Of The University Of Michigan |
Using phage epitopes to profile the immune response
|
WO2011119871A1
(en)
|
2010-03-24 |
2011-09-29 |
Rxi Phrmaceuticals Corporation |
Rna interference in ocular indications
|
JP6060071B2
(en)
|
2010-03-24 |
2017-01-11 |
アールエックスアイ ファーマシューティカルズ コーポレーション |
RNA interference in skin and fibrosis applications
|
EP2550000A4
(en)
|
2010-03-24 |
2014-03-26 |
Advirna Inc |
Reduced size self-delivering rnai compounds
|
WO2011120023A1
(en)
|
2010-03-26 |
2011-09-29 |
Marina Biotech, Inc. |
Nucleic acid compounds for inhibiting survivin gene expression uses thereof
|
EP2552460A1
(en)
|
2010-03-29 |
2013-02-06 |
Universite De Strasbourg |
Polymers for delivering molecules of interest
|
EP3329924B1
(en)
|
2010-03-29 |
2021-05-05 |
Alnylam Pharmaceuticals, Inc. |
Dsrna therapy for transthyretin (ttr) related ocular amyloidosis
|
EP2552953B1
(en)
|
2010-04-01 |
2017-05-17 |
OncoMed Pharmaceuticals, Inc. |
Frizzled-binding agents and uses thereof
|
JP2013523162A
(en)
|
2010-04-06 |
2013-06-17 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
Compositions and methods for inhibiting the expression of the CD274 / PD-L1 gene
|
WO2011133584A2
(en)
|
2010-04-19 |
2011-10-27 |
Marina Biotech, Inc. |
Nucleic acid compounds for inhibiting hras gene expression and uses thereof
|
WO2011133931A1
(en)
|
2010-04-22 |
2011-10-27 |
Genentech, Inc. |
Use of il-27 antagonists for treating inflammatory bowel disease
|
WO2011139710A1
(en)
|
2010-04-26 |
2011-11-10 |
Marina Biotech, Inc. |
Nucleic acid compounds with conformationally restricted monomers and uses thereof
|
WO2011139843A2
(en)
|
2010-04-28 |
2011-11-10 |
Marina Biotech, Inc. |
Multi-sirna compositions for reducing gene expression
|
WO2011140173A1
(en)
|
2010-05-04 |
2011-11-10 |
The Brigham And Women's Hospital, Inc. |
Detection and treatment of fibrosis
|
US9441233B2
(en)
|
2010-05-06 |
2016-09-13 |
Ceres, Inc. |
Transgenic plants having increased biomass
|
US8957052B2
(en)
|
2010-05-10 |
2015-02-17 |
Universite Paris Descartes |
Methods and compositions for the treatment of fluid accumulation in and/or under the retina
|
AU2011250904A1
(en)
|
2010-05-11 |
2012-11-08 |
Dow Agrosciences Llc |
spnK strains
|
US8658780B2
(en)
|
2010-05-18 |
2014-02-25 |
California Institute Of Technology |
Triggered covalent probes for imaging and silencing genetic expression
|
KR101223660B1
(en)
|
2010-05-20 |
2013-01-17 |
광주과학기술원 |
Pharmaceutical Compositions for Preventing or Treating Arthritis Comprising HIF-2α Inhibitor as an Active Ingredient
|
EP2571987B1
(en)
|
2010-05-21 |
2017-03-01 |
Peptimed, Inc. |
Reagents for treating cancer
|
CN107029222A
(en)
|
2010-05-26 |
2017-08-11 |
西莱克塔生物科技公司 |
Synthesize nano-carrier combined vaccine
|
WO2011147968A1
(en)
|
2010-05-28 |
2011-12-01 |
Nunhems B.V. |
Plants with increased fruit size
|
US20130149320A1
(en)
|
2010-05-31 |
2013-06-13 |
Centre National De La Recherche Scientifique |
Asf1b as a Prognosis Marker and Therapeutic Target in Human Cancer
|
CA2801066C
(en)
|
2010-06-02 |
2021-02-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods directed to treating liver fibrosis
|
DE102010022937A1
(en)
|
2010-06-04 |
2011-12-08 |
Universitätsklinikum Jena |
Cell-specific activatable biologically active molecules based on siRNA, methods for their activation and application kit for administration
|
GB201009601D0
(en)
|
2010-06-08 |
2010-07-21 |
Devgen Private Ltd |
Method for down-grading gene expression in fungi
|
JP6180930B2
(en)
|
2010-06-16 |
2017-08-16 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Methods and compositions for stimulating reepithelialization during wound healing processes
|
CN103080126B
(en)
|
2010-06-21 |
2016-05-11 |
诺维信股份有限公司 |
There are the polypeptide of C4-dicarboxylic acids transport protein activity and the polynucleotides of this polypeptide of coding
|
WO2011163466A1
(en)
|
2010-06-23 |
2011-12-29 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Regulation of skin pigmentation by neuregulin-1 (nrg-1)
|
WO2012000904A1
(en)
|
2010-06-28 |
2012-01-05 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Pharmaceutical composition for use in the treatment of glaucoma
|
US8581042B2
(en)
|
2010-06-30 |
2013-11-12 |
Novozymes A/S |
Polypeptides having beta-glucosidase activity and polynucleotides encoding same
|
BR112012033668A2
(en)
|
2010-07-01 |
2017-06-13 |
Du Pont |
transgenic plant and seed, method for producing a transgenic plant, product and / or by-product obtained from the transgenic seed, isolated polynucleotide and plant or seed comprising a recombinant DNA construct
|
WO2012007945A2
(en)
|
2010-07-12 |
2012-01-19 |
The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization, (A.R.O.), Volcani Center |
Isolated polynucleotides and methods and plants using same for regulating plant acidity
|
US8877438B2
(en)
|
2010-07-20 |
2014-11-04 |
California Institute Of Technology |
Self-assembled polynucleotide structure
|
US8962241B2
(en)
|
2010-07-20 |
2015-02-24 |
California Institute Of Technology |
Triggered molecular geometry based bioimaging probes
|
US9834439B2
(en)
|
2010-07-20 |
2017-12-05 |
California Institute Of Technology |
Biomolecular self-assembly
|
WO2012010696A1
(en)
|
2010-07-23 |
2012-01-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for cancer management targeting co-029
|
CN103068980B
(en)
|
2010-08-02 |
2017-04-05 |
瑟纳治疗公司 |
Using short interfering nucleic acid(siNA)The connection albumen led of mediated rnai(Cadherin related protein matter), β 1(CTNNB1)The suppression of gene expression
|
JP5903718B2
(en)
|
2010-08-09 |
2016-04-13 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Methods and pharmaceutical compositions for the treatment of HIV-1 infection
|
BR112013003224A2
(en)
|
2010-08-13 |
2016-06-07 |
Pioneer Hi Bred Int |
"chimeric promoter construct, expression cassette, expression vector, method of obtaining a plant, method for regulating expression of a polynucleotide of interest, polynucleotide, method for expressing a polynucleotide of interest"
|
CA2807307C
(en)
|
2010-08-17 |
2021-02-09 |
Merck Sharp & Dohme Corp. |
Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
|
EP3192880B1
(en)
|
2010-08-18 |
2019-10-09 |
Fred Hutchinson Cancer Research Center |
Nucleic acid agents for use in treating facioscapulohumeral dystrophy (fshd)
|
CN103140582A
(en)
|
2010-08-24 |
2013-06-05 |
默沙东公司 |
Single-stranded rnai agents containing an internal, non-nucleic acid spacer
|
WO2012027467A1
(en)
|
2010-08-26 |
2012-03-01 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF PROLYL HYDROXYLASE DOMAIN 2 (PHD2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US8624082B2
(en)
|
2010-08-30 |
2014-01-07 |
Novozymes A/S |
Polypeptides having xylanase activity and polynucleotides encoding same
|
WO2012030799A1
(en)
|
2010-08-30 |
2012-03-08 |
Novozymes A/S |
Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same
|
WO2012030858A2
(en)
|
2010-08-30 |
2012-03-08 |
Novozymes A/S |
Polypeptides having hemicellulolytic activity and polynucleotides encoding same
|
EP2611901B1
(en)
|
2010-08-30 |
2016-05-11 |
Novozymes A/S |
Polypeptides having beta-glucosidase activity, beta-xylosidase activity, or beta-glucosidase and beta-xylosidase activity and polynucleotides encoding same
|
WO2012030844A1
(en)
|
2010-08-30 |
2012-03-08 |
Novozymes A/S |
Polypeptides having endoglucanase activity and polynucleotides encoding same
|
US9187742B2
(en)
|
2010-08-30 |
2015-11-17 |
Novozymes, Inc. |
Polypeptides having cellobiohydrolase activity and polynucleotides encoding same
|
WO2012028703A1
(en)
|
2010-09-02 |
2012-03-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for the prognosis of the progression of cancer
|
WO2012042289A1
(en)
|
2010-09-28 |
2012-04-05 |
Inserm ( Institut National De La Sante Et De La Recherche Medicale) |
Methods and pharmaceutical compositions for the treatment of bone density related diseases
|
US20140079769A1
(en)
|
2010-10-01 |
2014-03-20 |
Fabiola Terzi |
Methods for predicting the progression and treating a chronic kidney disease in a patient
|
WO2012051055A2
(en)
|
2010-10-06 |
2012-04-19 |
Bp Corporation North America Inc. |
Variant cbh i polypeptides
|
US20140134231A1
(en)
|
2010-10-11 |
2014-05-15 |
Sanford-Burnham Medical Research Institute |
Mir-211 expression and related pathways in human melanoma
|
WO2012051491A1
(en)
|
2010-10-14 |
2012-04-19 |
The United States Of America, As Represented By The Secretary National Institutes Of Health |
Compositions and methods for controlling neurotropic viral pathogenesis by micro-rna targeting
|
CN108404115A
(en)
|
2010-10-15 |
2018-08-17 |
纽约市哥伦比亚大学理事会 |
The relevant gene of obesity-and their albumen and its purposes
|
CN107828820B
(en)
|
2010-10-27 |
2022-06-07 |
学校法人自治医科大学 |
Adeno-associated virus particles for gene transfer into nervous system cells
|
BR112013010278B1
(en)
|
2010-10-27 |
2020-12-29 |
Ceres, Inc |
method to produce a plant, method to modulate the biomass composition in a plant, isolated nucleic acid and method to alter the biomass composition in a plant
|
WO2012058073A2
(en)
|
2010-10-27 |
2012-05-03 |
Harrisvaccines, Inc. |
Methods and compositions to protect aquatic invertebrates from disease
|
US10004797B2
(en)
|
2010-10-27 |
2018-06-26 |
Harrisvaccines, Inc. |
Method of rapidly producing improved vaccines for animals
|
US8822427B2
(en)
|
2010-10-27 |
2014-09-02 |
Harrisvaccines |
Methods and compositions to protect aquatic invertebrates from disease
|
WO2012058210A1
(en)
|
2010-10-29 |
2012-05-03 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
|
US8728804B2
(en)
|
2010-10-29 |
2014-05-20 |
Novozymes A/S |
Polypeptides having succinyl-CoA: acetoacetate transferase activity and polynucleotides encoding same
|
WO2012061443A2
(en)
|
2010-11-01 |
2012-05-10 |
NanoOncology, Inc. |
Compositions of a peptide-based system for cell-specific targeting
|
SI2635299T1
(en)
|
2010-11-02 |
2020-02-28 |
The Trustees Of Columbia University In The City Of New York |
Methods for treating hair loss disorders
|
US9198911B2
(en)
|
2010-11-02 |
2015-12-01 |
The Trustees Of Columbia University In The City Of New York |
Methods for treating hair loss disorders
|
US9212354B2
(en)
|
2010-11-04 |
2015-12-15 |
Novozymes Inc. |
Polypeptides having cellobiohydrolase activitiy and polynucleotides encoding same
|
AU2011325875B2
(en)
|
2010-11-04 |
2016-03-17 |
Arista Cereal Technologies Pty Ltd |
High amylose wheat
|
JP6296536B2
(en)
|
2010-11-05 |
2018-03-20 |
メドベット サイエンス ピーティーワイエルティーディーMedvet Science Pty Ltd |
Endothelial progenitor cell markers and uses thereof
|
US9339513B2
(en)
|
2010-11-09 |
2016-05-17 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
|
WO2012062220A1
(en)
|
2010-11-12 |
2012-05-18 |
Novozymes A/S |
Polypeptides having endoglucanase activity and polynucleotides encoding same
|
EP2455456A1
(en)
|
2010-11-22 |
2012-05-23 |
Institut Curie |
Use of kinesin inhibitors in HIV infection treatment and a method for screening them
|
US20130336979A1
(en)
|
2010-12-01 |
2013-12-19 |
Fatima Smih |
Diagnostic and treatment of chronic heart failure
|
WO2012074868A2
(en)
|
2010-12-03 |
2012-06-07 |
Ms Technologies, Llc |
Optimized expression of glyphosate resistance encoding nucleic acid molecules in plant cells
|
WO2012072820A1
(en)
|
2010-12-03 |
2012-06-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of heart failure
|
CN103298939A
(en)
|
2010-12-06 |
2013-09-11 |
夸克医药公司 |
Double stranded oligonucleotide compounds comprising positional modifications
|
US9150926B2
(en)
|
2010-12-06 |
2015-10-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Diagnosis and treatment of adrenocortical tumors using human microRNA-483
|
WO2012102793A2
(en)
|
2010-12-10 |
2012-08-02 |
Zirus, Inc. |
Mammalian genes involved in toxicity and infection
|
US8575328B2
(en)
*
|
2010-12-14 |
2013-11-05 |
The United States Of America, As Represented By The Secretary Of Agriculture |
Formicidae (ant) control using double-stranded RNA constructs
|
MX2013007086A
(en)
|
2010-12-22 |
2013-07-29 |
Du Pont |
Viral promoter, truncations thereof, and methods of use.
|
CA2822621C
(en)
|
2010-12-22 |
2020-12-15 |
The Trustees Of Columbia University In The City Of New York |
Histone acetyltransferase modulators and uses thereof
|
CN103261425B
(en)
|
2010-12-22 |
2015-07-15 |
先锋国际良种公司 |
Viral promoter, truncations thereof, and methods of use
|
WO2012093384A1
(en)
|
2011-01-03 |
2012-07-12 |
Rosetta Genomics Ltd. |
Compositions and methods for treatment of ovarian cancer
|
JP2014505057A
(en)
|
2011-01-10 |
2014-02-27 |
ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、ミシガン |
Stem cell factor inhibitor
|
US20150018408A1
(en)
|
2013-07-10 |
2015-01-15 |
The Regents Of The University Of Michigan |
Therapeutic antibodies and uses thereof
|
WO2012103350A1
(en)
|
2011-01-26 |
2012-08-02 |
Novozymes A/S |
Polypeptides having cellobiohydrolase activity and polynucleotides encoding same
|
US9157075B2
(en)
|
2011-01-26 |
2015-10-13 |
Novozymes, Inc. |
Polypeptides having cellobiohydrolase activity and polynucleotides encoding same
|
EP2487242A1
(en)
|
2011-02-09 |
2012-08-15 |
Ruprecht-Karls-Universität Heidelberg |
B-type plexin antagonists and uses thereof
|
WO2012107589A1
(en)
|
2011-02-11 |
2012-08-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
|
CN103492576A
(en)
|
2011-02-14 |
2014-01-01 |
雷维维科公司 |
Genetically modified pigs for xenotransplantation of vascularized xenografts and derivatives thereof
|
CA2826276C
(en)
|
2011-02-15 |
2020-03-24 |
Pioneer Hi-Bred International, Inc. |
Root-preferred promoter and methods of use
|
WO2012116040A1
(en)
|
2011-02-22 |
2012-08-30 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
|
US9796979B2
(en)
|
2011-03-03 |
2017-10-24 |
Quark Pharmaceuticals Inc. |
Oligonucleotide modulators of the toll-like receptor pathway
|
SG193280A1
(en)
|
2011-03-03 |
2013-10-30 |
Quark Pharmaceuticals Inc |
Oligonucleotide modulators of the toll-like receptor pathway
|
KR101937498B1
(en)
|
2011-03-03 |
2019-04-10 |
쿠아크 파마수티칼스 인코퍼레이티드 |
Compositions and methods for treating lung disease and injury
|
WO2012120130A1
(en)
|
2011-03-09 |
2012-09-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods to characterize patients suffering from hemolysis
|
WO2012122477A1
(en)
|
2011-03-10 |
2012-09-13 |
Novozymes A/S |
Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same
|
WO2012125872A2
(en)
|
2011-03-15 |
2012-09-20 |
University Of Utah Research Foundation |
Methods of diagnosing and treating vascular associated maculopathy and symptoms thereof
|
US10184942B2
(en)
|
2011-03-17 |
2019-01-22 |
University Of South Florida |
Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
|
WO2012129145A1
(en)
|
2011-03-18 |
2012-09-27 |
OSI Pharmaceuticals, LLC |
Nscle combination therapy
|
US8648230B2
(en)
|
2011-03-18 |
2014-02-11 |
Ms Technologies, Llc |
Regulatory regions preferentially expressing in non-pollen plant tissue
|
CA2832972C
(en)
|
2011-04-13 |
2019-04-30 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of ptp1b expression
|
CA2834960A1
(en)
|
2011-04-13 |
2012-10-18 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Non human animal model for ulcerative colitis and its main complications
|
KR101291668B1
(en)
|
2011-04-21 |
2013-08-01 |
서울대학교산학협력단 |
Shuttle Vectors for Mycobacteria-Escherichia coli and Uses Thereof
|
US9896730B2
(en)
|
2011-04-25 |
2018-02-20 |
OSI Pharmaceuticals, LLC |
Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
|
WO2012146702A1
(en)
|
2011-04-28 |
2012-11-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for preparing accessory cells and uses thereof for preparing activated nk cells
|
MX2013012325A
(en)
|
2011-04-28 |
2013-11-01 |
Novozymes Inc |
Polypeptides having endoglucanase activity and polynucleotides encoding same.
|
US9677084B2
(en)
*
|
2011-04-29 |
2017-06-13 |
Pioneer Hi-Bred International, Inc. |
Down-regulation of a homeodomain-leucine zipper I-class homeobox gene for improved plant performance
|
EP2520658B1
(en)
|
2011-05-03 |
2015-10-07 |
Dow AgroSciences LLC |
Enhancing spinosyn production with oxygen binding proteins
|
EP2704688B1
(en)
|
2011-05-05 |
2019-07-10 |
Matinas BioPharma Nanotechnologies, Inc. |
Cochleate compositions and methods of making and using same
|
EP2527448A1
(en)
|
2011-05-23 |
2012-11-28 |
Novozymes A/S |
Simultaneous site-specific integrations of multiple gene-copies in filamentous fungi
|
EP2527432A1
(en)
|
2011-05-23 |
2012-11-28 |
Novozymes A/S |
Bi-directional cytosine deaminase-encoding selection marker
|
ES2703133T3
(en)
|
2011-05-24 |
2019-03-07 |
Rosetta Genomics Ltd |
Methods and compositions for determining heart failure or a risk of heart failure
|
CA2836364C
(en)
|
2011-05-25 |
2021-01-26 |
Universite Paris Descartes |
Erk inhibitors for use in treating spinal muscular atrophy
|
WO2012163848A1
(en)
|
2011-05-27 |
2012-12-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of crohn's disease
|
US9920327B2
(en)
|
2011-06-02 |
2018-03-20 |
The Regents Of The University Of California |
Plants with elevated levels of glucan
|
DK3011974T3
(en)
|
2011-06-02 |
2018-11-12 |
Univ Louisville Res Found Inc |
Anti-nucleolin agent-conjugated nanoparticles
|
TWI658830B
(en)
|
2011-06-08 |
2019-05-11 |
日東電工股份有限公司 |
Retinoid-liposomes for enhancing modulation of hsp47 expression
|
US10196637B2
(en)
|
2011-06-08 |
2019-02-05 |
Nitto Denko Corporation |
Retinoid-lipid drug carrier
|
GB201109966D0
(en)
|
2011-06-10 |
2011-07-27 |
Cancer Res Inst Royal |
Materials and methods for treating pten mutated or deficient cancer
|
AU2012267241B2
(en)
|
2011-06-10 |
2017-04-06 |
Temasek Life Sciences Laboratory Limited |
Genetic manipulation and expression systems for Pucciniomycotina and Ustilaginomycotina subphyla
|
GB201109965D0
(en)
|
2011-06-10 |
2011-07-27 |
Cancer Res Inst Royal |
Materials and methods for treating estrogen receptor alpher(ER) positive cancer
|
US9228188B2
(en)
|
2011-06-21 |
2016-01-05 |
Alnylam Pharmaceuticals, Inc. |
Compositions and method for inhibiting hepcidin antimicrobial peptide (HAMP) or HAMP-related gene expression
|
US20140275211A1
(en)
|
2011-06-21 |
2014-09-18 |
Alnylam Pharmaceuticals, Inc. |
Assays and methods for determining activity of a therapeutic agent in a subject
|
KR20230084331A
(en)
|
2011-06-21 |
2023-06-12 |
알닐람 파마슈티칼스 인코포레이티드 |
Compositions and methods for inhibition of expression of apolipoprotein c-iii(apoc3) genes
|
WO2012177949A2
(en)
|
2011-06-21 |
2012-12-27 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibition of expression of protein c (proc) genes
|
EP3597750B1
(en)
|
2011-06-23 |
2022-05-04 |
Alnylam Pharmaceuticals, Inc. |
Serpina1 sirnas: compositions of matter and methods of treatment
|
WO2012175711A1
(en)
|
2011-06-24 |
2012-12-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for predicting the responsiveness of a patient affected with an osteosarcoma to a chemotherapy
|
WO2013003697A1
(en)
|
2011-06-30 |
2013-01-03 |
Trustees Of Boston University |
Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
|
WO2013001372A2
(en)
|
2011-06-30 |
2013-01-03 |
University Of Oslo |
Methods and compositions for inhibition of activation of regulatory t cells
|
CA2840856C
(en)
|
2011-07-06 |
2017-09-19 |
Sykehuset Sorlandet Hf |
Egfr targeted therapy
|
WO2013022594A1
(en)
|
2011-07-21 |
2013-02-14 |
The Regents Of The University Of California |
Transcription factors for the production of cellulose degrading enzymes
|
JP5953617B2
(en)
|
2011-07-22 |
2016-07-20 |
公立大学法人横浜市立大学 |
Technology for inhibiting translation reaction by cleaving part of the poly (A) chain and / or 3 'terminal sequence of mRNA
|
US9120858B2
(en)
|
2011-07-22 |
2015-09-01 |
The Research Foundation Of State University Of New York |
Antibodies to the B12-transcobalamin receptor
|
WO2013014262A1
(en)
|
2011-07-27 |
2013-01-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosing and treating myhre syndrome
|
WO2013021064A1
(en)
|
2011-08-10 |
2013-02-14 |
Novozymes A/S |
Polypeptides having peroxygenase activity and polynucleotides encoding same
|
WO2013021059A1
(en)
|
2011-08-10 |
2013-02-14 |
Novozymes A/S |
Polypeptides having peroxygenase activity and polynucleotides encoding same
|
EP2742130B1
(en)
|
2011-08-10 |
2017-11-01 |
Novozymes A/S |
Polypeptides having peroxygenase activity and polynucleotides encoding same
|
WO2013021062A1
(en)
|
2011-08-10 |
2013-02-14 |
Novozymes A/S |
Polypeptides having peroxygenase activity and polynucleotides encoding same
|
CN103827297B
(en)
|
2011-08-10 |
2018-06-22 |
诺维信公司 |
Polypeptide with peroxidase activity and the polynucleotides for encoding the polypeptide
|
WO2013021065A1
(en)
|
2011-08-10 |
2013-02-14 |
Novozymes A/S |
Polypeptides having peroxygenase activity and polynucleotides encoding same
|
US9487761B2
(en)
|
2011-08-10 |
2016-11-08 |
Novozymes A/S |
Polypeptides having peroxygenase activity and polynucleotides encoding same
|
US20140271680A1
(en)
|
2011-08-12 |
2014-09-18 |
Universite Paris-Est Creteil Val De Marne |
Methods and pharmaceutical compositions for treatment of pulmonary hypertension
|
CN103717612A
(en)
*
|
2011-08-12 |
2014-04-09 |
拜尔作物科学公司 |
Guard cell-specific expression of transgenes in cotton
|
CN103890169A
(en)
|
2011-08-24 |
2014-06-25 |
诺维信股份有限公司 |
Aspergillus fumigatus cellulolytic enzyme compositions and uses thereof
|
CN103890165A
(en)
|
2011-08-24 |
2014-06-25 |
诺维信股份有限公司 |
Cellulolytic enzyme compositions and uses thereof
|
WO2013033380A1
(en)
|
2011-08-31 |
2013-03-07 |
Genentech, Inc. |
Diagnostic markers
|
CN103930165B
(en)
|
2011-09-02 |
2018-05-25 |
纽约市哥伦比亚大学理事会 |
To treat CaMKII, IP3R of the metabolic disorder of obesity, calcineurin, P38 and MK2/3 inhibitor
|
EA201490553A1
(en)
|
2011-09-02 |
2014-08-29 |
Новартис Аг |
ORGANIC COMPOSITIONS FOR THE TREATMENT OF HSF1-CONNECTED DISEASES
|
WO2013036868A1
(en)
|
2011-09-07 |
2013-03-14 |
Marina Biotech Inc. |
Synthesis and uses of nucleic acid compounds with conformationally restricted monomers
|
MX348941B
(en)
|
2011-09-07 |
2017-07-04 |
Deutsches Krebsforsch |
Means and methods for treating and/or preventing natural ahr ligand-dependent cancer.
|
WO2013036799A2
(en)
|
2011-09-09 |
2013-03-14 |
Fred Hutchinson Cancer Research Center |
Methods and compositions involving nkg2d inhibitors and cancer
|
AU2012305714A1
(en)
|
2011-09-09 |
2014-03-27 |
Biomed Realty, L.P. |
Methods and compositions for controlling assembly of viral proteins
|
UA116088C2
(en)
*
|
2011-09-13 |
2018-02-12 |
Монсанто Текнолоджи Ллс |
Method and compositions for weed control
|
CN104160028A
(en)
|
2011-09-13 |
2014-11-19 |
孟山都技术公司 |
Methods and compositions for weed control
|
WO2013040117A1
(en)
*
|
2011-09-13 |
2013-03-21 |
Monsanto Technology Llc |
Methods and compositions for weed control
|
UA116089C2
(en)
|
2011-09-13 |
2018-02-12 |
Монсанто Текнолоджи Ллс |
Methods and compositios for weed control
|
WO2013040251A2
(en)
|
2011-09-13 |
2013-03-21 |
Asurgen, Inc. |
Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
|
US9840715B1
(en)
|
2011-09-13 |
2017-12-12 |
Monsanto Technology Llc |
Methods and compositions for delaying senescence and improving disease tolerance and yield in plants
|
US10806146B2
(en)
|
2011-09-13 |
2020-10-20 |
Monsanto Technology Llc |
Methods and compositions for weed control
|
US10829828B2
(en)
|
2011-09-13 |
2020-11-10 |
Monsanto Technology Llc |
Methods and compositions for weed control
|
CA2848371A1
(en)
*
|
2011-09-13 |
2013-03-21 |
Monsanto Technology, Llc |
Method and composition for weed control comprising topical application_of als polynucleotide
|
CN107739737A
(en)
|
2011-09-13 |
2018-02-27 |
孟山都技术公司 |
Method and composition for Weeds distribution
|
WO2013040116A1
(en)
|
2011-09-13 |
2013-03-21 |
Monsanto Technology Llc |
Methods and compositions for weed control
|
US10760086B2
(en)
|
2011-09-13 |
2020-09-01 |
Monsanto Technology Llc |
Methods and compositions for weed control
|
WO2013039990A1
(en)
*
|
2011-09-13 |
2013-03-21 |
Monsanto Technology Llc |
Methods and compositions for weed control
|
US9920326B1
(en)
|
2011-09-14 |
2018-03-20 |
Monsanto Technology Llc |
Methods and compositions for increasing invertase activity in plants
|
WO2013043910A1
(en)
|
2011-09-20 |
2013-03-28 |
Novozymes A/S |
Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same
|
US9352312B2
(en)
|
2011-09-23 |
2016-05-31 |
Alere Switzerland Gmbh |
System and apparatus for reactions
|
MX2014003698A
(en)
|
2011-09-30 |
2014-07-28 |
Genentech Inc |
Diagnostic methylation markers of epithelial or mesenchymal phenotype and response to egfr kinase inhibitor in tumours or tumour cells.
|
WO2013050405A1
(en)
|
2011-10-03 |
2013-04-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of th2 mediated diseases
|
UA115132C2
(en)
|
2011-10-04 |
2017-09-25 |
Байєр Інтелекчуал Проперті Гмбх |
RNAi FOR THE CONTROL OF FUNGI AND OOMYCETES BY INHIBITING SACCHAROPINE DEHYDROGENASE GENE
|
US20150018383A1
(en)
|
2011-10-14 |
2015-01-15 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Biomarkers of renal disorders
|
CA2850032C
(en)
|
2011-10-14 |
2022-06-07 |
Genentech, Inc. |
Anti-htra1 antibodies and methods of use
|
PL3597644T3
(en)
|
2011-10-18 |
2022-01-17 |
Dicerna Pharmaceuticals, Inc. |
Amine cationic lipids and uses thereof
|
EP2768971A1
(en)
|
2011-10-20 |
2014-08-27 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Methods for the detection and the treatment of cardiac remodeling
|
BR112014010546B1
(en)
|
2011-11-02 |
2021-04-13 |
Ceres, Inc |
METHOD OF INCREASING PLANT Yield IN SOIL CONTAINING HIGH LEVELS OF AL3 +, METHOD OF INCREASING TOLERANCE IN A PLANT
|
BR112014010769B1
(en)
|
2011-11-03 |
2021-08-03 |
Quark Pharmaceuticals, Inc |
USE OF A DOUBLE TAPE RNA COMPOUND TO PREPARE A DRUG TO TREAT MEN'S DISEASE
|
WO2013063653A1
(en)
|
2011-11-04 |
2013-05-10 |
Arista Cereal Technologies Pty Limited |
High amylose wheat - ii
|
US20140286965A1
(en)
|
2011-11-07 |
2014-09-25 |
Inserm |
Ddr1 antagonist or an inhibitor of ddr1 gene expression for use in the prevention or treatment of crescentic glomerulonephritis
|
EP2776565A1
(en)
|
2011-11-08 |
2014-09-17 |
Quark Pharmaceuticals, Inc. |
Methods and compositions for treating diseases, disorders or injury of the nervous system
|
JP2015506911A
(en)
|
2011-11-22 |
2015-03-05 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Methods and pharmaceutical compositions for reducing airway hypersensitivity
|
EP3342860A1
(en)
|
2011-11-22 |
2018-07-04 |
Novozymes, Inc. |
Polypeptides having beta-xylosidase activity and polynucleotides encoding same
|
WO2013079015A1
(en)
|
2011-12-01 |
2013-06-06 |
Novozymes, Inc. |
Polypeptides having beta-xylosidase activity and polynucleotides encoding same
|
WO2013079531A2
(en)
|
2011-12-02 |
2013-06-06 |
Novozymes A/S |
Polypeptides having peroxygenase activity and polynucleotides encoding same
|
US9404093B2
(en)
|
2011-12-02 |
2016-08-02 |
Novozymes A/S |
Polypeptides having peroxygenase activity and polynucleotides encoding same
|
BR112014013853A2
(en)
|
2011-12-09 |
2020-01-14 |
Ceres Inc |
use of an isolated nucleic acid, method of obtaining a transgenic plant cell, method of obtaining a transgenic plant, method of producing a plant, method of producing biomass, method of biomass processing, method of altering the composition of biomass , biomass composition modulation method, production method of a forage product
|
UA116097C2
(en)
|
2011-12-11 |
2018-02-12 |
Зе Стейт Оф Ізраел, Міністрі Оф Агрікалче Енд Руерал Девелопмент, Агрікалчерал Рісьоч Організейшн, (А.Р.О.), Волкані Сентре |
Methods of modulating stomata conductance and plant expression constructs for executing same
|
DK2791330T3
(en)
|
2011-12-16 |
2017-11-06 |
Novozymes Inc |
Polypeptides with laccase activity and polynucleotides encoding them
|
EP2798066A4
(en)
|
2011-12-27 |
2016-02-24 |
Commw Scient Ind Res Org |
Processes for producing lipids
|
US9347067B2
(en)
|
2011-12-27 |
2016-05-24 |
Commonwealth Scientific And Industrial Research Organisation |
Production of dihydrosterculic acid and derivatives thereof
|
EP2798065B1
(en)
|
2011-12-27 |
2019-06-05 |
Commonwealth Scientific and Industrial Research Organisation |
Simultaneous gene silencing and supressing gene silencing in the same cell
|
EP2798089B1
(en)
|
2011-12-30 |
2018-05-23 |
Bio-rad Laboratories, Inc. |
Methods and compositions for performing nucleic acid amplification reactions
|
US9006515B2
(en)
|
2012-01-06 |
2015-04-14 |
Pioneer Hi Bred International Inc |
Pollen preferred promoters and methods of use
|
BR112014016791A2
(en)
|
2012-01-06 |
2019-09-24 |
Pioneer Hi Bred Int |
isolated nucleic acid molecule, expression cassette, vector, plant cell, plant, transgenic seed, method for expression of a polynucleotide in a plant or plant cell, method for expression of a polynucleotide, preferably in egg tissues of a plant
|
WO2013103369A1
(en)
|
2012-01-06 |
2013-07-11 |
Pioneer Hi-Bred International, Inc. |
Compositions and methods for the expression of a sequence in a reproductive tissue of a plant
|
EP2802658A2
(en)
|
2012-01-09 |
2014-11-19 |
Novartis AG |
Rnai agents to treat beta-catenin related diseases
|
AU2013209279B2
(en)
|
2012-01-11 |
2017-12-14 |
North Carolina State University |
Method for modulating plant root architecture
|
WO2013109738A1
(en)
|
2012-01-17 |
2013-07-25 |
The Trustees Of Columbia University In The City Of New York |
Novel phosphodiesterase inhibitors and uses thereof
|
GB201201332D0
(en)
|
2012-01-26 |
2012-03-14 |
Imp Innovations Ltd |
Method
|
WO2013113762A1
(en)
|
2012-01-31 |
2013-08-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and kits for predicting the risk of having a cutaneous melanoma in a subject
|
AP2014007885A0
(en)
|
2012-02-01 |
2014-08-31 |
Dow Agrosciences Llc |
Novel class of glyphosate resistance genes
|
WO2013121034A1
(en)
|
2012-02-17 |
2013-08-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for reducing adipose tissue inflammation
|
WO2013123871A1
(en)
|
2012-02-20 |
2013-08-29 |
Novozymes A/S |
Polypeptides having endoglucanase activity and polynucleotides encoding same
|
US9663560B2
(en)
*
|
2012-02-28 |
2017-05-30 |
The United States Of America, As Represented By The Secretary Of Agriculture |
Cotton PHYA1 RNAi improves fiber quality, root elongation, flowering, maturity and yield potential in Gossypium hirsutum L
|
JP2015511598A
(en)
|
2012-03-16 |
2015-04-20 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
Method of treating melanoma using PAK1 inhibitor
|
CN104334191A
(en)
|
2012-03-29 |
2015-02-04 |
纽约市哥伦比亚大学托管会 |
Methods for treating hair loss disorders
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
EP2650013A1
(en)
|
2012-04-10 |
2013-10-16 |
Deutsches Krebsforschungszentrum |
Inhibitors of Receptor for Advanced Glycation-End products (RAGE) for use in treating and/or preventing inflammation- and/or damage-induced cancer
|
WO2013158032A1
(en)
|
2012-04-19 |
2013-10-24 |
Temasek Life Sciences Laboratory Limited |
Methods for increasing cotton fiber length
|
BR112014025983A2
(en)
|
2012-04-20 |
2018-07-03 |
Futuragene Israel Ltd |
ribonucleic acid molecule, dsrna, vector, host cell, plant tissue, nucleic acid and plant production and pest infestation inhibition methods
|
CN104245930A
(en)
|
2012-04-23 |
2014-12-24 |
诺维信公司 |
Polypeptides having glucuronyl esterase activity and polynucleotides encoding same
|
BR112014026363A2
(en)
|
2012-04-23 |
2017-06-27 |
Futuragene Israel Ltd |
ribonucleic acid molecule, dsrna, vector, host cell, plant tissue, isolated nucleic acid, pest resistant plant production method and pest infestation inhibition method
|
WO2013160248A2
(en)
|
2012-04-23 |
2013-10-31 |
Novozymes A/S |
Polypeptides having alpha-glucuronidase activity and polynucleotides encoding same
|
KR102208924B1
(en)
|
2012-04-25 |
2021-01-29 |
커먼웰쓰 사이언티픽 앤 인더스트리알 리서치 오거니제이션 |
High oleic acid oils
|
EP3453762B1
(en)
|
2012-05-02 |
2021-04-21 |
Sirna Therapeutics, Inc. |
Short interfering nucleic acid (sina) compositions
|
EP2844668A1
(en)
|
2012-05-03 |
2015-03-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method and pharmaceutical composition for use in the treatment and diagnotic of anemia of inflammation
|
US20150126573A1
(en)
|
2012-05-09 |
2015-05-07 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and pharmaceutical compositions for prevention or treatment of chronic obstructive pulmonary disease
|
WO2013171296A1
(en)
|
2012-05-16 |
2013-11-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Diagnostic and treatment of sarcoidosis
|
JP2015520373A
(en)
|
2012-05-22 |
2015-07-16 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Method for diagnosing and treating focal segmental glomerulosclerosis
|
CA2873828A1
(en)
|
2012-05-24 |
2013-11-28 |
A.B. Seeds Ltd. |
Naked dsrna for silencing target molecules in plant seeds
|
JP6185574B2
(en)
|
2012-06-08 |
2017-08-23 |
センソリオン |
H4 receptor inhibitor for treating tinnitus
|
WO2013187556A1
(en)
|
2012-06-14 |
2013-12-19 |
Scripps Korea Antibody Institute |
Novel antibody specific for clec14a and uses thereof
|
EP2864485A4
(en)
|
2012-06-22 |
2016-03-02 |
Univ California |
Compositions and methods for mediating plant stomatal development in response to carbon dioxide and applications for engineering drought tolerance in plants
|
US20150204851A1
(en)
|
2012-06-27 |
2015-07-23 |
Metanomics Health Gmbh |
Methods for identifying diabetes drugs
|
WO2014006025A2
(en)
|
2012-07-02 |
2014-01-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Marker of pathogenicity in salmonella
|
WO2014013005A1
(en)
|
2012-07-18 |
2014-01-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for preventing and treating chronic kidney disease (ckd)
|
WO2014018554A1
(en)
|
2012-07-23 |
2014-01-30 |
La Jolla Institute For Allergy And Immunology |
Ptprs and proteoglycans in autoimmune disease
|
JP6431480B2
(en)
|
2012-08-31 |
2018-11-28 |
ザ ジェネラル ホスピタル コーポレイション |
Biotin conjugates for the treatment and diagnosis of Alzheimer's disease
|
WO2014045126A2
(en)
|
2012-09-18 |
2014-03-27 |
Uti Limited Partnership |
Treatment of pain by inhibition of usp5 de-ubiquitinase
|
BR112015006176B1
(en)
|
2012-09-21 |
2023-04-18 |
Intensity Therapeutics, Inc |
USE OF A THERAPEUTIC AGENT AND AN INTRACELLULAR PERMEATION ENHANCEMENT AGENT
|
WO2014053910A2
(en)
|
2012-10-03 |
2014-04-10 |
Futuragene Israel Ltd. |
Gall wasp control agents
|
WO2014055825A1
(en)
|
2012-10-04 |
2014-04-10 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
A formulation of mycobacterial components as an adjuvant for inducing th17 responses
|
WO2014053871A1
(en)
|
2012-10-04 |
2014-04-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
A method for screening a compound capable of inhibiting the notch1 transcriptional activity
|
WO2014054927A1
(en)
|
2012-10-05 |
2014-04-10 |
(주)바이오니아 |
Amphiregulin-specific double-helical oligo-rna, double-helical oligo-rna structure comprising double-helical oligo-rna, and composition for preventing or treating respiratory diseases containing same
|
DK2903412T3
(en)
|
2012-10-08 |
2019-12-16 |
Novozymes As |
Polypeptides with cellulolysis enhancing activity and polynucleotides encoding them
|
WO2014058915A2
(en)
|
2012-10-08 |
2014-04-17 |
St. Jude Children's Research Hospital |
Therapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis
|
EP2906589A1
(en)
|
2012-10-10 |
2015-08-19 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical compositions for treatment of gastrointestinal stromal tumors
|
CA2887571A1
(en)
|
2012-10-11 |
2014-04-17 |
Pioneer Hi-Bred International, Inc. |
Guard cell promoters and uses thereof
|
CN104704116B
(en)
|
2012-10-12 |
2018-09-28 |
诺维信公司 |
With the active polypeptide of peroxygenases
|
US9458435B2
(en)
|
2012-10-12 |
2016-10-04 |
Novozymes A/S |
Polypeptides having peroxygenase activity
|
US9453207B2
(en)
|
2012-10-12 |
2016-09-27 |
Novozymes A/S |
Polypeptides having peroxygenase activity
|
CN104704115B
(en)
|
2012-10-12 |
2018-11-02 |
诺维信公司 |
With the active polypeptide of peroxygenases
|
EP2906689B1
(en)
|
2012-10-12 |
2018-12-12 |
Novozymes A/S |
Polypeptides having peroxygenase activity
|
US9499801B2
(en)
|
2012-10-12 |
2016-11-22 |
Novozymes A/S |
Polypeptides having peroxygenase activity
|
US9719072B2
(en)
|
2012-10-12 |
2017-08-01 |
Novozymes A/S |
Polypeptides having peroxygenase activity
|
CA2888264A1
(en)
|
2012-10-18 |
2014-04-24 |
Monsanto Technology Llc |
Methods and compositions for plant pest control
|
AU2013336237A1
(en)
|
2012-10-22 |
2015-06-11 |
Sabag-Rfa Ltd |
A system for delivering therapeutic agents into living cells and cells nuclei
|
EP2911691B1
(en)
|
2012-10-23 |
2018-10-10 |
OncoMed Pharmaceuticals, Inc. |
Methods of treating neuroendocrine tumors using wnt pathway-binding agents
|
US20150297573A1
(en)
|
2012-10-24 |
2015-10-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING Beta-CELL SURVIVAL
|
WO2014066141A2
(en)
|
2012-10-24 |
2014-05-01 |
Novozymes A/S |
Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same
|
US20150246118A1
(en)
|
2012-10-26 |
2015-09-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Lyve-1 antagonists for preventing or treating a pathological condition associated with lymphangiogenesis
|
WO2014064192A1
(en)
|
2012-10-26 |
2014-05-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method and pharmaceutical composition for use in the treatment and prediction of myocardial infraction
|
US20150258127A1
(en)
|
2012-10-31 |
2015-09-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for preventing antiphospholipid syndrome (aps)
|
WO2014072416A1
(en)
|
2012-11-08 |
2014-05-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of bone metastases
|
EP2732815A1
(en)
|
2012-11-16 |
2014-05-21 |
Neurochlore |
Modulators of intracellular chloride concentration for treating fragile X syndrome
|
WO2014090765A1
(en)
|
2012-12-12 |
2014-06-19 |
Bayer Cropscience Ag |
Use of 1-[2-fluoro-4-methyl-5-(2,2,2-trifluoroethylsulfinyl)phenyl]-5-amino-3-trifluoromethyl)-1 h-1,2,4 tfia zole for controlling nematodes in nematode-resistant crops
|
WO2014093305A2
(en)
|
2012-12-13 |
2014-06-19 |
Ymir Genomics, Llc |
Micrornas and uses thereof
|
US10308954B2
(en)
|
2012-12-14 |
2019-06-04 |
Icar |
Method for the control of nematodes in plants
|
AU2013358981A1
(en)
|
2012-12-14 |
2015-06-04 |
Novozymes A/S |
Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same
|
US20150337280A1
(en)
|
2012-12-19 |
2015-11-26 |
Novozymes A/S |
Polypeptides Having Cellulolytic Enhancing Activity And Polynucleotides Encoding Same
|
WO2014095088A1
(en)
|
2012-12-21 |
2014-06-26 |
Sykehuset Sørlandet Hf |
Egfr targeted therapy of neurological disorders and pain
|
BR112015014624A2
(en)
|
2012-12-24 |
2017-10-10 |
Novozymes As |
isolated polypeptide, composition, isolated polynucleotide, nucleic acid construct or expression vector, recombinant host cell, and method for textile treatment
|
UY35252A
(en)
|
2013-01-01 |
2014-07-31 |
Seeds Ltd Ab |
METHODS TO INTRODUCE dsRNA IN PLANT SEEDS TO MODULATE GENETIC EXPRESSION
|
US10683505B2
(en)
|
2013-01-01 |
2020-06-16 |
Monsanto Technology Llc |
Methods of introducing dsRNA to plant seeds for modulating gene expression
|
US10258682B2
(en)
|
2013-01-16 |
2019-04-16 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Attenuated chlamydia vaccine
|
US10000767B2
(en)
|
2013-01-28 |
2018-06-19 |
Monsanto Technology Llc |
Methods and compositions for plant pest control
|
WO2014118317A1
(en)
|
2013-02-01 |
2014-08-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting and preventing metastasis in triple negative breast cancers
|
WO2014121196A1
(en)
|
2013-02-04 |
2014-08-07 |
Oncomed Pharmaceuticals, Inc. |
Methods and monitoring of treatment with a wnt pathway inhibitor
|
WO2014122199A1
(en)
|
2013-02-06 |
2014-08-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treatment of chronic intestinal pseudo-obstruction
|
WO2014128127A1
(en)
|
2013-02-19 |
2014-08-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treatment of prostate cancer
|
EP2767594A1
(en)
|
2013-02-19 |
2014-08-20 |
Deutsches Krebsforschungszentrum |
The signature of Wnt/ß-catenin signaling in Cancer
|
WO2014134202A1
(en)
|
2013-02-26 |
2014-09-04 |
Triact Therapeutics, Inc. |
Cancer therapy
|
WO2014134179A1
(en)
|
2013-02-28 |
2014-09-04 |
The Board Of Regents Of The University Of Texas System |
Methods for classifying a cancer as susceptible to tmepai-directed therapies and treating such cancers
|
WO2014135655A1
(en)
|
2013-03-06 |
2014-09-12 |
Institut Curie |
Compositions and methods for treating muscle-invasive bladder cancer
|
AU2014224205C1
(en)
|
2013-03-08 |
2019-04-04 |
Novartis Ag |
Lipids and lipid compositions for the delivery of active agents
|
US9273322B2
(en)
|
2013-03-12 |
2016-03-01 |
Pioneer Hi Bred International Inc |
Root-preferred promoter and methods of use
|
US9243258B2
(en)
|
2013-03-12 |
2016-01-26 |
Pioneer Hi Bred International Inc |
Root-preferred promoter and methods of use
|
AR095232A1
(en)
|
2013-03-13 |
2015-09-30 |
Monsanto Technology Llc |
METHODS AND COMPOSITIONS FOR WEED CONTROL
|
BR112015023108A8
(en)
|
2013-03-13 |
2018-01-23 |
Geneweave Biosciences Inc |
bacterial cell packaging system, method for packaging a reporter nucleic acid molecule, composition, method for detecting a bacterial cell presence or absence in a sample, vector, method for detecting a target transcript in a cell, method for detect the presence of a bacterial cell in a sample and kit.
|
CN105263329B
(en)
|
2013-03-13 |
2020-09-18 |
孟山都技术公司 |
Methods and compositions for weed control
|
US9168300B2
(en)
|
2013-03-14 |
2015-10-27 |
Oncomed Pharmaceuticals, Inc. |
MET-binding agents and uses thereof
|
US20140283211A1
(en)
|
2013-03-14 |
2014-09-18 |
Monsanto Technology Llc |
Methods and Compositions for Plant Pest Control
|
WO2014140165A1
(en)
|
2013-03-14 |
2014-09-18 |
Dsm Ip Assets B.V. |
Cell wall deconstruction enzymes of paecilomyces byssochlamydoides and uses thereof
|
WO2014140167A1
(en)
|
2013-03-14 |
2014-09-18 |
Dsm Ip Assets B.V. |
Cell wall deconstruction enzymes of malbranchea cinnamomea and uses thereof
|
US10568328B2
(en)
|
2013-03-15 |
2020-02-25 |
Monsanto Technology Llc |
Methods and compositions for weed control
|
US9688767B2
(en)
|
2013-03-15 |
2017-06-27 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Method of predicting survival time in myocardial infarction patients by measuring BAFF levels
|
US9546364B2
(en)
|
2013-03-15 |
2017-01-17 |
Carnegie Mellon University |
Synthetic lariat RNA for RNA interference
|
WO2014145254A2
(en)
|
2013-03-15 |
2014-09-18 |
Sutter West Bay Hospitals |
Falz for use as a target for therapies to treat cancer
|
EP2968551B1
(en)
|
2013-03-15 |
2021-05-05 |
The Trustees of Columbia University in the City of New York |
Fusion proteins and methods thereof
|
EP2976085A1
(en)
|
2013-03-21 |
2016-01-27 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression
|
WO2014170712A1
(en)
|
2013-04-15 |
2014-10-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Rac-1 inhibitors or pi3k inhibitors for preventing intestinal barrier dysfunction
|
CA2909434A1
(en)
|
2013-04-18 |
2014-10-23 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and pharmaceutical compositions for inhibiting lymphocyte proliferation in a subject in need thereof
|
US20160083424A1
(en)
|
2013-04-26 |
2016-03-24 |
Oslo Universitetssykehus Hf |
Compositions and methods for targeting antigen-presenting cells
|
EP2810952A1
(en)
|
2013-06-03 |
2014-12-10 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Novel pest control methods
|
CA2914687C
(en)
|
2013-06-13 |
2021-08-24 |
Commonwealth Scientific And Industrial Research Organisation |
Barley with very low levels of hordeins
|
US10155001B2
(en)
|
2013-06-14 |
2018-12-18 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
RAC1 inhibitors for inducing bronchodilation
|
US20160145628A1
(en)
|
2013-06-18 |
2016-05-26 |
Ramot At Tel-Aviv University Ltd. |
Nanocarrier system for micrornas and uses thereof
|
WO2014205516A1
(en)
|
2013-06-25 |
2014-12-31 |
The Walter And Eliza Hall Institute Of Medical Research |
Method of treating intracellular infection
|
US9856472B2
(en)
|
2013-07-01 |
2018-01-02 |
California Institute Of Technology |
Small conditional RNAs
|
WO2015001053A1
(en)
|
2013-07-03 |
2015-01-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the screening of substances that may be useful for the prevention and treatment of infections by enterobacteriaceae family
|
WO2015002969A1
(en)
|
2013-07-03 |
2015-01-08 |
City Of Hope |
Anticancer combinations
|
ES2776353T3
(en)
|
2013-07-17 |
2020-07-30 |
Univ Columbia |
Novel Phosphodiesterase Inhibitors and Uses Thereof
|
US9850496B2
(en)
|
2013-07-19 |
2017-12-26 |
Monsanto Technology Llc |
Compositions and methods for controlling Leptinotarsa
|
PL3030663T3
(en)
|
2013-07-19 |
2020-04-30 |
Monsanto Technology Llc |
Compositions and methods for controlling leptinotarsa
|
US20160208247A1
(en)
|
2013-07-31 |
2016-07-21 |
Qbi Enterprises Ltd. |
Methods of use of sphingolipid polyalkylamine oligonucleotide compounds
|
US9889200B2
(en)
|
2013-07-31 |
2018-02-13 |
Qbi Enterprises Ltd. |
Sphingolipid-polyalkylamine-oligonucleotide compounds
|
EP2835423A1
(en)
|
2013-08-09 |
2015-02-11 |
Commissariat à l'Énergie Atomique et aux Énergies Alternatives |
Ligase E3 RNF185 inhibitors and uses thereof
|
EP3044593A4
(en)
|
2013-09-09 |
2017-05-17 |
Triact Therapeutics, Inc. |
Cancer therapy
|
CA2923629A1
(en)
|
2013-09-11 |
2015-03-19 |
Pioneer Hi-Bred International, Inc. |
Plant regulatory elements and methods of use thereof
|
US10016424B2
(en)
|
2013-09-16 |
2018-07-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale |
Method and pharmaceutical composition for use in the treatment of epilepsy
|
EP3052133A2
(en)
|
2013-10-03 |
2016-08-10 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical compositions for modulating autophagy in a subject in need thereof
|
WO2015051044A2
(en)
|
2013-10-04 |
2015-04-09 |
Novartis Ag |
Novel formats for organic compounds for use in rna interference
|
CN105792832B
(en)
|
2013-10-04 |
2021-03-23 |
诺华股份有限公司 |
Organic compounds for the treatment of hepatitis B virus
|
US10227588B2
(en)
|
2013-10-04 |
2019-03-12 |
Novartis Ag |
3′end caps for RNAi agents for use in RNA interference
|
WO2015051366A2
(en)
|
2013-10-04 |
2015-04-09 |
Novartis Ag |
Novel formats for organic compounds for use in rna interference
|
EP3055426B1
(en)
|
2013-10-09 |
2019-06-19 |
The United States of America as represented by The Secretary Department of Health and Human Services |
Detection of hepatitis delta virus (hdv) for the diagnosis and treatment of sjögren's syndrome and lymphoma
|
JP2016537965A
(en)
|
2013-10-11 |
2016-12-08 |
ジェネンテック, インコーポレイテッド |
NSP4 inhibitors and methods of use
|
AU2014336957B2
(en)
|
2013-10-16 |
2018-07-12 |
The Australian National University |
Method for modulating plant growth
|
EP2862928A1
(en)
|
2013-10-18 |
2015-04-22 |
Université de Strasbourg |
Dynamin 2 inhibitor for the treatment of centronuclear myopathies
|
AP2016009227A0
(en)
|
2013-11-04 |
2016-05-31 |
Dow Agrosciences Llc |
Optimal maize loci
|
RU2694950C2
(en)
|
2013-11-04 |
2019-07-18 |
Монсанто Текнолоджи Ллс |
Compositions and methods for controlling arthropod parasites and pest infestations
|
US9909131B2
(en)
|
2013-11-04 |
2018-03-06 |
Dow Agrosciences Llc |
Optimal soybean loci
|
CN107223156A
(en)
|
2013-11-04 |
2017-09-29 |
美国陶氏益农公司 |
Optimal corn seat
|
US10203327B2
(en)
|
2013-11-05 |
2019-02-12 |
Novartis Ag |
Organic compounds
|
EP3065775B1
(en)
|
2013-11-08 |
2020-09-30 |
The Board of Regents of the University of Texas System |
Vh4 antibodies against gray matter neuron and astrocyte
|
CA2929574A1
(en)
|
2013-11-11 |
2015-05-14 |
Sirna Therapeutics, Inc. |
Systemic delivery of myostatin short interfering nucleic acids (sina) conjugated to a lipophilic moiety
|
WO2015073922A2
(en)
|
2013-11-15 |
2015-05-21 |
Northwestern University |
Inhibition of oxidative stress in atrial fibrillation
|
US20170166939A1
(en)
|
2013-11-26 |
2017-06-15 |
Novozymes A/S |
Enzyme Compositions and Uses Thereof
|
CN105873608A
(en)
|
2013-11-28 |
2016-08-17 |
杰特有限公司 |
Method of treating nephropathy
|
EP3079707A4
(en)
|
2013-12-02 |
2017-10-18 |
RXi Pharmaceuticals Corporation |
Immunotherapy of cancer
|
UA119253C2
(en)
|
2013-12-10 |
2019-05-27 |
Біолоджикс, Інк. |
Compositions and methods for virus control in varroa mite and bees
|
EP3079475B1
(en)
|
2013-12-11 |
2020-10-07 |
Sloan-kettering Institute For Cancer Research |
Glucocorticoid inhibitors for treatment of prostate cancer
|
AU2014366837B2
(en)
|
2013-12-18 |
2020-06-25 |
B-Creative Sweden Ab |
Method of treating wounds
|
PL3083556T3
(en)
|
2013-12-19 |
2020-06-29 |
Novartis Ag |
Lipids and lipid compositions for the delivery of active agents
|
WO2015095346A1
(en)
|
2013-12-19 |
2015-06-25 |
Novartis Ag |
Lipids and lipid compositions for the delivery of active agents
|
US9682123B2
(en)
|
2013-12-20 |
2017-06-20 |
The Trustees Of Columbia University In The City Of New York |
Methods of treating metabolic disease
|
EP3083959B1
(en)
|
2013-12-20 |
2019-02-06 |
Fondazione Istituto Italiano di Tecnologia |
Inhibitors of intracellular chloride concentration for treating down syndrome
|
US9274117B2
(en)
|
2013-12-21 |
2016-03-01 |
Catholic University Industry Academic |
Use of SIRT7 as novel cancer therapy target and method for treating cancer using the same
|
WO2015098113A1
(en)
|
2013-12-27 |
2015-07-02 |
独立行政法人医薬基盤研究所 |
Therapeutic drug for malignant tumors
|
TW201527313A
(en)
|
2013-12-31 |
2015-07-16 |
Dow Agrosciences Llc |
Novel maize ubiquitin promoters
|
TW201527312A
(en)
|
2013-12-31 |
2015-07-16 |
Dow Agrosciences Llc |
Novel maize ubiquitin promoters
|
TW201527316A
(en)
|
2013-12-31 |
2015-07-16 |
Dow Agrosciences Llc |
Novel maize ubiquitin promoters
|
TW201527314A
(en)
|
2013-12-31 |
2015-07-16 |
Dow Agrosciences Llc |
Novel maize ubiquitin promoters
|
CA2935985A1
(en)
|
2014-01-09 |
2015-07-16 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
US10334848B2
(en)
|
2014-01-15 |
2019-07-02 |
Monsanto Technology Llc |
Methods and compositions for weed control using EPSPS polynucleotides
|
WO2015118167A1
(en)
|
2014-02-10 |
2015-08-13 |
Institut Curie |
Use of mcoln-1 modulators to regulate cell migration
|
TW201538518A
(en)
|
2014-02-28 |
2015-10-16 |
Dow Agrosciences Llc |
Root specific expression conferred by chimeric gene regulatory elements
|
WO2015136001A1
(en)
|
2014-03-11 |
2015-09-17 |
Cellectis |
Method for generating t-cells compatible for allogenic transplantation
|
WO2015140351A1
(en)
|
2014-03-21 |
2015-09-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for enhancing myelination
|
CN106460025A
(en)
|
2014-03-25 |
2017-02-22 |
阿克丘勒斯治疗公司 |
UNA oligomers having reduced off-target effects in gene silencing
|
WO2015148582A1
(en)
|
2014-03-25 |
2015-10-01 |
Arcturus Therapeutics, Inc. |
Transthyretin allele selective una oligomers for gene silencing
|
US9856475B2
(en)
|
2014-03-25 |
2018-01-02 |
Arcturus Therapeutics, Inc. |
Formulations for treating amyloidosis
|
CN106413390B
(en)
|
2014-04-01 |
2019-09-27 |
孟山都技术公司 |
For controlling the composition and method of insect pest
|
JP6426268B2
(en)
|
2014-04-04 |
2018-11-21 |
バイオニア コーポレーションBioneer Corporation |
Novel double helix oligo RNA and pharmaceutical composition for preventing or treating fibrosis or respiratory disease comprising the same
|
EP3639843A1
(en)
|
2014-04-16 |
2020-04-22 |
Philippe Rouet |
Apoo for use in a method for treating cancer and various pathophysiological situations
|
EP2932969A1
(en)
|
2014-04-17 |
2015-10-21 |
Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts |
Pancreatic cancer therapy and diagnosis
|
EP3137119B1
(en)
|
2014-04-28 |
2020-07-01 |
Phio Pharmaceuticals Corp. |
Methods for treating cancer using a nucleic acid targeting mdm2
|
US9101100B1
(en)
|
2014-04-30 |
2015-08-11 |
Ceres, Inc. |
Methods and materials for high throughput testing of transgene combinations
|
US9545417B2
(en)
|
2014-05-01 |
2017-01-17 |
The Johns Hopkins University |
Methods of inhibiting cancer stem cells with HMGA1 inhibitors
|
US10258639B2
(en)
|
2014-05-06 |
2019-04-16 |
Research Development Foundation |
Methods for treating insulin resistance and for sensitizing patients to GLP1 agonist therapy
|
KR101633881B1
(en)
|
2014-05-08 |
2016-06-28 |
고려대학교 산학협력단 |
REV-ERB Use of REV-ERB for treating dopamine-dependent disorders
|
KR101633876B1
(en)
|
2014-05-08 |
2016-06-28 |
고려대학교 산학협력단 |
REV-ERB Use of REV-ERB for treating affective and addictive disorders
|
WO2015187935A1
(en)
|
2014-06-06 |
2015-12-10 |
Novozymes A/S |
Enzyme compositions and uses thereof
|
CA2953347A1
(en)
|
2014-06-23 |
2015-12-30 |
Monsanto Technology Llc |
Compositions and methods for regulating gene expression via rna interference
|
WO2015200281A1
(en)
|
2014-06-24 |
2015-12-30 |
The Regents Of The University Of California |
Methods for production of xylosyl-xylitol oligomers
|
US11807857B2
(en)
|
2014-06-25 |
2023-11-07 |
Monsanto Technology Llc |
Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression
|
RU2743384C2
(en)
|
2014-07-07 |
2021-02-17 |
Коммонвелт Сайентифик Энд Индастриал Рисерч Организейшн |
Methods of obtaining industrial products from plant lipids
|
US9932594B2
(en)
|
2014-07-09 |
2018-04-03 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and compositions for treating neuropathic pain
|
AU2015289691B2
(en)
|
2014-07-15 |
2020-12-24 |
Ceres, Inc. |
Methods of increasing crop yield under abiotic stress
|
US10342761B2
(en)
|
2014-07-16 |
2019-07-09 |
Novartis Ag |
Method of encapsulating a nucleic acid in a lipid nanoparticle host
|
EP3169337A1
(en)
|
2014-07-17 |
2017-05-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for treating neuromuscular junction-related diseases
|
RU2021123470A
(en)
|
2014-07-29 |
2021-09-06 |
Монсанто Текнолоджи Ллс |
COMPOSITIONS AND METHODS FOR COMBATING PESTS
|
WO2016022947A1
(en)
|
2014-08-07 |
2016-02-11 |
The Johns Hopkins University |
Nanoparticle modification of human adipose-derived mesenchymal stem cells for treating brain cancer and other neurological diseases
|
WO2016022516A1
(en)
|
2014-08-08 |
2016-02-11 |
Pioneer Hi-Bred International, Inc. |
Ubiquitin promoters and introns and methods of use
|
CN114010788A
(en)
|
2014-08-22 |
2022-02-08 |
奥克兰联合服务有限公司 |
Channel modulators
|
CN114796497A
(en)
|
2014-08-22 |
2022-07-29 |
广州英恩迈生物医药科技有限公司 |
Methods and compositions for treating and/or preventing diseases or disorders associated with abnormal levels and/or activity of the IFP35 protein family
|
JP6731912B2
(en)
|
2014-09-05 |
2020-07-29 |
ノバルティス アーゲー |
Lipids and lipid compositions for delivery of active substances
|
EP3188746B1
(en)
|
2014-09-05 |
2024-06-19 |
The Johns Hopkins University |
Targeting capn9 activity as a therapeutic strategy for the treatment of myofibroblast differentiation and associated pathologies
|
CN107073294A
(en)
|
2014-09-05 |
2017-08-18 |
阿克赛医药公司 |
Use the method for targeting TYR or MMP1 exonuclease treatment aging and skin disorder
|
KR102617137B1
(en)
|
2014-09-15 |
2023-12-27 |
칠드런'즈 메디컬 센터 코포레이션 |
Methods and compositions to increase somatic cell nuclear transfer (scnt) efficiency by removing histone h3-lysine trimethylation
|
CN107106544B
(en)
|
2014-09-19 |
2021-09-24 |
纪念斯隆-凯特琳癌症中心 |
Methods for treating brain metastases
|
RU2017110868A
(en)
|
2014-09-25 |
2018-10-25 |
Колд Спринг Харбор Лаборатори |
TREATMENT OF RETT SYNDROME
|
WO2016046414A2
(en)
|
2014-09-26 |
2016-03-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cdc25a inhibitor for the treatment of drug resistant cancer or for the prevention of tumor relapse
|
WO2016050680A1
(en)
|
2014-09-29 |
2016-04-07 |
Novozymes A/S |
Yoqm-inactivation in bacillus
|
US9705501B2
(en)
|
2014-10-01 |
2017-07-11 |
Maxim Integrated Products, Inc. |
Systems and methods for enhancing confidentiality via logic gate encryption
|
JP6991857B2
(en)
|
2014-10-10 |
2022-01-13 |
イデラ ファーマシューティカルズ インコーポレイテッド |
Treatment of cancer with TLR9 agonists with checkpoint inhibitors
|
EP3009147A1
(en)
|
2014-10-16 |
2016-04-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for treating resistant glioblastoma
|
WO2016059220A1
(en)
|
2014-10-16 |
2016-04-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Tcr-activating agents for use in the treatment of t-all
|
WO2016064347A1
(en)
|
2014-10-22 |
2016-04-28 |
Temasek Life Sciences Laboratory Limited |
Terpene synthases from ylang ylang (cananga odorata var. fruticosa)
|
WO2016066608A1
(en)
|
2014-10-28 |
2016-05-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treatment of pulmonary cell senescence and peripheral aging
|
WO2016066671A1
(en)
|
2014-10-29 |
2016-05-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for treating resistant cancers using progastrin inhibitors
|
CA2974716A1
(en)
|
2014-11-12 |
2016-05-19 |
Nmc, Inc. |
Transgenic plants with engineered redox sensitive modulation of photosynthetic antenna complex pigments and methods for making the same
|
WO2016079527A1
(en)
|
2014-11-19 |
2016-05-26 |
Tetralogic Birinapant Uk Ltd |
Combination therapy
|
WO2016094342A1
(en)
|
2014-12-08 |
2016-06-16 |
The Board Of Regents Of The University Of Texas System |
Lipocationic polymers and uses thereof
|
ES2747842T3
(en)
|
2014-12-15 |
2020-03-11 |
Dicerna Pharmaceuticals Inc |
Ligand-modified double-stranded nucleic acids
|
WO2016097773A1
(en)
|
2014-12-19 |
2016-06-23 |
Children's Cancer Institute |
Therapeutic iap antagonists for treating proliferative disorders
|
EP3237452A4
(en)
|
2014-12-23 |
2018-12-05 |
The Trustees of Columbia University in the City of New York |
Fusion proteins and methods thereof
|
KR102360028B1
(en)
*
|
2014-12-26 |
2022-02-08 |
삼성전자주식회사 |
Composition for reducing senescence of a cell or a subject comprising Smurf2 inhibitor and use thereof
|
US10264976B2
(en)
|
2014-12-26 |
2019-04-23 |
The University Of Akron |
Biocompatible flavonoid compounds for organelle and cell imaging
|
US9434947B2
(en)
*
|
2015-01-20 |
2016-09-06 |
Oregon Health & Science University |
Modulation of KCNH2 isoform expression by oligonucleotides as a therapeutic approach for long QT syndrome
|
CN108064288B
(en)
|
2015-01-22 |
2021-11-26 |
孟山都技术公司 |
Compositions and methods for controlling phyllometaca
|
US20180031579A1
(en)
|
2015-02-12 |
2018-02-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease
|
WO2016131944A1
(en)
|
2015-02-20 |
2016-08-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method for treating cardiovascular diseases
|
US20180036404A1
(en)
|
2015-03-02 |
2018-02-08 |
180 Therapeutics Lp |
Method of treating a localized fibrotic disorder using a tnf receptor 2 antagonist
|
MA41629A
(en)
|
2015-03-04 |
2018-01-09 |
Center For Human Reproduction |
COMPOSITIONS AND METHODS OF USE OF ANTI-MÜLLERIAN HORMONE FOR THE TREATMENT OF INFERTILITY
|
WO2016139331A1
(en)
|
2015-03-05 |
2016-09-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of melanoma
|
WO2016145005A1
(en)
|
2015-03-09 |
2016-09-15 |
University Of Kentucky Research Foundation |
Rna nanoparticles for brain tumor treatment
|
WO2016145008A2
(en)
|
2015-03-09 |
2016-09-15 |
University Of Kentucky Research Foundation |
Mirna for treatment of breast cancer
|
WO2016145003A1
(en)
|
2015-03-09 |
2016-09-15 |
University Of Kentucky Research Foundation |
Rna nanoparticle for treatment of gastric cancer
|
WO2016142427A1
(en)
|
2015-03-10 |
2016-09-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method ank kit for reprogramming somatic cells
|
WO2016146587A1
(en)
|
2015-03-13 |
2016-09-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Hepcidin antagonists for use in the treatment of inflammation
|
KR101797569B1
(en)
|
2015-03-18 |
2017-11-22 |
한국교통대학교산학협력단 |
Liver Targeting Metal Nano-particle Based Nucleic Acid Delivery System And Manufacturing Method Thereof
|
EP3277289A4
(en)
|
2015-04-01 |
2018-12-05 |
Arcturus Therapeutics, Inc. |
Therapeutic una oligomers and uses thereof
|
US11279768B1
(en)
|
2015-04-03 |
2022-03-22 |
Precision Biologics, Inc. |
Anti-cancer antibodies, combination therapies, and uses thereof
|
EP3078378B1
(en)
|
2015-04-08 |
2020-06-24 |
Vaiomer |
Use of factor xa inhibitors for regulating glycemia
|
ES2841437T3
(en)
|
2015-04-13 |
2021-07-08 |
Inst Nat Sante Rech Med |
Methods and pharmaceutical compositions for the treatment of hemorrhagic diseases
|
US10828381B2
(en)
|
2015-04-17 |
2020-11-10 |
University Of Kentucky Research Foundation |
RNA nanoparticles and method of use thereof
|
EP3085785A1
(en)
|
2015-04-22 |
2016-10-26 |
Université de Strasbourg |
Dynamin 2 inhibitor for the treatment of duchenne's muscular dystrophy
|
EP3286221A1
(en)
|
2015-04-22 |
2018-02-28 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical compositions for the treatment of th17 mediated diseases
|
WO2016170382A1
(en)
|
2015-04-23 |
2016-10-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Pharmaceutical compositions comprising a bradykinin 2 receptor antagonist for prevention or treatment of impaired skin wound healing
|
US20180156807A1
(en)
|
2015-04-29 |
2018-06-07 |
New York University |
Method for treating high-grade gliomas
|
US10857237B2
(en)
|
2015-05-05 |
2020-12-08 |
University Of Louisville Research Foundation, Inc. |
Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and MRI and/or X-ray contrast agents
|
US20180148793A1
(en)
|
2015-05-19 |
2018-05-31 |
Fred Hutchinson Cancer Research Center |
Biomarkers and uses thereof for selecting pancreas cancer intervention
|
EP3297615A1
(en)
|
2015-05-20 |
2018-03-28 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical composition for modulation polarization and activation of macrophages
|
US20180134788A1
(en)
|
2015-05-26 |
2018-05-17 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and Pharmaceutical Compositions (NTSR1 Inhibitors) for the Treatment of Hepatocellular Carcinomas
|
WO2016191734A1
(en)
|
2015-05-28 |
2016-12-01 |
University Of California Berkeley |
Monofunctional aldehyde and alcohol dehydrogenases for production of fuels and commodity chemicals
|
US10750690B2
(en)
|
2015-05-29 |
2020-08-25 |
Arcadia Biosciences, Inc. |
Reduced gluten grains and compositions thereof
|
EP3302053B1
(en)
|
2015-06-02 |
2021-03-17 |
Monsanto Technology LLC |
Compositions and methods for delivery of a polynucleotide into a plant
|
US10655136B2
(en)
|
2015-06-03 |
2020-05-19 |
Monsanto Technology Llc |
Methods and compositions for introducing nucleic acids into plants
|
EP3307771A2
(en)
|
2015-06-12 |
2018-04-18 |
Alector LLC |
Anti-cd33 antibodies and methods of use thereof
|
WO2016201389A2
(en)
|
2015-06-12 |
2016-12-15 |
Alector Llc |
Anti-cd33 antibodies and methods of use thereof
|
CN107771218B
(en)
|
2015-06-17 |
2021-12-31 |
先锋国际良种公司 |
Plant regulatory elements and methods of use thereof
|
WO2016210292A1
(en)
|
2015-06-25 |
2016-12-29 |
Children's Medical Center Corporation |
Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
|
US10808247B2
(en)
|
2015-07-06 |
2020-10-20 |
Phio Pharmaceuticals Corp. |
Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
|
WO2017007813A1
(en)
|
2015-07-06 |
2017-01-12 |
Rxi Pharmaceuticals Corporation |
Nucleic acid molecules targeting superoxide dismutase 1 (sod1)
|
WO2017013270A1
(en)
|
2015-07-23 |
2017-01-26 |
Universite De Strasbourg |
Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy
|
WO2017015671A1
(en)
|
2015-07-23 |
2017-01-26 |
Arcturus Therapeutics, Inc. |
Compositions for treating amyloidosis
|
WO2017029391A1
(en)
|
2015-08-20 |
2017-02-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method for treating cancer
|
US10072065B2
(en)
|
2015-08-24 |
2018-09-11 |
Mayo Foundation For Medical Education And Research |
Peptide-mediated delivery of immunoglobulins across the blood-brain barrier
|
CA2995995A1
(en)
|
2015-08-24 |
2017-03-02 |
Halo-Bio Rnai Therapeutics, Inc. |
Polynucleotide nanoparticles for the modulation of gene expression and uses thereof
|
CN108137702B
(en)
|
2015-08-28 |
2023-01-06 |
艾利妥 |
anti-SIGLEC-7 antibodies and methods of use thereof
|
CA2996873A1
(en)
|
2015-09-02 |
2017-03-09 |
Alnylam Pharmaceuticals, Inc. |
Programmed cell death 1 ligand 1 (pd-l1) irna compositions and methods of use thereof
|
JP6978152B2
(en)
|
2015-09-04 |
2021-12-08 |
キージーン ナムローゼ フェンノートシャップ |
Multiphase spore reproductive gene
|
MA44908A
(en)
*
|
2015-09-08 |
2018-07-18 |
Sylentis Sau |
ARNSI MOLECULES AND THEIR USE IN PROCESSES AND COMPOSITIONS TO INHIBIT NRARP GENE EXPRESSION
|
EP3702470A3
(en)
|
2015-09-09 |
2020-10-07 |
The Trustees of Columbia University in the City of New York |
Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
|
WO2017048789A1
(en)
|
2015-09-14 |
2017-03-23 |
The Board Of Regents Of The University Of Texas System |
Lipocationic dendrimers and uses thereof
|
US10086063B2
(en)
|
2015-09-23 |
2018-10-02 |
Regents Of The University Of Minnesota |
Methods of making and using live attenuated viruses
|
US10383935B2
(en)
|
2015-09-23 |
2019-08-20 |
Regents Of The University Of Minnesota |
Methods of making and using live attenuated viruses
|
WO2017059118A1
(en)
|
2015-09-29 |
2017-04-06 |
Duke University |
Compositions and methods for identifying and treating dystonia disorders
|
WO2017058944A1
(en)
|
2015-09-29 |
2017-04-06 |
Amgen Inc. |
Asgr inhibitors
|
JP2018531037A
(en)
|
2015-10-19 |
2018-10-25 |
アールエックスアイ ファーマシューティカルズ コーポレーション |
Reduced size self-delivering nucleic acid compounds targeting long non-coding RNAs
|
WO2017067944A1
(en)
|
2015-10-19 |
2017-04-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of subjects suffering from triple negative breast cancer
|
KR20180084817A
(en)
|
2015-10-29 |
2018-07-25 |
알렉터 엘엘씨 |
Anti-SIGLEC-9 antibodies and methods of using the same
|
SG10202001808VA
(en)
|
2015-10-30 |
2020-04-29 |
Genentech Inc |
Anti-htra1 antibodies and methods of use thereof
|
WO2017083920A1
(en)
|
2015-11-18 |
2017-05-26 |
Commonwealth Scientific And Industrial Research Organisation |
Rice grain with thickened aleurone
|
WO2017085566A1
(en)
|
2015-11-20 |
2017-05-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for increase/induction of immune responses
|
CN108473999B
(en)
|
2015-11-30 |
2022-12-23 |
先锋国际良种公司 |
Plant regulatory elements and methods of use thereof
|
WO2017093354A1
(en)
|
2015-11-30 |
2017-06-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Nmdar antagonists for the treatment of diseases associated with angiogenesis
|
JP6975720B2
(en)
|
2015-11-30 |
2021-12-01 |
シェ、ヤンホイXie Yanhui |
Use of Akt2 in the diagnosis and treatment of tumors
|
US20180353486A1
(en)
|
2015-12-01 |
2018-12-13 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and pharmaceutical compositions for the treatment of darier disease
|
US20180371551A1
(en)
|
2015-12-03 |
2018-12-27 |
Agios Pharmaceuticals, Inc. |
Mat2a inhibitors for treating mtap null cancer
|
EP3386519B1
(en)
|
2015-12-13 |
2021-03-24 |
Nitto Denko Corporation |
Sirna structures for high activity and reduced off target
|
GB201522186D0
(en)
|
2015-12-16 |
2016-01-27 |
Singapore Health Services Pte Ltd And Nat University Of Singapore The |
Treatment of fibrosis
|
CA3004056C
(en)
|
2015-12-22 |
2024-01-23 |
Pioneer Hi-Bred International, Inc. |
Tissue-preferred promoters and methods of use
|
WO2017129558A1
(en)
|
2016-01-25 |
2017-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting or treating myelopoiesis-driven cardiometabolic diseases and sepsis
|
US20170360815A1
(en)
|
2016-02-25 |
2017-12-21 |
Applied Biological Laboratories, Inc. |
Compositions and methods for protecting against airborne pathogens and irritants
|
JP7071933B2
(en)
|
2016-02-25 |
2022-05-19 |
アプライド バイオロジカル ラボラトリーズ インコーポレイテッド |
Compositions and methods for protection against airborne pathogens and irritants
|
US11072777B2
(en)
|
2016-03-04 |
2021-07-27 |
University Of Louisville Research Foundation, Inc. |
Methods and compositions for ex vivo expansion of very small embryonic-like stem cells (VSELs)
|
AU2017234163B2
(en)
|
2016-03-15 |
2023-01-19 |
Mersana Therapeutics, Inc. |
NaPi2b-targeted antibody-drug conjugates and methods of use thereof
|
KR102402444B1
(en)
|
2016-03-15 |
2022-05-27 |
엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔 (인쎄름) |
Early and non-invasive methods for assessing the risk of a subject suffering from pancreatic ductal adenocarcinoma and methods of treating such disease
|
DK3429603T3
(en)
|
2016-03-15 |
2022-03-14 |
Childrens Medical Center |
PROCEDURES AND COMPOSITIONS FOR EXPANSION OF HEMATOPOETIC STEM CELLS
|
WO2017158396A1
(en)
|
2016-03-16 |
2017-09-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cytidine deaminase inhibitors for the treatment of pancreatic cancer
|
EP3433615A1
(en)
|
2016-03-21 |
2019-01-30 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Methods for diagnosis and treatment of solar lentigo
|
EP3432911A1
(en)
|
2016-03-23 |
2019-01-30 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Targeting the neuronal calcium sensor 1 for treating wolfram syndrome
|
CA3018306A1
(en)
|
2016-03-24 |
2017-09-28 |
Universiteit Leiden |
Methods for transfecting plants and for reducing random integration events
|
US10883108B2
(en)
|
2016-03-31 |
2021-01-05 |
The Schepens Eye Research Institute, Inc. |
Endomucin inhibitor as an anti-angiogenic agent
|
MA45469A
(en)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
BETA-CATENIN NUCLEIC ACIDS AND THEIR USES
|
MA45349A
(en)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
EGFR NUCLEIC ACIDS AND THEIR USES
|
MA45470A
(en)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
KRAS NUCLEIC ACIDS AND THEIR USES
|
MA45328A
(en)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF
|
WO2017182834A1
(en)
|
2016-04-19 |
2017-10-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method for treating resistant glioblastoma
|
WO2017182442A1
(en)
|
2016-04-19 |
2017-10-26 |
Novozymes A/S |
Rlma-inactivated filamentous fungal host cell
|
US20190119364A1
(en)
|
2016-04-29 |
2019-04-25 |
The Regents Of The University Of Colorado, A Body Corporate |
Compounds and compositions useful for treating metabolic syndrome, and methods using same
|
CN109476707B
(en)
|
2016-05-13 |
2022-12-02 |
4D分子治疗有限公司 |
Adeno-associated virus variant capsids and methods of use thereof
|
BR112018073699A2
(en)
|
2016-05-16 |
2019-05-07 |
The Board Of Regents Of The University Of Texas System |
amino cationic sulfonamide lipids and amphiphilic zwitterionic amino lipids
|
WO2017202813A1
(en)
|
2016-05-24 |
2017-11-30 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of pulmonary bacterial infections
|
PT109454A
(en)
|
2016-06-14 |
2017-12-14 |
Phyzat Biopharmaceuticals Lda |
NUCLEIC ACIDS OF INTERFERENCE AND COMPOSITIONS THAT UNDERSTAND THEM
|
US10829563B2
(en)
|
2016-06-16 |
2020-11-10 |
INSERM (Institute National de la Santé et de la Recherche Médicale) |
Method of screening a candidate compound for activity as an elastase 2A (ELA2A) inhibitor
|
CN109642237B
(en)
|
2016-06-24 |
2022-09-30 |
先锋国际良种公司 |
Plant regulatory elements and methods of use thereof
|
EP3478321A4
(en)
|
2016-06-30 |
2020-04-22 |
Oncorus, Inc. |
Pseudotyped oncolytic viral delivery of therapeutic polypeptides
|
AU2017292646A1
(en)
|
2016-07-05 |
2019-02-07 |
Blade Therapeutics, Inc. |
Calpain modulators and therapeutic uses thereof
|
EP3943613A1
(en)
|
2016-07-05 |
2022-01-26 |
California Institute of Technology |
Fractional initiator hybridization chain reaction
|
AU2017298385A1
(en)
|
2016-07-19 |
2019-03-07 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Oncolytic viruses targeting STAT3
|
US20190262363A1
(en)
|
2016-07-26 |
2019-08-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale |
Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
|
WO2018019990A1
(en)
|
2016-07-28 |
2018-02-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of treatement of cancer disease by targetting tumor associated macrophage
|
EP3519582A1
(en)
|
2016-07-29 |
2019-08-07 |
Danmarks Tekniske Universitet |
Methods for decoupling cell growth from production of biochemicals and recombinant polypeptides
|
US20190183114A1
(en)
|
2016-08-05 |
2019-06-20 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and compositions for the preservationof organs
|
WO2018044939A1
(en)
|
2016-08-30 |
2018-03-08 |
California Institute Of Technology |
Immunohistochemistry via hybridization chain reaction
|
JP2019533139A
(en)
|
2016-09-08 |
2019-11-14 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Methods for diagnosing and treating nephrotic syndrome
|
WO2018057575A1
(en)
|
2016-09-21 |
2018-03-29 |
Alnylam Pharmaceuticals, Inc |
Myostatin irna compositions and methods of use thereof
|
WO2018055023A1
(en)
|
2016-09-22 |
2018-03-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of lung cancer
|
PE20191153A1
(en)
|
2016-09-28 |
2019-09-05 |
Blade Therapeutics Inc |
CALPAINE MODULATORS AND THERAPEUTIC USES OF THE SAME
|
WO2018069232A1
(en)
|
2016-10-10 |
2018-04-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the risk of having cardiac hypertrophy
|
WO2018078083A1
(en)
|
2016-10-28 |
2018-05-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method for treating multiple myeloma
|
EP3318277A1
(en)
|
2016-11-04 |
2018-05-09 |
Institut du Cerveau et de la Moelle Epiniere-ICM |
Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases
|
WO2018089772A1
(en)
|
2016-11-10 |
2018-05-17 |
Memorial Sloan-Kettering Cancer Center |
Inhibition of kmt2d for the treatment of cancer
|
WO2018087391A1
(en)
|
2016-11-14 |
2018-05-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for modulating stem cells proliferation or differentiation
|
EP3541938A1
(en)
|
2016-11-17 |
2019-09-25 |
Deutsches Krebsforschungszentrum Heidelberg Stiftung des öffentlichen Rechts (DKFZ) |
Cancer treatment by glycerol-3-phosphate dehydrogenase 1 inhibition
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
US11147249B2
(en)
|
2016-12-08 |
2021-10-19 |
Alector Llc |
Siglec transgenic mice and methods of use thereof
|
WO2018104909A2
(en)
|
2016-12-09 |
2018-06-14 |
St. Jude Children's Research Hospital |
Dna methylation profiling for t-cell immunotherapy
|
WO2018112237A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor
|
WO2018112256A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor
|
CN116869457A
(en)
|
2016-12-14 |
2023-10-13 |
比奥拉治疗股份有限公司 |
Treatment of gastrointestinal disorders and devices using JAK inhibitors
|
WO2018112235A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with a smad7 inhibitor
|
US20190343425A1
(en)
|
2016-12-14 |
2019-11-14 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
|
CN116712540A
(en)
|
2016-12-14 |
2023-09-08 |
比奥拉治疗股份有限公司 |
Treatment of gastrointestinal disorders using integrin inhibitors
|
WO2018112232A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor released using an ingestible device
|
CN110312737A
(en)
|
2016-12-16 |
2019-10-08 |
波尔多大学 |
MMP9 inhibitor and its purposes in prevention or treatment depigmentation illness
|
WO2018115083A1
(en)
|
2016-12-21 |
2018-06-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method of treatment of gut diseases such as irritable bowel syndrome (ibs)
|
WO2018115477A1
(en)
|
2016-12-23 |
2018-06-28 |
Universite De Strasbourg |
Dynamin 2 inhibitor for the treatment of myotonic dystrophy
|
WO2018131551A1
(en)
|
2017-01-13 |
2018-07-19 |
学校法人自治医科大学 |
Aav vector for disrupting clotting-related factor gene on liver genome
|
WO2018134386A1
(en)
|
2017-01-23 |
2018-07-26 |
Novozymes A/S |
Host cells and methods for producing double-stranded rna
|
WO2018138106A1
(en)
|
2017-01-27 |
2018-08-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of heart failure
|
WO2018141753A1
(en)
|
2017-01-31 |
2018-08-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for treating squamous cell carcinomas
|
US11920156B2
(en)
|
2017-02-09 |
2024-03-05 |
Indapta Therapeutics, Inc. |
Engineered natural killer (NK) cells and compositions and methods thereof
|
WO2018160538A1
(en)
|
2017-02-28 |
2018-09-07 |
Mersana Therapeutics, Inc. |
Combination therapies of her2-targeted antibody-drug conjugates
|
WO2018162676A1
(en)
|
2017-03-08 |
2018-09-13 |
Université De Strasbourg |
DISINTEGRATABLE POROUS ORGANOSILICA OR ORGANOMETALOXIDE NANOPARTICLES AND USES THEREOF AS VEHICLE FOR CONTROLLED DELIVERY OF siRNA
|
WO2018167283A1
(en)
|
2017-03-17 |
2018-09-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
|
WO2018172155A1
(en)
|
2017-03-23 |
2018-09-27 |
Novozymes A/S |
Improved filamentous fungal host cells
|
WO2018183932A1
(en)
|
2017-03-30 |
2018-10-04 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor
|
CA3054159A1
(en)
|
2017-03-30 |
2018-10-04 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a chst15 inhibitor
|
US20210138213A1
(en)
|
2017-03-30 |
2021-05-13 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
|
WO2018185516A1
(en)
|
2017-04-05 |
2018-10-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy
|
EP3610264A1
(en)
|
2017-04-13 |
2020-02-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
|
WO2018189403A1
(en)
|
2017-04-14 |
2018-10-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of cancer
|
US20210283068A1
(en)
|
2017-04-19 |
2021-09-16 |
St. Jude Children's Research Hospital |
Tumor suppression by modulation of non-canonical autophagy (lap) in myeloid cells
|
CN106942162A
(en)
*
|
2017-04-25 |
2017-07-14 |
遵义医学院 |
A kind of device and its application method suitable for white backed planthopper feeding method RNA interference experiments
|
WO2018199777A1
(en)
|
2017-04-28 |
2018-11-01 |
Auckland Uniservices Limited |
Methods of treatment and novel constructs
|
WO2018201144A1
(en)
|
2017-04-28 |
2018-11-01 |
Precision Biosciences, Inc. |
Methods for reducing dna-induced cytotoxicity and enhancing gene editing in primary cells
|
CA3062698A1
(en)
|
2017-05-08 |
2018-11-15 |
Precision Biosciences, Inc. |
Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof
|
US11359014B2
(en)
|
2017-05-16 |
2022-06-14 |
Alector Llc |
Anti-siglec-5 antibodies and methods of use thereof
|
CN111093640A
(en)
|
2017-05-17 |
2020-05-01 |
国家健康与医学研究院 |
FLT3 inhibitors for improving opioid pain therapy
|
CA3064774A1
(en)
|
2017-05-25 |
2018-11-29 |
The Governors Of The University Of Alberta |
Methods of preventing or treating atherosclerosis with inhibitors of specific isoenzymes of human neuraminidase
|
EP3412288A1
(en)
|
2017-06-08 |
2018-12-12 |
Galderma Research & Development |
Vegf inhibitors for use for preventing and/or treating acne
|
EP3641739A1
(en)
|
2017-06-20 |
2020-04-29 |
Institut Curie |
Inhibitor of suv39h1 histone methyltransferase for use in cancer combination therapy
|
CN114058590A
(en)
|
2017-06-20 |
2022-02-18 |
居里研究所 |
SUV39H1 deficient immune cells
|
WO2018234538A1
(en)
|
2017-06-23 |
2018-12-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Hepcidin antagonist or agonist for use in the treatment of dysregulation of mo and/or mn metabolism
|
WO2019012030A1
(en)
|
2017-07-13 |
2019-01-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Dhodh inhibitor and chk1 inhibitor for treating cancer
|
PE20200486A1
(en)
|
2017-08-03 |
2020-03-03 |
Alector Llc |
ANTI-CD33 ANTIBODIES AND METHODS OF USING THEM
|
EP3444347A1
(en)
|
2017-08-18 |
2019-02-20 |
Universität Heidelberg |
Use of anti-crispr polypeptides for specific activation of cas nucleases
|
CN117866959A
(en)
|
2017-09-07 |
2024-04-12 |
北京泰德制药股份有限公司 |
CKIP-1-targeted double-stranded RNA molecules and uses thereof
|
US11118192B2
(en)
|
2017-09-20 |
2021-09-14 |
4D Molecular Therapeutics Inc. |
Adeno-associated virus variant capsids and methods of use thereof
|
JP2020536515A
(en)
|
2017-09-25 |
2020-12-17 |
パイオニア ハイ−ブレッド インターナショナル, インコーポレイテッド |
Tissue-preferred promoters and how to use them
|
WO2019072832A1
(en)
|
2017-10-10 |
2019-04-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating fibrotic interstitial lung disease
|
WO2019072885A1
(en)
|
2017-10-11 |
2019-04-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Magnetic nanoparticles for the treatment of cancer
|
AU2018356642A1
(en)
|
2017-10-26 |
2020-04-30 |
Commissariat A L'energie Atomique Et Aux Energies Alternatives |
Methods and pharmaceutical compositions for treating tubulin carboxypeptidases associated diseases
|
CA3081910A1
(en)
|
2017-11-13 |
2019-05-16 |
Silence Therapeutics Gmbh |
Nucleic acids for inhibiting expression of a target gene comprising phosphorodithioate linkages
|
WO2019096787A1
(en)
|
2017-11-14 |
2019-05-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Regulatory t cells genetically modified for the lymphotoxin alpha gene and uses thereof
|
WO2019101882A1
(en)
|
2017-11-23 |
2019-05-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method for treating dengue virus infection
|
EP3717021A1
(en)
|
2017-11-27 |
2020-10-07 |
Mersana Therapeutics, Inc. |
Pyrrolobenzodiazepine antibody conjugates
|
FI3717636T3
(en)
|
2017-11-27 |
2023-06-01 |
4D Molecular Therapeutics Inc |
Adeno-associated virus variant capsids and use for inhibiting angiogenesis
|
WO2019108835A1
(en)
|
2017-11-29 |
2019-06-06 |
The Trustees Of Columbia University In The City Of New York |
Delta-2-tubulin as a biomarker and therapeutic target for peripheral neuropathy
|
WO2019106126A1
(en)
|
2017-12-01 |
2019-06-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Mdm2 modulators for the diagnosis and treatment of liposarcoma
|
MA51103A
(en)
|
2017-12-06 |
2020-10-14 |
Avidity Biosciences Inc |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF MUSCLE ATROPHY AND MYOTONIC DYSTROPHY
|
US11470827B2
(en)
|
2017-12-12 |
2022-10-18 |
Alector Llc |
Transgenic mice expressing human TREM proteins and methods of use thereof
|
EP3502259A1
(en)
|
2017-12-19 |
2019-06-26 |
Universiteit Leiden |
A combinational strategy for reducing random integration events when transfecting plants
|
WO2019121872A1
(en)
|
2017-12-20 |
2019-06-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the diagnosis and treatment of liver cancer
|
TW201929908A
(en)
|
2017-12-21 |
2019-08-01 |
美商梅爾莎納醫療公司 |
Pyrrolobenzodiazepine antibody conjugates
|
US11865081B2
(en)
|
2017-12-29 |
2024-01-09 |
Virogin Biotech Canada Ltd. |
Oncolytic viral delivery of therapeutic polypeptides
|
WO2019140009A1
(en)
|
2018-01-09 |
2019-07-18 |
Cibus Us Llc |
Shatterproof genes and mutations
|
US20210031012A1
(en)
|
2018-01-26 |
2021-02-04 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
|
WO2019155387A1
(en)
|
2018-02-07 |
2019-08-15 |
St. Jude Children's Research Hospital |
Epigenetic histone regulation mediated by cxorf67
|
WO2019158512A1
(en)
|
2018-02-13 |
2019-08-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the prognosis and the treatment of glioblastoma
|
JP2021517127A
(en)
|
2018-03-06 |
2021-07-15 |
アンスティテュ キュリィ |
Inhibitor of SETDB1 histone methyltransferase for use in cancer combination therapy
|
US20210047696A1
(en)
|
2018-03-28 |
2021-02-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cancer
|
JP2021519587A
(en)
|
2018-03-30 |
2021-08-12 |
ユニバーシティ オブ ジュネーブ |
MicroRNA expression constructs and their use
|
WO2019199673A1
(en)
|
2018-04-09 |
2019-10-17 |
President And Fellows Of Harvard College |
Modulating nuclear receptors and methods of using same
|
WO2019207066A1
(en)
|
2018-04-26 |
2019-10-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for the treatment of sjögren's syndrome
|
WO2019211370A1
(en)
|
2018-05-03 |
2019-11-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cancer
|
WO2019211369A1
(en)
|
2018-05-03 |
2019-11-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cancer
|
CA3096516A1
(en)
|
2018-05-22 |
2019-11-28 |
Pioneer Hi-Bred International, Inc. |
Plant regulatory elements and methods of use thereof
|
GB201808927D0
(en)
|
2018-05-31 |
2018-07-18 |
Institute Of Cancer Res Royal Cancer Hospital |
Materials and methods for monitoring the development of resistance of cancers to treatment
|
WO2019234099A1
(en)
|
2018-06-06 |
2019-12-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosing, predicting the outcome and treating a patient suffering from heart failure with preserved ejection fraction
|
WO2019234221A1
(en)
|
2018-06-08 |
2019-12-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia
|
WO2019246317A1
(en)
|
2018-06-20 |
2019-12-26 |
Progenity, Inc. |
Treatment of a disease or condition in a tissue originating from the endoderm
|
US20210363233A1
(en)
|
2018-06-20 |
2021-11-25 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
|
WO2019246312A1
(en)
|
2018-06-20 |
2019-12-26 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an immunomodulator
|
EP3810095A1
(en)
|
2018-06-20 |
2021-04-28 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
|
EP3810085A1
(en)
|
2018-06-20 |
2021-04-28 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
|
US20220257600A1
(en)
|
2018-06-20 |
2022-08-18 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor
|
EP3833747A1
(en)
|
2018-06-28 |
2021-06-16 |
Pioneer Hi-Bred International, Inc. |
Methods for selecting transformed plants
|
WO2020016160A1
(en)
|
2018-07-16 |
2020-01-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method to treat neurological diseases
|
WO2020016377A1
(en)
|
2018-07-19 |
2020-01-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combination for treating cancer
|
JP2021531027A
(en)
|
2018-07-27 |
2021-11-18 |
アレクトル エルエルシー |
Anti-Siglec-5 antibody and how to use it
|
WO2020026968A1
(en)
|
2018-07-30 |
2020-02-06 |
株式会社遺伝子治療研究所 |
Method for enhancing gene expression by aav vector
|
EP3833757A4
(en)
|
2018-08-10 |
2022-05-18 |
City of Hope |
Programmable conditional sirnas and uses thereof
|
WO2020049026A1
(en)
|
2018-09-05 |
2020-03-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating asthma and allergic diseases
|
WO2020061381A1
(en)
|
2018-09-19 |
2020-03-26 |
La Jolla Institute For Immunology |
Ptprs and proteoglycans in rheumatoid arthritis
|
EP3864136A1
(en)
|
2018-10-09 |
2021-08-18 |
Novozymes A/S |
Modified filamentous fungal host cell
|
EP3866807A1
(en)
|
2018-10-16 |
2021-08-25 |
F. Hoffmann-La Roche AG |
Use of akt inhibitors in ophthalmology
|
CN112955462B
(en)
|
2018-10-18 |
2024-05-07 |
国家医疗保健研究所 |
Combination of a beta IG-H3 antagonist and an immune checkpoint inhibitor for the treatment of solid tumors
|
KR20210084546A
(en)
|
2018-10-29 |
2021-07-07 |
메르사나 테라퓨틱스, 인코포레이티드 |
Cysteine Engineered Antibody-Drug Conjugates with Peptide-Containing Linkers
|
AU2019369415A1
(en)
|
2018-10-31 |
2021-03-25 |
Pioneer Hi-Bred International, Inc. |
Compositions and methods for Ochrobactrum-mediated plant transformation
|
US20220000893A1
(en)
|
2018-10-31 |
2022-01-06 |
|Nserm (Institut National De La Santé Et De La Recherche Médicale) |
Method for treating t-helper type 2 mediated disease
|
AU2019371161A1
(en)
|
2018-10-31 |
2021-06-17 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Biomarkers and methods of use for radiation-induced lung injury
|
EP3650040A1
(en)
|
2018-11-07 |
2020-05-13 |
Galderma Research & Development |
Vegf inhibitors for use for preventing and/or treating atopic dermatitis
|
WO2020102668A1
(en)
|
2018-11-16 |
2020-05-22 |
Nitto Denko Corporation |
Rna interference delivery formulation and methods for malignant tumors
|
WO2020112881A1
(en)
|
2018-11-28 |
2020-06-04 |
Novozymes A/S |
Modified filamentous fungal host cells
|
US11883401B2
(en)
|
2019-01-08 |
2024-01-30 |
Duke University |
Compositions for the treatment of pathogenic- and/or chemical-induced lung injury and for the treatment of cancer and methods of using same
|
CN113316722A
(en)
|
2019-01-17 |
2021-08-27 |
豪夫迈·罗氏有限公司 |
E3 ubiquitin ligase (UBE3A) protein targets
|
AU2020211695A1
(en)
|
2019-01-21 |
2021-09-02 |
National University Of Singapore |
Treatment of hepatotoxicity
|
SG11202107018RA
(en)
|
2019-02-01 |
2021-07-29 |
Univ Basel |
Calcineurin inhibitor resistant immune cells for use in adoptive cell transfer therapy
|
EP3921031A1
(en)
|
2019-02-04 |
2021-12-15 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods and compositions for modulating blood-brain barrier
|
JP2022519718A
(en)
|
2019-02-08 |
2022-03-24 |
ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム |
Telomerase-containing exosomes for the treatment of age-related and age-related organ failure-related diseases
|
WO2020169707A1
(en)
|
2019-02-21 |
2020-08-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Foxo1 inhibitor for use in the treatment of latent virus infection
|
GB201902419D0
(en)
|
2019-02-22 |
2019-04-10 |
Singapore Health Serv Pte Ltd |
Treatment of kidney injury
|
WO2020178193A1
(en)
|
2019-03-01 |
2020-09-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method of treatment of sarcoidosis
|
EP3938521A1
(en)
|
2019-03-11 |
2022-01-19 |
Pioneer Hi-Bred International, Inc. |
Methods for clonal plant production
|
WO2020183011A1
(en)
|
2019-03-14 |
2020-09-17 |
Institut Curie |
Htr1d inhibitors and uses thereof in the treatment of cancer
|
WO2020198408A1
(en)
|
2019-03-27 |
2020-10-01 |
Pioneer Hi-Bred International, Inc. |
Plant explant transformation
|
WO2020193740A1
(en)
|
2019-03-28 |
2020-10-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New strategy for treating pancreatic cancer
|
CA3127173A1
(en)
|
2019-03-28 |
2020-10-01 |
Pioneer Hi-Bred International, Inc. |
Modified agrobacterium strains and use thereof for plant transformation
|
WO2020208082A1
(en)
|
2019-04-09 |
2020-10-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for treating cmv related diseases
|
CA3137224A1
(en)
|
2019-04-19 |
2020-10-22 |
Sorbonne Universite |
P16ink4a inhibitor for preventing or treating huntington's disease
|
GB201906291D0
(en)
|
2019-05-03 |
2019-06-19 |
Singapore Health Serv Pte Ltd |
Treatment and prevention of metabolic diseases
|
MX2021013356A
(en)
|
2019-05-03 |
2022-03-11 |
Singapore Health Serv Pte Ltd |
Treatment and prevention of metabolic diseases.
|
KR20220012261A
(en)
|
2019-05-07 |
2022-02-03 |
이뮤니컴 인코포레이티드 |
Increased response to checkpoint inhibitors by in vitro apheresis
|
US20220227859A1
(en)
|
2019-05-16 |
2022-07-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method to treat type 2 inflammation or mast-cell dependent disease
|
WO2020249769A1
(en)
|
2019-06-14 |
2020-12-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating ocular diseases related to mitochondrial dna maintenance
|
US11473086B2
(en)
|
2019-06-19 |
2022-10-18 |
Ut-Battelle, Llc |
Loss of function alleles of PtEPSP-TF and its regulatory targets in rice
|
WO2021001539A1
(en)
|
2019-07-04 |
2021-01-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New strategy to detect and treat eosinophilic fasciitis
|
EP3997225A1
(en)
|
2019-07-10 |
2022-05-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of epilepsy
|
EP4006160A4
(en)
|
2019-07-12 |
2023-06-28 |
Gene Therapy Research Institution Co., Ltd. |
Adeno-associated virus virion for gene transfer to human liver
|
US20220251581A1
(en)
|
2019-07-26 |
2022-08-11 |
Novozymes A/S |
Modified filamentous fungal host cell
|
WO2021019536A1
(en)
|
2019-07-30 |
2021-02-04 |
The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) |
Methods of controlling cannabinoid synthesis in plants or cells and plants and cells produced thereby
|
AU2020329525A1
(en)
|
2019-08-14 |
2022-03-03 |
Vanarix Sa |
Method for in vitro production of hyaline cartilage tissue
|
US20220290156A1
(en)
|
2019-08-27 |
2022-09-15 |
Sanofi |
Compositions and methods for inhibiting pcsk9
|
EP4025712A1
(en)
|
2019-09-05 |
2022-07-13 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Method of treatment and pronostic of acute myeloid leukemia
|
GB201913030D0
(en)
|
2019-09-10 |
2019-10-23 |
Francis Crick Institute Ltd |
Treatment of hr deficient cancer
|
KR102100163B1
(en)
|
2019-09-24 |
2020-04-13 |
테고사이언스 (주) |
Compositions of Prevention or Treatment of Keloid or Hypertrophic scar
|
US20220290151A1
(en)
|
2019-09-27 |
2022-09-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of müllerian inhibiting substance inhibitors for treating cancer
|
WO2021099394A1
(en)
|
2019-11-19 |
2021-05-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antisense oligonucleotides and their use for the treatment of cancer
|
EP3825408A1
(en)
|
2019-11-19 |
2021-05-26 |
FRAUNHOFER-GESELLSCHAFT zur Förderung der angewandten Forschung e.V. |
Methods of multi-species insect pest control
|
WO2021105384A1
(en)
|
2019-11-27 |
2021-06-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Targeting the nls region of nupr1 protein to treat cancer
|
WO2021105391A1
(en)
|
2019-11-27 |
2021-06-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combination comprising nupr1 inhibitors to treat cancer
|
PE20230159A1
(en)
|
2019-12-18 |
2023-02-01 |
Novartis Ag |
3-(5-METHOXY-1-OXOISOINDOLIN-2-IL)PIPERIDIN-2,6-DIONE DERIVATIVES AND USES
|
EP4077676A1
(en)
|
2019-12-18 |
2022-10-26 |
Novartis AG |
Compositions and methods for the treatment of hemoglobinopathies
|
KR20220139886A
(en)
|
2020-01-08 |
2022-10-17 |
리제너론 파아마슈티컬스, 인크. |
Treatment of Progressive Osteogenic Fibrodysplasia
|
US20210222128A1
(en)
|
2020-01-22 |
2021-07-22 |
Massachusetts Institute Of Technology |
Inducible tissue constructs and uses thereof
|
EP4100525A1
(en)
|
2020-02-05 |
2022-12-14 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods of treatment of cancer disease by targeting an epigenetic factor
|
CN115052974A
(en)
|
2020-02-10 |
2022-09-13 |
生物马林药物股份有限公司 |
Virus-free cell culture
|
US11642407B2
(en)
|
2020-02-28 |
2023-05-09 |
Massachusetts Institute Of Technology |
Identification of variable influenza residues and uses thereof
|
AU2021237465A1
(en)
|
2020-03-19 |
2022-10-13 |
Avidity Biosciences, Inc. |
Compositions and methods of treating Facioscapulohumeral muscular dystrophy
|
EP4138791A1
(en)
|
2020-04-20 |
2023-03-01 |
Board of Regents, The University of Texas System |
Biologically active dry powder compositions and method of their manufacture and use
|
JP2023524639A
(en)
|
2020-04-22 |
2023-06-13 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
Manufacturing adjustment system and adjustment method of cells for patient-specific immunotherapy
|
WO2021219708A1
(en)
|
2020-04-28 |
2021-11-04 |
Phyzat Biopharmaceuticals, Lda |
Sina molecules, methods of production and uses thereof
|
WO2021224401A1
(en)
|
2020-05-07 |
2021-11-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for determining a reference range of β-galactose exposure platelet
|
WO2021228585A1
(en)
|
2020-05-09 |
2021-11-18 |
Phyzat Biopharmaceuticals, Lda |
Sina molecules, methods of production and uses thereof
|
EP4153192A1
(en)
|
2020-05-19 |
2023-03-29 |
Institut Curie |
Methods for the diagnosis and treatment of cytokine release syndrome
|
JP2023537558A
(en)
|
2020-05-27 |
2023-09-04 |
アンチオン バイオサイエンシーズ エスアー |
Adapter molecules for redirecting CAR T cells to antigens of interest
|
EP4157288A2
(en)
|
2020-06-02 |
2023-04-05 |
Institut Gustave-Roussy |
Modulators of purinergic receptors and related immune checkpoint for treating acute respiratory distress syndrom
|
EP3919062A1
(en)
|
2020-06-02 |
2021-12-08 |
Institut Gustave-Roussy |
Modulators of purinergic receptors and related immune checkpoint for treating acute respiratory distress syndrom
|
EP4162417A1
(en)
|
2020-06-03 |
2023-04-12 |
Xenotherapeutics, Inc. |
Selection and monitoring methods for xenotransplantation
|
JP2023527578A
(en)
|
2020-06-05 |
2023-06-29 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Methods and pharmaceutical compositions for treating eye diseases
|
WO2021250076A1
(en)
|
2020-06-09 |
2021-12-16 |
Genethon |
Treatment of genetic dilated cardiomyopathies
|
EP4162049A1
(en)
|
2020-06-09 |
2023-04-12 |
Genethon |
Cilp-1 inhibitors for use in the treatment of dilated cardiomyopathies
|
US20230218608A1
(en)
|
2020-06-18 |
2023-07-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New strategy for treating pancreatic cancer
|
GB202009292D0
(en)
|
2020-06-18 |
2020-08-05 |
Singapore Health Serv Pte Ltd |
Treatment and prevention of disease caused by type IV collagen dysfunction
|
US20230305023A1
(en)
|
2020-06-25 |
2023-09-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of treatment and diagnostic of pathological conditions associated with intense stress
|
CN115989415A
(en)
|
2020-06-30 |
2023-04-18 |
健肺生命人工智能公司 |
Methods for detecting lung cancer
|
US20240018524A1
(en)
|
2020-07-10 |
2024-01-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating epilepsy
|
WO2022018667A1
(en)
|
2020-07-24 |
2022-01-27 |
Pfizer Inc. |
Combination therapies using cdk2 and cdc25a inhibitors
|
EP4188395A1
(en)
|
2020-07-30 |
2023-06-07 |
Institut Curie |
Immune cells defective for socs1
|
EP4210722A1
(en)
|
2020-09-07 |
2023-07-19 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods of treatment of inflammatory bowel diseases
|
EP4222165A2
(en)
|
2020-09-30 |
2023-08-09 |
Pioneer Hi-Bred International, Inc. |
Rapid transformation of monocot leaf explants
|
GB202017244D0
(en)
|
2020-10-30 |
2020-12-16 |
Nat Univ Singapore |
Methods to extend health-span and treat age-related diseases
|
EP4247952A2
(en)
|
2020-11-23 |
2023-09-27 |
Phyzat Biopharmaceuticals, Lda. |
Sina molecules, methods of production and uses thereof
|
WO2022129166A1
(en)
|
2020-12-15 |
2022-06-23 |
Novozymes A/S |
Mutated host cells with reduced cell motility
|
WO2022147480A1
(en)
|
2020-12-30 |
2022-07-07 |
Ansun Biopharma, Inc. |
Oncolytic virus encoding sialidase and multispecific immune cell engager
|
EP4284925A1
(en)
|
2021-01-26 |
2023-12-06 |
California Institute of Technology |
Allosteric conditional guide rnas for cell-selective regulation of crispr/cas
|
EP4284513A1
(en)
|
2021-01-26 |
2023-12-06 |
Universite Brest Bretagne Occidentale |
Novel stim1 splicing variants and uses thereof
|
WO2022165111A1
(en)
|
2021-01-28 |
2022-08-04 |
Precision Biosciences, Inc. |
Modulation of tgf beta signaling in genetically-modified eukaryotic cells
|
US20240132974A1
(en)
|
2021-02-12 |
2024-04-25 |
Institut National de la Santé et de la Recherche Médicale |
Method for prognosis and treating a patient suffering from cancer
|
WO2022218998A1
(en)
|
2021-04-13 |
2022-10-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for treating hepatitis b and d virus infection
|
WO2022219076A1
(en)
|
2021-04-14 |
2022-10-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method to improve the anti-tumoral activity of macrophages
|
WO2022219080A1
(en)
|
2021-04-14 |
2022-10-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method to improve nk cells cytotoxicity
|
EP4328313A1
(en)
|
2021-04-21 |
2024-02-28 |
Jichi Medical University |
Adeno-associated virus virion for treating ornithine transcarbamylase deficiency
|
IL308018A
(en)
|
2021-04-30 |
2023-12-01 |
Kalivir Immunotherapeutics Inc |
Oncolytic viruses for modified mhc expression
|
TW202313096A
(en)
|
2021-05-28 |
2023-04-01 |
大陸商江蘇恆瑞醫藥股份有限公司 |
Recombinant adeno-associated virus with capsid variant and its application
|
WO2022253910A1
(en)
|
2021-06-02 |
2022-12-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
A new method to treat an inflammatory skin disease
|
EP4359527A2
(en)
|
2021-06-23 |
2024-05-01 |
Novartis AG |
Compositions and methods for the treatment of hemoglobinopathies
|
US11593428B2
(en)
|
2021-07-08 |
2023-02-28 |
Bank Of America Corporation |
System and method for detecting errors in a task workflow from a video stream
|
EP4376948A1
(en)
|
2021-07-26 |
2024-06-05 |
Boehringer Ingelheim International GmbH |
Treatment and prevention of alcoholic liver disease
|
WO2023012165A1
(en)
|
2021-08-02 |
2023-02-09 |
Universite De Montpellier |
Compositions and methods for treating cmt1a or cmt1e diseases with rnai molecules targeting pmp22
|
CA3227511A1
(en)
|
2021-08-06 |
2023-02-09 |
Lætitia LINARES |
Methods for the treatment of cancer
|
EP4388122A1
(en)
|
2021-08-16 |
2024-06-26 |
F. Hoffmann-La Roche AG |
E3 ubiquitin ligase (ube3a) protein targets
|
WO2023041744A1
(en)
|
2021-09-17 |
2023-03-23 |
Institut Curie |
Bet inhibitors for treating pab1 deficient cancer
|
WO2023041805A1
(en)
|
2021-09-20 |
2023-03-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor
|
WO2023057484A1
(en)
|
2021-10-06 |
2023-04-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting and improving the efficacy of mcl-1 inhibitor therapy
|
WO2023073099A1
(en)
|
2021-10-28 |
2023-05-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method to improve phagocytosis
|
WO2023078906A1
(en)
|
2021-11-03 |
2023-05-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for treating acute myeloid leukemia
|
WO2023078900A1
(en)
|
2021-11-03 |
2023-05-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating triple negative breast cancer (tnbc)
|
WO2023081767A1
(en)
|
2021-11-05 |
2023-05-11 |
Precision Biosciences, Inc. |
Methods for immunotherapy
|
WO2023089032A1
(en)
|
2021-11-19 |
2023-05-25 |
Institut Curie |
Methods for the treatment of hrd cancer and brca-associated cancer
|
WO2023089159A1
(en)
|
2021-11-22 |
2023-05-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New strategy targeting stroma/tumor cell crosstalk to treat a cancer
|
WO2023099763A1
(en)
|
2021-12-03 |
2023-06-08 |
Institut Curie |
Sirt6 inhibitors for use in treating resistant hrd cancer
|
WO2023111173A1
(en)
|
2021-12-16 |
2023-06-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
An ezh2 degrader or inhibitor for use in the treatment of resistant acute myeloid leukemia
|
WO2023111196A1
(en)
|
2021-12-16 |
2023-06-22 |
Singapore Health Services Pte. Ltd. |
Treatment and prevention of glomerular disease
|
WO2023122805A1
(en)
|
2021-12-20 |
2023-06-29 |
Vestaron Corporation |
Sorbitol driven selection pressure method
|
WO2023118546A2
(en)
|
2021-12-23 |
2023-06-29 |
Boehringer Ingelheim International Gmbh |
METHODS AND MOLECULES FOR RNA INTERFERENCE (RNAi)
|
EP4215614A1
(en)
|
2022-01-24 |
2023-07-26 |
Dynacure |
Combination therapy for dystrophin-related diseases
|
US12004476B2
(en)
|
2022-01-26 |
2024-06-11 |
Monsanto Technology Llc. |
Cotton variety 20R750B3XF
|
WO2023201369A1
(en)
|
2022-04-15 |
2023-10-19 |
Iovance Biotherapeutics, Inc. |
Til expansion processes using specific cytokine combinations and/or akti treatment
|
GB202206507D0
(en)
|
2022-05-04 |
2022-06-15 |
Antion Biosciences Sa |
Expression construct
|
WO2023230531A1
(en)
|
2022-05-24 |
2023-11-30 |
Lunglife Ai, Inc. |
Methods for detecting circulating genetically abnormal cells
|
WO2024003350A1
(en)
|
2022-06-30 |
2024-01-04 |
Universite De Strasbourg |
Combination therapy for melanoma
|
EP4299742A1
(en)
|
2022-06-30 |
2024-01-03 |
Université de Strasbourg |
Combination therapy for melanoma
|
WO2024017990A1
(en)
|
2022-07-21 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Methods and compositions for treating chronic pain disorders
|
EP4311546A1
(en)
|
2022-07-26 |
2024-01-31 |
Dynacure |
Combination therapy for myopathies
|
WO2024028794A1
(en)
|
2022-08-02 |
2024-02-08 |
Temple Therapeutics BV |
Methods for treating endometrial and ovarian hyperproliferative disorders
|
WO2024028476A1
(en)
|
2022-08-05 |
2024-02-08 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of th2-mediated diseases
|
WO2024037910A1
(en)
|
2022-08-17 |
2024-02-22 |
Institut National de la Santé et de la Recherche Médicale |
Syk inhibitors for use in the treatment of cancer
|
GB202212077D0
(en)
|
2022-08-18 |
2022-10-05 |
Tribune Therapeutics Ab |
Agents that inhibit ccn ligand-induced signalling for treating disease
|
WO2024047110A1
(en)
|
2022-08-31 |
2024-03-07 |
Institut National de la Santé et de la Recherche Médicale |
Method to generate more efficient car-t cells
|
WO2024052503A1
(en)
|
2022-09-08 |
2024-03-14 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies having specificity to ltbp2 and uses thereof
|
WO2024056659A1
(en)
|
2022-09-13 |
2024-03-21 |
Institut National de la Santé et de la Recherche Médicale |
Method for treating prostate cancer and other epithelial cancers
|
WO2024059618A2
(en)
|
2022-09-13 |
2024-03-21 |
Arsenal Biosciences, Inc. |
Immune cells having co-expressed tgfbr shrnas
|
WO2024059824A2
(en)
|
2022-09-16 |
2024-03-21 |
Arsenal Biosciences, Inc. |
Immune cells with combination gene perturbations
|
WO2024074713A1
(en)
|
2022-10-07 |
2024-04-11 |
Institut National de la Santé et de la Recherche Médicale |
Method to generate improving car-t cells
|
US20240166750A1
(en)
|
2022-10-25 |
2024-05-23 |
Ablynx N.V. |
GLYCOENGINEERED Fc VARIANT POLYPEPTIDES WITH ENHANCED EFFECTOR FUNCTION
|
WO2024112571A2
(en)
|
2022-11-21 |
2024-05-30 |
Iovance Biotherapeutics, Inc. |
Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom
|
WO2024110458A1
(en)
|
2022-11-22 |
2024-05-30 |
Institut Curie |
Lnc-znf30-3 as cancer biomarker and therapeutic target
|